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ABSTRACT 
Rotavirus infection causes acute gastroenteritis in children younger than five years of age, 
and commonly occurring human rotavirus strains include G1 - G4 and G9 associated with 
P[4], P[6] and P[8].  In this study, of 6050 stool samples collected from a Private Pathology 
Practice in Pretoria, March 2010 - August 2011, 664 tested positive using Coris test-strips.  
Of these samples, 752 were retested using EIA and, results showed: Coris sensitivity was 
93,7% and specificity 99,8%; the winter epidemic peaked in July of both years; more males 
and children under 30 months of age were particularly vulnerable to infections. Rotavirus-
positive samples from Trichardt, Rustenburg and Middelburg were analysed by PAGE and 
RT-PCR showing circulating strains as mainly G8P[4] (60%) with short electropherotypes, 
G12P[8] (66%) with long electropherotypes, and G1P[8] at low incidence in the 2010/2011 
seasons. These results suggest additional research to monitor the impacts of recently 
introduced rotavirus vaccines on changing strain profiles in South African communities.  
 
Key words: diarrhoeal disease, rotavirus, incidence, seasonality, genotypes, 
electropherotypes, Pathology practice, Trichardt, Middelburg, Rustenburg  
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CHAPTER 1 
 
THE RESEARCH PROBLEM 
 
1.1 Introduction 
Annually, millions of young children die from various causes including diseases.  In a report 
by the World Health Organisation (WHO) in 2008 on the burden of disease for 2004, the 
annually mortality was estimated to be 10.4 million children younger than four years of age, 
accounting for 18% of the total population, Black et al. (2010) estimated the annual mortality 
in children younger than five years of age to be 8.8 million in 2008.  This decrease in 
mortality was mainly due to the successful implementations of child survival interventions 
and changes in socioeconomic development.  The highest mortality rates observed were in 
Africa, with 4.7 million deaths, and South East Asian region, with 3.1 million deaths (WHO 
2008b).  Black et al. (2003) estimated that 90% of deaths in children younger than five years 
of age occur in only 42 countries of the world, including South Africa where around 77 000 
deaths occur annually.  The WHO classifies South Africa as a country with an intermediate 
mortality rate among children younger than five years of age (WHO 2009a).   
 
Various risk factors are associated with high mortality rates in young children.  These include 
poverty, unsafe water, poor sanitation, overcrowding, indoor air pollution, poor maternal 
nutrition, lack of exclusive breastfeeding during the first six months of life, malnutrition and 
recurrent infectious diseases (Rosenberg 2007).  In lower income countries, high mortality 
may be due to ineffective treatment involving oral or intravenous rehydration, and 
inappropriate hospital care in the case of diarrhoeal disease (Ciarlet and Schödel 2009; 
Rodrigo et al. 2010).   
 
1.1.1 The leading causes of mortality 
Globally the leading causes of child mortality include neonatal-related deaths, acute 
respiratory infections, diarrhoeal diseases, non-communicable diseases, malaria, measles, 
infection with human immunodeficiency virus (HIV) and acquired immune deficiency 
syndrome (AIDS), injuries and other parasitic and infectious diseases.  These causes are 
illustrated in Figure 1.1 (WHO 2008b; Black et al. 2010), and indicates a high proportion of 
the total deaths as being represented by neonatal-related deaths.  Diarrhoeal diseases together 
with acute respiratory disorders are each responsible for the highest number of deaths in 
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young children, as illustrated in Figure 1.2 (WHO 2008b; Black et al. 2010).  It is important 
to note that even though malnutrition is not listed as the direct cause of death in young 
children, it is associated with over 50% of deaths observed (Rosenberg 2007).  A comparison 
between the mortality observed in 2004 and 2008 is also made in Figures 1.1 and 1.2, thereby 
identifying illnesses that decreased or increased over the four year period.    
 
 
Figure 1.1 The leading causes of death in young children, as observed globally (WHO 
2008b; Black et al. 2010). 
 
 
Figure 1.2 Distribution of causes of death among all children younger than five years of 
age, as observed globally (WHO 2008b; Black et al. 2010). 
0 
5 
10 
15 
20 
25 
30 
35 
40 
H
IV
/A
ID
S 
M
ea
sl
es
 
M
al
ar
ia
 
D
ia
rr
ho
ea
l d
is
ea
se
s 
O
th
er
 in
fe
ct
io
us
 a
nd
 p
ar
as
iti
c 
di
se
as
es
 
A
cu
te
 re
sp
ira
to
ry
 in
fe
ct
io
ns
 
N
on
co
m
m
un
ic
ab
le
 d
is
ea
se
s 
N
eo
na
ta
l r
el
at
ed
 d
ea
th
s 
In
ju
rie
s 
M
en
en
gi
tis
 
Pe
rt
us
si
s 
G
lo
ba
l c
hi
ld
ho
od
 m
or
ta
lit
y 
ra
te
s 
Disease Causes 
2004 
2008 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
In
ju
rie
s 
N
on
co
m
m
un
ic
ab
le
 d
is
ea
se
s 
O
th
er
 in
fe
ct
io
us
 a
nd
 p
ar
as
iti
c 
di
se
as
es
 H
IV
/A
ID
S 
M
ea
sl
es
 
M
al
ar
ia
 
D
ia
rr
ho
ea
l d
is
ea
se
s 
A
cu
te
 re
sp
ira
to
ry
 in
fe
ct
io
ns
 
N
eo
na
ta
l c
on
ge
ni
ta
l a
no
m
al
ie
s 
N
eo
na
ta
l t
et
an
us
 
N
eo
na
ta
l n
on
-in
fe
ct
io
us
 
pe
rin
at
al
 c
au
se
s 
N
eo
na
ta
l s
ep
si
s 
N
eo
na
ta
l i
nf
ec
tio
ns
 (o
th
er
) 
Bi
rt
h 
as
ph
yx
ia
 a
nd
 b
irt
h 
tr
au
m
a 
Pr
em
at
ur
ity
 a
nd
 lo
w
 b
irt
h 
w
ei
gh
t 
M
en
en
gi
tis
 
Pe
rt
us
si
s G
lo
ba
l c
hi
ld
ho
od
 m
or
ta
lit
y 
ra
te
s 
Disease causes 
2004 
2008 
3 
 
As can be seen in the data published by the WHO (2008b) and estimations by Black et al. 
(2010) there has been a sharp decrease in mortality due to measles, but diarrhoeal diseases, 
acute respiratory infections especially pneumonia, and neonatal-related deaths are still the 
most common causes of mortality in children younger than five years of age. 
 
As can be observed in Figure 1.3, the distribution of the causes of death among young 
children shows significant geographical variations as to incidence of disease (WHO 2008b).  
This indicates the highest mortality rates observed in young children to be associated with the 
African and South East Asian regions.     
 
 
Figure 1.3 Distribution of selected causes of childhood deaths within specific WHO 
regions, 2004 (WHO 2008b). 
 
1.1.2 Diarrhoeal disease 
Acute gastrointestinal infection, or gastroenteritis, is generally associated with the occurrence 
of diarrhoea presenting as three or more loose stools within 24 hours and/or vomiting.  
Diarrhoeal disease is linked to a high morbidity rate, as during the first five years of life 
almost all children will contract more than one diarrhoeal disease per year (Basu et al. 2003).  
Rosenberg (2007) indicated that children in developing countries have, on average, 3.2 
diarrhoeal episodes per year, and Sherchand et al. (2012) indicated that on average a child 
will experience between 10 and 15 episodes of diarrhoea during their first five years of life.  
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Diarrhoeal disease can therefore be associated with an increased emotional and financial 
burden on the family and caregivers of children ill with diarrhoea.   
 
In 2008 the WHO estimated that more than 85% of all deaths associated with diarrhoeal 
disease occur in the lower income countries of Africa and Asia (WHO 2009a).  Elliot (2007) 
estimated that diarrhoeal disease is responsible for approximately 3.5 billion cases of acute 
gastroenteritis globally and approximately 2 million deaths in children under the age of five 
years.  The WHO and the World Bank estimated that diarrhoeal disease is responsible for a 
mortality rate of 25 to 30% in children younger than five years of age living in developing 
countries (Basu et al. 2003).  A meta-analysis, of 131 studies, by Tate et al. (2012) showed a 
decrease in diarrhoeal related deaths from 1.8 million deaths in 2003 to 1.3 million deaths in 
2008, of which 1.24 million of 1.3 million deaths were observed in children younger than five 
years of age.  Black et al. (2010) indicated that of the approximate 1.3 million deaths in 2008, 
19% occurred in Africa, 18% in the Eastern Mediterranean region, 14% in Southeast Asia, 
7% in the Americas, 5% in Europe and 4% in the Western Pacific region.    
 
In South Africa, the South African Health Review of 2006 indicated that diarrhoeal disease 
was responsible for approximately 10.2% of the deaths in children aged younger than five 
years in 2000 (King 2006; Seheri et al. 2010a); and Murray et al. (2008) classified diarrhoeal 
disease as one of the top three causes of mortality in children younger than one year of age.   
 
1.1.3 Sources of diarrhoeal disease 
Diarrhoeal diseases are associated with various agents, including microorganisms and toxins.  
Acute viral gastroenteritis, however, occurs at a higher incidence compared to bacterial and 
parasitic gastroenteritis, responsible for higher morbidity and mortality among children in 
developing countries (Logan et al. 2006; Elliot 2007; Ospino et al. 2008).   
 
Bacterial agents, protozoa and helminths: 
Bacterial gastroenteritis in children generally presents with high fevers and the presence of 
blood and white blood cells and, in some cases, mucous in the stool samples (Webb and Starr 
2005; Elliot 2007).  It may be transmitted by person-to-person contact, by the ingestion of 
undercooked and/or inappropriately stored foods (Webb and Starr 2005) and/or contaminated 
water sources (Elliot 2007).  Various bacterial agents are responsible for acute gastroenteritis 
and the most common bacteria include Campylobacter jejuni, Salmonella typhi, Salmonella 
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parathypi, Non-typhoid Salmonella species, Escherichia coli, Shigella species, Yersinia 
enterocolitica and Vibrio cholerae (Elliot 2007).   
 
The most important protozoa associated with gastroenteritis include Cryptosporidium 
parvum, Giardia lamblia, Entamoeba histolytica (Webb and Starr 2005; Elliot 2007; 
Sherchand et al. 2012), and Cyclospora cayetanesis (Sherchand et al. 2012), with Giardia 
lamblia being identified as the most common cause of protozoan-associated gastroenteritis 
(Webb and Starr 2005).  Protozoan-associated gastroenteritis clinically presents as fever, 
bloody diarrhoea, a constant need to pass stools and abdominal pain (Rosenberg 2007). 
 
Helminths generally associated with gastroenteritis include Strongyloides stercoralis (Elliot 
2007), Ascaris lumbricoides and Trichuris trichiura (Rosenberg 2007).  The large parasites 
infecting the intestinal tract can lead to obstructions and thereby cause chronic malabsorption 
of nutrients which results in a decrease in appetite and food intake.  Hookworms have also 
been associated with significant protein losses in infected patients (Rosenberg 2007). 
 
Viral Gastroenteritis: 
Various viruses are associated with gastroenteritis including astrovirus, adenovirus, 
calicivirus, coronavirus, enterovirus, norovirus, pestivirus, picobirnavirus, rotavirus and 
torovirus (Wilhelmi et al. 2003; Elliot 2007; Ospino et al. 2008), and more recently 
picornavirus (Knox et al. 2012).  It is estimated that more than 75% of all gastroenteritis 
cases are caused by viruses (Sherchand et al. 2012).   
 
Globally, rotaviruses have been identified as the most common cause of severe diarrhoea in 
children younger than five years of age (Bernstein et al. 1998; Bernstein et al. 1999; 
Arguelles et al. 2000; Barnes et al. 2002; Bernstein et al. 2002), accounting for more than 
70% of all serious diarrhoeal cases (Adler et al. 2005).  The WHO estimated in 2008 that 
rotavirus infections are responsible for an average of 527 000 (range of 475 000 – 580 000) 
deaths annually (WHO 2006; Parashar et al. 2009; WHO 2008a; WHO 2009c; Todd et al. 
2010), however more recent data showed a decrease in the mortality to 453 000 (range of 
420 000 – 494 000) (Babji and Kang 2012; Fu et al. 2012; Matthijnssens and van Ranst 2012; 
Tate et al. 2012), and, thereby, an association with 37% of the total deaths due to diarrhoea 
(Babji and Kang 2012).  The WHO (2006) also estimated that more than 90% of these annual 
deaths occur in developing countries, and it is estimated that between 140 000 and 230 000 of 
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the annual deaths due to rotavirus infections occur in sub-Saharan Africa (Page 2006; Van 
Zyl et al. 2006; Steele et al. 2008; Aminu et al. 2010; Madhi et al. 2010).  The WHO, in 
2004, indicated that of the 13 countries globally showing the highest mortality in children 
younger than five years of age who die due to rotavirus infections, 12 of these countries can 
be found in Africa (Neuzil et al. 2010).  Tate et al. (2012) reported the highest number of 
deaths associated with rotaviruses is observed in Africa and Asia.  Sanchez-Padilla et al. 
(2009) calculated that infection with rotavirus is responsible for ~323 deaths annually in 
South Africa.  The annual mortality rate calculated by Sanchez-Padilla et al. (2009) 
corresponds with the mortality rate reported by the WHO in 2004 of 224-318 deaths.  The 
death rate in South Africa represents 0.4% of all deaths associated with rotavirus infections 
(Neuzil et al. 2010). 
 
The morbidity rate of rotavirus infections is similar in developing and developed countries.  
However, the severity and mortality of the disease is higher in developing countries (Audu et 
al. 2002a; Perez-Schael et al. 2009).  Virtually all children will be infected by rotavirus at 
least once before the age of five (Woods et al. 1992; WHO 2002; Page 2006; Ramani et al. 
2007; Rosenberg 2007; van Damme et al. 2007a; Chouikha et al. 2009; Ciarlet and Schödel 
2009; Hauber et al. 2011), and many children will also be infected more than once during this 
time period (van Damme et al. 2007a).  In South Africa, rotavirus has been identified as a 
significant cause of both sporadic and epidemic gastroenteritis in infants (Van Zyl et al. 
2006).      
 
In 2009, the WHO recommended that a rotavirus vaccine for infants should be included as 
part of the national immunisation programmes.  Various studies have indicated that natural 
infections leads to children experiencing less severe re-infections and, therefore, it is 
expected that vaccines would mimic the protection as seen during natural infections 
(Velazquez et al. 1996; Perez-Vargas et al. 2006; Vesikari et al. 2006).  The reduction in the 
mortality of children younger than five years of age due to rotavirus-associated diarrhoea, 
527 000 in 2008 compared to 453 000 in 2012, can, therefore, be associated with the 
successful implementations of child survival interventions such as vaccinations, and changes 
in socioeconomic development, as suggested by Black et al. (2010). 
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1.2 Research Formulation 
The WHO “Generic protocols for (i) hospital-based surveillance to estimate the burden of 
rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of 
health care services for gastroenteritis in children” (WHO 2002) listed the objectives for 
rotavirus surveillance to include the following:  
• the determination of the age and seasonal distribution of rotavirus infections in 
children younger than five years of age;  
• the estimation of the proportion of rotavirus associated diarrhoea, and  
• the identification of the prevalent strains in the population within the study area/areas.  
 
The WHO recommends the main objective for the development of a surveillance system to 
include the collection of data, determining the disease and epidemiological burden of 
rotavirus infections within specific geographical areas, to facilitate and support the 
introduction of rotavirus vaccines (WHO 2002).  As South Africa has introduced rotavirus 
vaccination as part of prescribed immunization schedules, the same data can be used to 
evaluate the potential effectiveness of a rotavirus vaccine following its introduction. 
 
The research problem / aim investigated in this research project can be summarised as: 
To investigate rotavirus infections and the molecular epidemiology of rotavirus infections for 
2010 and 2011 in Gauteng and selected areas within the North West and Limpopo provinces, 
and to evaluate the potential impact of the introduction of vaccines on the spread of rotavirus 
disease.  
 
The main objectives of the research project included: 
• a surveillance study of rotavirus infections for the 2010 and 2011 seasons in Gauteng 
and selected areas within the North West and Limpopo provinces 
• a study on the geographical distribution of rotavirus strains within the study area 
• a study on the molecular epidemiology of samples collected from Middelburg, 
Rustenburg and Trichardt 
• determining the potential impact and expected effectiveness of the introduction of 
rotavirus vaccines within the study area 
• an evaluation on the effectiveness of the test-strips used by the Private Pathology 
Practice during routine testing in the identification of rotavirus positive samples.  
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1.2.1 Study Objective One 
Study objective one focused on the evaluation of rotavirus infections during the 2010 and 
2011 seasons in selected areas within Gauteng, the North West and Limpopo provinces. 
 
Sub-objectives: 
• Determination of the seasonality of rotavirus infections during the 2010 and 2011 
seasons, 
• A determination of the gender and age of children infected with rotavirus,  
• Comparison on the findings on seasonality, age and gender occurrence with findings in 
studies conducted locally and internationally, 
• A comparative study on the geographical distribution of rotavirus strains within the study 
towns. 
 
Motivation: 
Continuous evaluation of the incidence of rotavirus disease plays an important role in 
identifying trends and changes in trends observed in rotavirus infections.   
 
1.2.2 Study Objective Two 
Study objective two focused on the evaluation of the effectiveness of the test-strips used by 
Pathology Practices during the routine testing for rotaviruses in samples analysed. 
 
Motivation: 
As a follow-up to an evaluation previously performed by Dewar et al. (2005), results from 
enzyme immunoassay (EIA) analysis were compared with the results of screening stool 
samples using rapid test strips.  These rapid tests are routinely used by the Private Pathology 
Practice to detect the presence of rotaviruses in the samples.  It should also be noted that the 
Practice generously supplied their gastroenteritis stool samples for further evaluation by EIA 
so as to determine the effectiveness of the rapid test strips. 
 
1.2.3 Study Objective Three 
Study objective three focused on the molecular characterization of rotavirus strains present 
during the 2010 and 2011 seasons in Middelburg, Rustenburg and Trichardt. 
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Sub-objectives: 
• Determining the predominant strain/strains during the 2010 and 2011 seasons in 
Middelburg, Rustenburg and Trichardt, through genotyping using reverse-transcription 
polymerase chain reaction (RT-PCR) analysis, 
• Determining the electropherotypes present during the 2010 and 2011 seasons in 
Middelburg, Rustenburg and Trichardt, using polyacrylamide gel electrophoresis 
(PAGE), 
• Characterisation of the genetic diversity of rotavirus strains, 
• Evaluating the potential impact of the relatively recent introduction of rotavirus vaccines 
by profiling the circulating strains and comparing these to historical strain data. 
 
Motivation: 
As data from rotavirus vaccine trials have indicated the effectiveness of the vaccines against 
certain strains of rotavirus, information on the strains circulating within the study areas 
contributes towards determining the effectiveness of introduced rotavirus vaccines.  There are 
currently two rotavirus vaccines available in South Africa.  This research project serves to 
motivate the vaccination of children against rotavirus by comparing data gathered in the 
communities surveyed for rotavirus gastroenteritis and by comparing this data to the potential 
impact of vaccine introduction as seen in vaccine effectiveness literature.   
 
Gathering information on the strains circulating within the study area therefore act as a basis 
to determine if the rotavirus vaccines developed and available in South Africa will be 
effective within the study areas.  This may be determined by comparing study results against 
the strains for which the vaccines have been created, particularly the Rotarix(TM) vaccine that 
is an attenuated G1P[8] strain.  The effectiveness of current rotavirus vaccines against novel 
strains are not well known and, therefore, information on the emergence of new or previously 
uncommon strains is important for vaccine studies.   
 
Identification of different electropherotypes of rotaviruses was included in the study in 
characterising the genomic diversity of rotaviruses responsible for infections in the 
communities within the study area. 
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In conclusion, scientific results and answers as to these objectives were used to discuss the 
original research problem.  The study was used to determine the incidence of rotavirus 
infections during the 2010 and 2011 seasons in Gauteng and selected areas within the North 
West and Limpopo provinces in stool samples received from a Private Pathology Practice in 
Pretoria, i.e. determining, evaluating and monitoring rotavirus infection trends with regard to 
seasonality, as well as age- and gender-specific incidence rates.  The project evaluated these 
trends in rotavirus infections to compare similarities and identify any changes in current 
trends observed in South Africa and internationally.  The data obtained from the study 
assisted in identifying the prevalent strains during the study period in Rustenburg, 
Middelburg and Trichardt.  The effectiveness of rapid tests strips currently used by 
commercial diagnostic practices was evaluated for sensitivity and specificity regarding 
rotavirus detection and formed the basis for a follow-up evaluation on an article published on 
the effectiveness of the rapid these test-strips in the analysis of rotaviruses in samples, by 
comparison against the gold standard ProsPect EIA test.  Rotavirus vaccines have only 
recently been introduced to South Africa and the study was used to gather information on the 
prevalent strains responsible for gastroenteritis and to evaluate the potential effectiveness of 
these vaccines within the areas included in the study.  Information gathered can also be used 
in future studies within other communities to gain greater knowledge on the burden of 
rotavirus disease, the prevalent strains responsible for illness and the potential impact of 
rotavirus vaccines in specific communities.   
 
Knowledge of strains circulating in countries and areas contribute towards the success of 
vaccines; therefore, there is a continuous need to identify the strains responsible for rotavirus 
infections.  A literature review was conducted as to the genetic characterisation, 
classification, clinical characteristics and pathogenesis, the burden of infections (globally, in 
Africa and in South Africa), the epidemiology, methods of detection, methods of control and 
vaccination regarding rotavirus infection.  This was performed so as to gather information on 
the current status of rotavirus infection and vaccines. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
Rotaviruses, part of the Reoviridae family, were first observed in 1963 during electron 
microscopic examination of stool samples collected from monkeys and mice (Carter and 
Saunders 2007).  In 1973, rotaviruses were identified in the stool samples collected from 
children suffering from diarrhoea (Bishop et al. 1973; White and Fenner 1994; Lundgren and 
Svensson 2001; Jiang et al. 2002; Desselberger et al. 2005; Carter and Saunders 2007), and 
was also observed using electron microscopy of the duodenal mucosa of children suffering 
from acute diarrhoea (White and Fenner 1994; Murray et al. 2005).   
 
2.1 Genetic characteristics and structure of Rotaviruses 
Morphological and biochemical characteristics shared by rotaviruses include the following: 
the mature virus particles are non-enveloped and have a multi-layered icosahedral protein 
capsid; the virus is encapsulated in a three-layered capsid; the genome is made up of 11 
fragments of double stranded ribonucleic acid (dsRNA); the particles contain RNA-
dependant RNA polymerases and other enzymes that synthesise capped RNA transcripts, 
and; genetic reassortment between rotaviruses can occur (Estes and Cohen 1989). 
 
Rotaviruses are non-enveloped, viruses, approximately 75 – 100 nm in diameter with a 
wheel-like appearance (Estes and Cohen 1989; WHO 2002; Dey et al. 2009; van Doorn et al. 
2009; Kargar et al. 2011).   
 
The 11 fragments of the dsRNA encode six structural or viral proteins (VP), VP1 – VP4, VP6 
and VP7; and six non-structural proteins (NSP), NSP1 – NSP6.  Each segment encodes one 
protein except for one segment which encodes two proteins (Jayaram et al. 2004; 
Desselberger et al. 2005; Carter and Saunders 2007; Farkas and Jiang 2007; Mascarenhas et 
al. 2007; Lin et al. 2008; Moe et al. 2009; Esona et al. 2010; Kargar et al. 2011), as seen in 
Figure 2.1, where fragment 11 is seen to encode NSP5 and NSP6.  The total rotavirus 
genome has a size of  ~18 500 base pairs (bp) and the fragments range in size from ~660 bp 
(segment 11) to ~3300 bp (segment 1) (Estes and Cohen 1989; Arias et al. 2004; Farkas and 
Jiang 2007).  Table 2.1 summarises the size of each rotavirus RNA fragment and associated 
protein.  The functions of the encoded proteins will be discussed in sections 2.1.1 to 2.1.5. 
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Table 2.1 Genes and associated proteins of the Group A rotavirus.  (Adapted from 
Jayaram et al. 2004; Desselberger et al. 2005). 
RNA fragment  Fragment size (in bp) Associated protein 
1 3302 VP1 
2 2690 VP2 
3 2591 VP3 
4 2362 VP4 
5 1611 NSP1 
6 1356 VP6 
7 1059 NSP2 
8 1104 NSP3 
9 1062 VP7 
10 751 NSP4 
11 667 NSP5 and NSP6 
  
 
 
Figure 2.1 Location of rotavirus proteins, virion schematic and the 3D reconstruction of a 
SA11 virion (Figure supplied by Eric Mossel, Mary Estes and Frank Ramig, from 
http://www.reoviridae.org/dsRNA_virus_proteins/rotavirus%20figure.htm [Accessed 16 Oct. 
2012]). 
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Rotavirus particles are encapsulated within a three layered capsid, the inner layer consisting 
of VP1, VP2, VP3, the middle layer consisting of VP6 proteins, while the outer capsid 
consists of VP7 with VP4 forming the spikes on the virus surface (Percival et al. 2004; Carter 
and Saunders 2007; WHO 2009b).     
 
2.1.1 The innermost capsid layer and core 
The innermost layer and core consists of three structural proteins, VP1, VP2 and VP3 
(Desselberger et al. 2005), and is formed by 12 copies of VP1, 120 copies of VP2 
surrounding the genome, and 12 copies of VP3 (Arias et al. 2004).  The VP1 and VP3 
proteins are anchored to the interior side of the VP2 protein (Trask et al. 2012) forming the 
core of the virus. 
 
VP2: 
The innermost capsid layer consists of the VP2 protein.  The outer surface of this protein 
interacts with the inner surface of the VP6 layer and on its inside, with the genomic RNA 
(Jayaram et al. 2004).  The VP2 protein is a comma-shaped, plate-like protein, in which the 
11 dsRNA fragments are packed (Trask et al. 2012).  The VP2 protein has been identified as 
a transcriptase component (Murray et al. 2005) and is required as part of the replicase activity 
of VP1 (Desselberger et al. 2005). 
 
VP1: 
The VP1 protein is a RNA-dependant RNA polymerase (Arias et al. 2004; Jayaram et al. 
2004; Desselberger et al. 2005; Murray et al. 2005; Greenberg and Estes 2009; Trask et al. 
2012) and provides enzymatic functions required by the cell to produce the capped mRNA 
transcripts (Jayaram et al. 2004).  This protein is roughly globular with the large central 
cavity acting as the active site for RNA polymerisation (Trask et al. 2012).   
 
VP3: 
The VP3 protein is a guanylyl-transferase and methylase (Arias et al. 2004; Jayaram et al. 
2004). The VP3 protein, together with the VP1 protein, provides enzymatic functions 
required by the cell to produce the capped mRNA transcripts (Jayaram et al. 2004) and plays 
a role in messenger RNA (mRNA) capping (Murray et al. 2005; Greenberg and Estes 2009; 
Trask et al. 2012).   
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2.1.2 Intermediate layer (VP6) 
Double-layered particles are formed by the 260 trimers of VP6 stacked on top of the VP2 
layer of the virus (Arias et al. 2004; Trask et al. 2012).  The VP6 protein makes up 50% of 
the virus (Donelli and Superti 1994) and is, thus, the most abundant protein in the virus.  It is 
the target protein for performing antigen detection assays e.g. EIA (WHO 2002).  The 
functions of VP6 includes binding to NSP4 at the endoplasmic reticulum thereby promoting 
the assembly of the outer capsid (Murray et al. 2005) and is also involved in the endogenous 
transcription of the rotavirus genome (Jayaram et al. 2004).  The VP6 protein also functions 
as the adaptor site for the VP4 and VP7 proteins that mediate the entry of the virus into the 
host cell (Trask et al. 2012).     
 
2.1.3 Outer capsid 
The outer layer of the viral capsid is made up of the structural proteins VP4 and VP7, and 
consists of 780 copies of glycoprotein VP7 and 120 copies of protein VP4 (Pando et al. 
2002).     
 
The VP4 and VP7 protein layers are involved in the initial contact with the host cell (Pando 
et al. 2002).  In addition to playing a role in this cellular attachment of the virus, structural 
proteins VP4 and VP7 are involved in hemagglutination (Armah et al. 2001; Armah et al. 
2003; Jayaram et al. 2004), and in delivering transcriptionally active double-layered particles 
to the host cytoplasm, as these proteins are shed during the initial entry of the virus into the 
cell (Jayaram et al. 2004; Trask et al. 2012).  Importantly, VP7 and VP4 are also the primary 
targets of neutralizing antibodies (Estes and Cohen 1989; Steele et al. 1995; Mphahlele et al. 
1999; Iturriza-Gomara et al. 2000a; Pager et al. 2000; Armah et al. 2001; Honma et al. 2007; 
Greenberg and Estes 2009; McCormack and Keam 2009; Sanchez-Padilla et al. 2009; 
AnnaRita et al. 2010; Seheri et al. 2010b).  Early research conducted by Hoshino et al. (1985) 
and Offit et al. (1986a) originally indicated VP3 and VP7 as exhibiting neutralizing activity, 
as fragments 4 and 9 segregated with serotype specific neutralization phenotypes (Offit et al. 
1986a).  Segment 4 was associated with VP3 in early research (Offit et al. 1986a, Offit et al. 
1986b). 
 
VP4: 
The VP4 protein plays an important role in the life cycle of the virus, in receptor binding and 
in cell penetration (Estes and Cohen 1989; Pando et al. 2002; Arias et al. 2004; Jayaram et al. 
15 
 
2004; Desselberger et al. 2005; Murray et al. 2005; Trask et al. 2012).  The VP4 protein is 
cleaved into VP5* and VP8* proteins by proteolytic enzymes (Pando et al. 2002; Jayaram et 
al. 2004; Mascarenhas et al. 2007).  These two fragments remain non-covalently associated 
after cleaving (Trask et al. 2012).  The cleavage involves the proteolytic enzyme, trypsin, and 
enhances rotavirus infectivity (Estes and Cohen 1989; Donelli and Superti 1994; Pando et al. 
2002).  Following comparison of sequences of different strains of P genotypes, the VP8* 
protein was shown to contain a hyperdivergent region between nucleotides 205 and 554 
(Mphahlele et al. 1999) and the VP8* subunit contains the major antigenic site responsible 
for the neutralisation of VP4 (Pager et al. 2000). 
 
VP7: 
The VP7 protein is encoded by gene 7, 8 or 9, depending on the strain (Estes and Cohen 
1989; Steele et al. 1995; Mphahlele et al. 1999; Asmah et al. 2001; Armah et al. 2003; Laird 
et al. 2003; Lin et al. 2008; Chouikha et al. 2009; van Doorn et al. 2009; Esona et al. 2010).  
The VP7 protein plays an important role in the calcium-driven uncoating of the virus and 
results in transcriptionally competent double-layered particles required for virus replication 
(Jayaram et al. 2004).  The VP7 protein coats the surface of the virus and acts as lock the 
VP4 protein to the surface, locking of the VP4 spike is possible as the VP7 protein partly 
covers the base of the spike (Trask et al. 2012).   
 
2.1.4 NSP4 
The non-structural protein, NSP4, is a transmembrane, endoplasmic reticulum-specified 
glycoprotein (Lundgren and Svensson 2001; Huang et al. 2004; van Doorn et al. 2009), 
which is encoded by gene 10 (Mascarenhas et al. 2007; Lin et al. 2008).  The NSP4 protein 
has been identified as a viral enterotoxin (Lundgren and Svensson 2001; Huang et al. 2004; 
Desselberger et al. 2005; Farkas and Jiang 2007; Greenberg and Estes 2009; Tate et al. 2010).  
Lundgren and Svensson (2001) and Desselberger et al. (2005) indicated that NSP4 plays a 
role in increasing intracellular calcium levels by mobilising calcium from the endoplasmic 
reticulum.  Lundgren and Svensson (2001) also indicated that NSP4 plays a role in the 
destabilisation of the plasma membrane and the subsequent permeability leads to leakage of 
e.g. lactate dehydrogenase (LDH) from cells.  The NSP4 protein also plays an important role 
during the maturation process by functioning as an intracellular receptor at the endoplasmic 
reticulum (Huang et al. 2004). 
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2.1.5 Other non-structural proteins 
The non-structural proteins NSP1, NSP2, NSP3 and NSP5 play a role in RNA binding 
(Desselberger et al. 2005; Murray et al. 2005).   
 
The NSP1 protein has also been identified as an interferon antagonist (Greenberg and Estes 
2009; Hu et al. 2012) as this protein counters the antiviral response of the host and suppresses 
the induction of apoptosis during early stages of the infection, thereby promoting viral growth 
(Hu et al. 2012).   
 
The NSP2 protein might play a role in the formation of viroplasms (Greenberg and Estes 
2009; Hu et al. 2012) and in replication and packaging of the genome (Jayaram et al. 2004; 
Hu et al. 2012).   
 
The NSP3 plays a role in disrupting the translation machinery, thereby enhancing the 
translation of virally encoded mRNA, and also plays a role in the systemic spread of the virus 
(Greenberg and Estes 2009; Hu et al. 2012).  The NSP3 protein also suppresses host protein 
synthesis (Hu et al. 2012). 
 
The NSP5 protein acts as a calcium binding protein and this protein might play a role in the 
formation of viroplasms (Greenberg and Estes 2009; Hu et al. 2012) and in replication and 
packaging of the genome (Jayaram et al. 2004). 
 
The NSP6 protein might play a role in the formation of viroplasms (Greenberg and Estes 
2009; Hu et al. 2012).  This protein is not encoded by all rotavirus strains (Hu et al. 2012). 
 
2.2 Rotavirus Classification 
Rotaviruses can be classified into groups and subgroups, based on the reactivity of antibodies 
to VP6 and into serotypes and/or genotypes based on the two outer capsid proteins, VP4 and 
VP7.   
 
Traditionally, rotavirus classification was based on the clinical, morphological and 
serological characteristics of the virus (Matthijnssens et al. 2012).  In 2008 a rotavirus group 
A classification system involving all 11 gene fragments was introduced by the Rotavirus 
Classification Working Group (RCWG), whose report reflected the findings of next 
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generation sequencing methods (Matthijnssens and van Ranst 2012).  The schematic 
nomenclature proposed to include the complete genetic structure of the virus is GX-P[X]-IX-
RX-CX-MX-AX-NX-TX-EX-HX (X – Arabic numbers starting from 1) representing the different 
structural and non-structural proteins; VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-
NSP4-NSP5/6, and based on the nucleotide sequence of complete open reading frames 
(Matthijnssens et al. 2008). 
 
2.2.1 Group classification 
The major protein in the central layer of the capsid, VP6, determines the eight serogroups of 
rotavirus, thereby classifying rotaviruses into Groups A – E, two tentative groups, F and G, 
and a newly renamed group, group H, previously ADRV-N (Matthijnssens et al. 2012; 
Kindler et al. 2012).  The groups or species, can be differentiated into the different 
serological defined species and can be done by using indirect immunofluorescence 
techniques, the antisera used during these methods are directed against the VP6 protein 
(Matthijnssens et al. 2012).  Rotaviruses within Groups A – C have been identified as causing 
infections in humans (Estes and Cohen 1989; Donelli and Superti 1994; White and Fenner 
1994; Lundgren and Svensson 2001; Mwenda et al. 2003; Percival et al. 2004; Murray et al. 
2005; Barman et al. 2006; Logan et al. 2006; Perez-Vargas et al. 2006; Farkas and Jiang 
2007; van Damme et al. 2007b; Heymann 2008; Dey et al. 2009; Sanchez-Padilla et al. 2009; 
Atchison et al. 2010).   
 
Group A rotaviruses can be subdivided into subgroups including I, II, I+II, non-I and non-II 
(Laird et al. 2003; Desselberger et al. 2005; Lin et al. 2008; Esona et al. 2009; Khamrin et al. 
2009; van Doorn et al. 2009; Aminu et al. 2010; Matthijnssens et al. 2008).  Classification of 
rotaviruses into groups is based on the presence of specific epitopes of the VP6 protein 
(Greenberg et al. 1983; Hasing et al. 2009) and Lin et al. (2008) mapped amino acid positions 
296-299 to subgroup I and position 315 to subgroup II.   Rotaviruses can be divided into two 
genogroups, genogroup I, which include subgroup I and genogroup II that includes subgroup 
II, subgroup I+II and subgroup non-I and non-II (Lin et al. 2008; Matthijnssens et al. 2008). 
 
2.2.2 Rotavirus dsRNA electropherotypes 
Rotaviruses can be classified according to electropherotypes where the 11 dsRNA fragments 
can be categorised into long or short RNA patterns following separation of the dsRNA by 
electrophoresis (Chouikha et al. 2009; Cunliffe et al. 2009; Page et al. 2009; Aminu et al. 
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2010).  Donelli and Superti (1994) and Page et al. (2009) indicated that a super short 
electropherotype could also be observed.  The observation of various electropherotypes is 
based on the mobility of the last fragment, fragment 11, as seen in Figure 2.2.   
 
 
Figure 2.2 Examples of a Short and Long electropherotype migration pattern 
 
Polyacrylamide gel electrophoresis (PAGE) and gel staining of rotavirus gene fragments 
produce an electropherotype migration pattern characteristic of rotaviruses (Herring et al. 
1982; Laird et al. 2003).  The human Group A rotavirus electropherotype consists of a pattern 
of gene fragments grouped as four large fragments, followed by two fragments, three 
fragments and two small fragments (Dzikwi et al. 2008; Chouikha et al. 2009; Potgieter et al. 
2010).  The Group C rotavirus electropherotype consists of a pattern of fragments grouped in 
a four, three, two, two configuration (Mwenda et al. 2003).   
 
2.2.3 Rotavirus genotypes and serotypes 
Rotavirus strains can be classified into serotypes (the viruses are classified based on their 
surface antigens) and genotypes (the viruses are classified based on their genetic 
constitution).  Classification of rotaviruses is based on the two outer capsid proteins, the 
glycoprotein VP7 (G-types) and the protease-sensitive protein VP4 (P-types).  As indicated, 
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these proteins are the targets of neutralising antibodies that are produced following natural 
rotavirus infection (Estes and Cohen 1989; Steele et al. 1995; Mphahlele et al. 1999; 
Arguelles et al. 2000; Iturriza-Gomara et al. 2000a; Pager et al. 2000; Armah et al. 2001; 
Honma et al. 2007; Greenberg and Estes 2009; McCormack and Keam 2009; Sanchez-Padilla 
et al. 2009; AnnaRita et al. 2010; Seheri et al. 2010b; Matthijnssens et al. 2008).  Hoshino et 
al. (1985) originally suggested a dual classification system by identifying both of the 
neutralization proteins, as these proteins segregate independently.  The serotypes and 
genotypes for G-types are generally the same and, therefore, G-types are generally referred to 
only according to their serotypes.  For P-types, there is a contrast in nomenclature for 
genotypes and serotypes and P-types are, therefore, generally referred to by their genotype 
with the genotype number denoted in brackets (van Damme et al. 2007b; Greenberg and 
Estes 2009; AnnaRita et al. 2010).  As the VP4 and VP7 genes segregate independently, there 
is, therefore, a need to have a dual typing system that is able to characterise the strains of 
rotavirus circulating in an area during a specific time of year (Chouikha et al. 2009; 
Matthijnssens and van Ranst 2012).   
 
To date VP7 types found infecting humans include G1 – G4, G8 - G10 and G12; and VP4 
types P[4], P[6], P[8] - P[11] (Aladin et al. 2010).  However, some of these types have only 
been identified in specific areas of the world (Ciarlet and Schödel 2009; AnnaRita et al. 
2010).   
 
The most important VP7 serotypes identified to date include G1 - G4, with the G1 strain 
being the strain that is most often detected (Woods et al. 1992; Steele et al. 1995; Trabelsi et 
al. 2000; Audu et al. 2002a; Damme et al. 2007a; Kargar et al. 2011).  Desselberger et al. 
(2005) estimated that approximately 95% of circulating strains of rotavirus could be 
classified as types of G1 - G4.  Linhares et al. (2006) indicated a difference in circulating 
strains in specific regions, with G1 – G4 being responsible for 90 – 95% of the rotavirus 
cases diagnosed in Europe, North America and Australia but for only 68% of cases in South 
America and Asia, and only 50% of cases in Africa.  In South Africa, the G2 strain has been 
observed to follow a cyclical pattern (Todd et al. 2010).   
 
The G9 strain was first identified as an infectious strain in humans in 1983 in the United 
States (Iturriza-Gomara et al. 2000a; Laird et al. 2003) and more recently G9 strains have 
also been identified as being important infectious agents (Audu et al. 2002a; Laird et al. 
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2003; Steele and Ivanoff 2003; Desselberger et al. 2005; Linhares et al. 2006; van Zyl et al. 
2006; van Damme et al. 2007a; Chouikha et al. 2009; Dey et al. 2009; Hasing et al. 2009; 
AnnaRita et al. 2010; Kargar et al. 2011), accounting for approximately 4.1% of infections 
(O’Ryan 2009).  A wide variety of G9 strains has been observed, including strains associated 
with both long and short electropherotypes, suggesting that the G9 strain may show an 
unusual ability to genetically reassort (Laird et al. 2003).   
 
Other rotavirus G-types identified as emerging across the globe as important infectious agents 
include G5, G8 and G12 (Iturriza-Gomara et al. 2000a; Barnes et al. 2002; WHO 2002; 
Gurgel et al. 2008; AnnaRita et al. 2010; Kargar et al. 2011).  The G5 strain was first 
identified as circulating in Brazil during 1982 and has since been identified as a commonly 
circulating strain there (Santos and Hoshino 2005), this strain has rarely been observed 
outside South America (O’Ryan 2009).  The G8 strain was previously identified as an 
important strain responsible for infections in animals with only sporadic observations in 
humans (Todd et al. 2010).  It has been suggested that the G8 strain could have originated 
from the G3 strain, as a high cross-reactivity has previously been observed between the G3 
and G8 strains when performing RT-PCR analysis (Potgieter et al. 2010).  The G8 strain was 
first identified in Indonesia (Esona et al. 2009), and in Africa it was first identified in Nigeria 
(Todd et al. 2010).  This strain has been identified as increasingly being associated with 
diarrhoea in Africa (13%) but has rarely been reported elsewhere (O’Ryan 2009).  A review 
study conducted by Todd et al. (2010) indicated a notable increase in the G8 strain in African 
countries.  In addition, a Pan African study conducted by Mwenda et al. (2010) noted that the 
G8 strain appeared in certain countries only.  During the 1997 and 1998 rotavirus season in 
Malawi, the G8 strain was identified as a predominant strain (Todd et al. 2010).  The G12 
strain was first identified in 1987 in the Philippines and between 1998 and 1999, sporadic 
detection of this strain was again observed in Thailand, Argentina and the United States of 
America (Page et al. 2009).  By 2007, serotype G12 had been identified as an emerging strain 
in countries including India, Japan and Korea (Ramani et al. 2007), between 2003 and 2005, 
G12 was identified as being responsible for an increasing number of infections in eastern 
India (Samajdar et al. 2006).  Ramani et al. (2007) identified the G12 strain as being 
responsible for severe symptomatic diarrhoea in children older than two years of age.  To 
date, the G12 strain has also been detected in samples from South America, Europe, Australia 
and South Africa (Gurgel et al. 2008; Page et al. 2009).  In a study in Nepal, high incidences 
of the G12 strain was observed during the 2004 to 2005 season with 23% (Pun et al. 2007), 
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the 2005 to 2006 and 2006 to 2007 seasons, associated with 50% and 29% of infections 
respectively (Sherchand et al. 2009).  
 
Additional G-types identified in human patients include G6 and G10, but these appear to be 
limited to specific regions.  G6 was identified in samples from Italy and Australia; and G10 
in Brazil, Paraguay and India (Page et al. 2009).  The G15 strain has also been identified in as 
responsible for human rotavirus gastroenteritis (Gurgel et al. 2008). 
 
The most important VP4 genotypes include P[8], P[4] and P[6] (Trabelsi et al. 2000; Dey et 
al. 2009; Hasing et al. 2009).  Pietruchinski et al. (2006) reported the P[8] genotype as being 
associated with more than 90% of infections globally.  Globally, the P[6] genotype has 
generally been associated with the shedding of rotavirus in neonates (Bos and Steele 1995; 
Steele et al. 1995; Trabelsi et al. 2000; Steele et al. 2002) as well as in young children 
(Mascarenhas et al. 2007), however studies have indicated that the P[6] strain was becoming 
more commonly observed globally (Potgieter et al. 2010), and results from a review by Todd 
et al. (2010) showed P[6] being associated with more than 25% of infections in Africa.  The 
P[10] strain has to date only rarely been identified in humans (Khamrin et al. 2009). 
 
The P[8] genotype is most often associated with serotypes G1, G3 and G4 and the genotype 
P[4] is generally associated with G2 whereas the P[6] genotype is associated with all four 
serotypes (Bos and Steele 1995; Steele et al. 1995; Trabelsi et al. 2000; WHO 2002; Esona et 
al. 2010).  The P[8] and P[6] genotypes are also associated with G9 (Linhares et al. 2006).  
Ramani et al. (2007) reported that various P genotypes are associated with G12 including 
P[4], P[6], P[8] and P[9].  Todd et al. (2010) reported the P genotypes associated with G8 to 
include P[4], P[6], and P[14], and the P[10] genotype has also been associated with this strain 
(Santos and Hoshino 2005).  The G5 strain is mainly associated with the P[8] genotype 
(Santos and Hoshino 2005). 
 
There are five major G-P combinations responsible for rotavirus gastroenteritis including 
G1P[8], G2P[4], G3P[8], G4P[8] and more recently also G9P[8], with G1P[8] being the most 
common (Woods et al. 1992; Audu et al. 2002b; Iturriza-Gomara et al. 2000a; Pietruchinski 
et al. 2006; Linhares et al. 2008; Antunes et al. 2009; Dey et al. 2009; McCormack and Keam 
2009; van Doorn et al. 2009; Aminu et al. 2010; AnnaRita et al. 2010; Aladin et al. 2010).  It 
is important to take into account that mixed infections occur frequently in areas where there 
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are high numbers of rotavirus infections (Antunes et al. 2009).  Gurgel et al. (2008) also 
noted that G9P[6] together with G9P[8] could be classified as a common combination in 
various countries.    
 
2.2.4 New and non-typeable rotavirus strains 
All studies or surveys indicate non-typeable rotavirus strains. However the number of non-
typeable strains is declining because of improvements in test systems (Antunes et al. 2009).       
 
The diversity observed in rotavirus strains could be due to the ability of natural reassortment 
of the segmented genome, or because of an incomplete global geographical account of 
diversity (Moe et al. 2009).  Steele (1991) suggested that new rotavirus strains could occur in 
one of two ways, via antigenic drift where small sequential changes in the genome result in a 
new strain, or via reassortment of two viruses that infect the same host.  Rotaviruses have 
been shown to undergo constant genetic variations due to antigenic drift, genetic 
reassortment, genomic rearrangement or intragenic recombination, leading to the emergence 
of new strains which may not be recognized by the currently used methods of molecular 
characterisation (Santos and Hoshino 2005). 
 
2.3 Clinical characteristics of Rotavirus infections / Pathogenesis 
The rotavirus infection incubation period of 24 to 72 hours (White and Fenner 1994; van 
Doorn et al. 2009), but generally less than 48 hours (Hagbom et al. 2012) is usually followed 
by the onset of watery diarrhoea and vomiting, leading in many cases, to rapid dehydration 
(Desselberger et al. 2005; Atchison et al. 2010).  Only as few as ten rotavirus particles are 
required to infect small children (Adler et al. 2005).  The clinical symptoms of rotavirus 
infections may differ significantly, varying from asymptomatic infections to severe diarrhoea.  
The asymptomatic rotavirus infections may be particularly associated with infants younger 
than three months of age and may be due to the presence of maternal antibodies (Arguelles et 
al. 2000; Pager et al. 2000; WHO 2002; Page 2006; CDC 2009; Aminu et al. 2010), the 
physiological immaturity of the gut of the infants (Pager et al. 2000; WHO 2002) or the 
virulence factors associated with these strains (Pager et al. 2000).  Bos and Steele (1995) 
speculated that host factors, and not virus factors, might play a role in the clinical 
characteristics, i.e. symptomatic or asymptomatic diarrhoea, as identical rotavirus strains 
were isolated from community-acquired and hospital-acquired samples.   
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The symptoms usually continue for two to seven days, with an average duration of five days 
(Atchison et al. 2010), but have been documented to last up to 22 days (WHO 2002).  The 
peak viral shedding in stools can generally be observed on day three of the illness 
(McCormack and Keam 2009).  Symptoms of rotavirus infections include vomiting, 
diarrhoea, fever and dehydration (WHO 2002; Murray et al. 2005; CDC 2009; van Doorn et 
al. 2009; Potgieter et al. 2010; Tate et al. 2010).  Fever and vomiting are prominent during 
the first few days of infection (WHO 2002; Tate et al. 2010).  Diarrhoea is generally self-
limiting (Murray et al. 2005), but may last longer in infants compared to the duration in 
young children (WHO 2002).  Hospitalisation due to rotavirus infections is primarily due to 
dehydration caused by the diarrhoea (Bos et al. 1992; Chouikha et al. 2009), as severe 
dehydration could lead to an electrolyte imbalance, shock and death (McCormack and Keam 
2009).  Malnutrition in children may also play an important role as it may lead to more 
symptomatic infections and poor access to treatment in developing countries may also 
prolong the duration of rotavirus infections (Atchison et al. 2010).  The high number of infant 
deaths could be attributed to the failure to promptly treat the symptoms of rotavirus 
infections. Treatment is usually symptomatic and generally includes oral or intravenous 
rehydration therapy (Donelli and Superti 1994; Percival et al. 2004; Desselberger et al. 2005). 
 
Viral infections generally differ from bacterial infections by there being limited inflammation 
of the intestines during viral infections (Greenberg and Estes 2009).  Rotavirus infections 
generally start in the proximal section of the small intestine before spreading to the jejunum 
and ileum and infections have also been observed in the colon.  As indicated above, various 
factors play a role in the spreading of the infection within the intestine, including: the initial 
dose to which the patient was exposed, the virulence of the virus and the immunological 
status of the infected child (White and Fenner 1994).  Rotaviruses only infect the enterocytes 
on the tip of the intestinal villi (Pando et al. 2002; Greenberg and Estes 2009) causing a 
shortening of the villi and a reduction in the absorptive surface area of the intestine.  In 
addition, occasional fusion of adjacent villi might also take place.  The shortening of the villi 
causes an accumulation of fluid in the lumen of the gut, thereby causing diarrhoea (White and 
Fenner 1994; Atlas 1997; Percival et al. 2004).  Replication of virus particles generally takes 
place in the cytoplasm of the infected cells (Percival et al. 2004).  The replication cycle 
during infection is strongly dependant on the calcium concentration of the environment 
(Pando et al. 2002).  The infected villi cells are replaced by immature cuboidal epithelial cells 
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that are relatively resistant to viral infection (White and Fenner 1994; Atlas 1997).  Cellular 
recovery begins from 48 hours after an infection (Percival et al. 2004). 
 
Fluid loss during rotavirus infections is due to the damage to the small intestine leading to 
loss of extracellular fluid caused by impaired absorption, loss of enzymes responsible for 
digestion of disaccharides and osmotic loss due to the presence of undigested lactose in the 
lumen.  Damage or destruction of the differentiated cells causes a reduction in glucose 
carrier, sodium carrier and sodium-potassium adenosine triphosphatase activities, leading to a 
loss of sodium, potassium, chloride, bicarbonate and water and resultant in acidosis.  
Acidosis can also be caused by increased microbial activity due to the fermentation of 
undigested milk.  Such acidosis could lead to a potassium ion exchange across the cellular 
membrane, leading to changes in cellular functions maintaining normal potassium 
concentrations (White and Fenner 1994).  Various types of diarrhoea can be associated with 
rotavirus infections.  Osmotic diarrhoea is characterised by a high concentration of 
unabsorbed water-soluble compounds in the intestine, due to the damage to the small 
intestine, this can create an osmotic force that causes a loss of fluids across the intestinal 
epithelium.  Secretory diarrhoea, where there is an overstimulation of the intestinal tract’s 
secretory capacity.  Exudative diarrhoea, characterised by hydrostatic pressure in the blood 
vessels and lymphatic’s due to the loss of epithelial cells, causing water and electrolytes to 
accumulate in the gut (Hagbom et al. 2012).  Decreases in the absorption of water during 
rotavirus infections therefore leads to a net secretion of water and a loss of electrolyte ions 
(Murray et al. 2005).     
 
Rotaviruses are not limited to the intestine but have been associated with systemic infections 
(Greenberg and Estes 2009).  Extra-intestinal spread of rotavirus RNA has been observed in 
cerebrospinal fluid, where it can be associated with meningitis, encephalopathy and 
encephalitis.  In immune compromised patients, rotavirus infections have also shown to be 
associated with abnormalities in the liver, spleen, heart, lymph nodes, kidneys and other 
organs (Hagbom et al. 2012). 
 
2.4 The burden of Rotavirus infections 
Group A rotaviruses have been identified as most frequently being responsible for acute 
gastroenteritis in young children worldwide (Estes and Cohen 1989; Donelli and Superti 
1994; White and Fenner 1994; Nimzing et al. 1998; Iturriza-Gomara et al. 2000a; Audu et al. 
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2002a; Mwenda et al. 2003; Percival et al. 2004; Logan et al. 2006; van Zyl et al. 2006; 
Mascarenhas et al. 2007; Ramani et al. 2007; van Damme et al. 2007b; Ospino et al. 2008; 
Chouikha et al. 2009; Esona et al. 2009; Hasing et al. 2009; Sanchez-Padilla et al. 2009; 
AnnaRita et al. 2010; Atchison et al. 2010; Kargar et al. 2011) resulting in approximately 111 
million cases of gastroenteritis requiring home care, 25 million cases requiring hospital or 
emergency room visits and 2 million cases requiring hospitalisation (Dewar et al. 2005; 
Santos and Hoshino 2005; WHO 2008a; Wang et al. 2009).  Group A rotaviruses have also 
been identified as being responsible for more than 90% of all rotavirus infections diagnosed 
(Armah et al. 2003; Pietruchinski et al. 2006).  This group has also been identified as being 
responsible for symptomatic diarrhoea in elderly patients (Estes and Cohen 1989). 
 
Group B rotaviruses are predominately responsible for infections in adults but do, in some 
cases, cause diarrhoea in children (Nimzing et al. 1998; Fischer and Gentsch 2004; Barman et 
al. 2006; Logan et al. 2006).  Group B rotaviruses were first identified as responsible for 
human gastroenteritis during an epidemic in China in 1982 – 1983 that affected over one 
million people.  Other countries where group B rotavirus infections have been identified 
include India and Bangladesh (Barman et al. 2006).     
 
Group C rotaviruses are generally associated with sporadic or limited outbreaks of infection 
(Estes and Cohen 1989; Donelli and Superti 1994; Nimzing et al. 1998; Mwenda et al. 2003; 
Fischer and Gentsch 2004; Logan et al. 2006) and have also been more commonly identified 
in older patients (Mwenda et al. 2003).  Because of the sporadic nature of infections caused 
by Group C rotaviruses, the general burden of Group C rotavirus infections is considered to 
be insignificant in estimating the total burden of rotavirus infections in humans globally 
(Mwenda et al. 2003).  Group C rotaviruses have been identified in studies conducted in 
Latin America, India, Malaysia, China and Nigeria (Nimzing et al. 1998) and Australia, 
North America, United Kingdom, Finland and Japan (Mwenda et al. 2003). 
 
Rotavirus has been identified as an important causative agent of hospital-acquired infection, 
specifically in newborn nurseries (Steele et al. 2002), and not only have an economic impact 
on hospitalisation costs but also have an impact on the family or caregiver time (Ciarlet and 
Schödel 2009). 
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2.4.1 Rotavirus around the Globe 
Globally, G1 - G4 and, more recently G9 have been identified as common sources of 
rotavirus infections in children with the G1 strains of rotavirus being very commonly 
identified (Woods et al. 1992; Trabelsi et al. 2000; Audu et al. 2002a; Steele and Ivanoff 
2003; Desselberger et al. 2005; Linhares et al. 2006; van Damme et al. 2007a; 
Tcheremenskaia, et al. 2007; Chouikha et al. 2009; Hasing et al. 2009; AnnaRita et al. 2010; 
Kargar et al. 2011).  In a meta-analysis of various studies conducted between 1973 and 2003, 
Santos and Hoshino (2005) identified that G1P[8], G2P[4], G3P[8] and G4P[8] were 
responsible for 88.5% of rotavirus infections.  When, however, these results were broken 
down by continent and subcontinent, the distribution of the G/P combinations varied 
dramatically.  These four combinations were cited as being responsible for more than 90% of 
infections in North America and Europe, whereas in South America and in Asia they only 
represented 68% and in Africa, 50% (Santos and Hoshino 2005).  There is, thus, a great 
variation in serotype distribution globally.  As seen with G1P[8], this strain is responsible for 
approximately 73% of rotavirus disease in Europe and North America, but is only responsible 
for 34% in South America and 23% in Africa and Asia.  With the emergence of G9 as an 
important strain, the following five strains has been identified as the most common 
combination strains: G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8].  These represent 
approximately 88% of rotavirus gastroenteritis globally (Madhi 2008).  In addition to the 
most prevalent strain, G1P[8], recent studies have shown the following G9 strains to be 
commonly responsible for diarrhoea, including G9P[6] in India, and G9P[8] in Brazil (Audu 
et al. 2002b) and also Portugal in 2006 (Antunes et al. 2009).  It should also be noted that 
different G types have been shown to co-circulate in any geographical location at any time 
(Desselberger et al. 2005).   
 
Uncommon G and P types have been identified globally to be an important cause of rotavirus 
gastroenteritis in the countries where they are found.  These include G5, G6, G8, G10, G12, 
P[9], P[11] and P[14], with important combinations G8P[6] in Malawi, G5P[8] in Brazil and 
G10P[11] in India (Esona et al. 2010).   
 
It is estimated that approximately 2.7 million children are infected with rotavirus annually in 
the United States of America (USA), resulting in approximately 20 deaths and 500 000 
doctor visits accounting for over one billion U.S. dollars in costs (Bernstein et al. 2002; 
Honma et al. 2007).  Thus, in the USA, rotavirus gastroenteritis is associated with relatively 
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few deaths but is an important cause of morbidity, with an estimated 13 out of 10 000 
children (approximately 55 000 to 70 000 children) being hospitalised annually in children 
younger than five years of age.  This figure was determined prior to the introduction of a 
rotavirus vaccine, whereafter this morbidity figure dropped to approximately 2.5 per 10 000 
post vaccine introduction (Chang et al. 2010; Rodrigo et al. 2010).  In the USA, the most 
common G/P combinations include G1P[8], G2P[4]; G3P[8], G4P[8], G9P[8] and G9P[6] 
(CDC 2009).  Salvadori and le Saux (2010) indicated that mortality due to rotavirus is very 
rare in Canada, but as rotavirus diagnosis is not a routine diagnostic test many cases could be 
overlooked and not recorded. 
 
Data from Columbia identified G1P[8], G2P[4] and G3P[8] to be responsible for 79.4% of 
diarrhoeal cases from 1998 – 2000, and 72.9% in 2002 – 2003 (Ospino et al. 2008).  
Rotavirus gastroenteritis has also been identified as being the major cause of infant deaths in 
Venezuala (Perez-Schael et al. 2009). 
 
In a study conducted in Nepal during 2009 and 2010 showed G12P[6] to be the predominant 
strain (45.7% and 28.5% respectively) while other strains included G1P[8] (2.7% and 8.6%), 
G12P[8] (3.2% and 2.6%), G2P[4] (14.5% and 4.6%), G1P[6] (4.1% and 1.9%), G9P[8] 
(1.3% and 1.9%), G9P[4] (0.9% and 1.9%) and G9P[6] (only observed during 2010, 6.6%) 
(Sherchand et al. 2012). 
 
In a review study conducted by Gurgel et al. (2008) on samples analysed in 117 studies 
between 1986 and 2006 in Brazil, the following G-types were identified as responsible for 
gastroenteritis: G1 (44%), G9 (19%), G2(17%), G3 (7%), G4 (5%), G5 (4%), G8, G10 and 
G12 (<1%), and mixed or non-typeable strains (4%).  The G/P combinations identified in this 
review study included; G1P[8] (43%), G9P[8] (22%), G2P[4] (7%), G1P[NT*] (5%), G4P[8] 
(4%), G2P[6] (3%), G3P[8] (2%), G5P[8] (2%), G2P[8] (2%), G1P[6] (1%), G3P[4] (1%), 
G1P[4] (1%), G9P[NT] (1%), G2P[NT] (1%), G9P[6] (1%), G9P[4] (1%), G4P[6] (1%), 
G10P[8] (<1%), G3P[9] (<1%), and 2% mixed or other types.  Prior to vaccine introduction, 
this meta-analysis identified G1P[8] to be the most frequently found strain, but data showed 
the emergence of uncommon strains such as G5 and G9 from different regions of Brazil. 
*NT refers to non-typeable strains 
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A study conducted by Arguelles et al. (2000) in Buenos Aires, Argentina, between 1996 and 
1998, showed G1 (39%), G2 (43%), G4 (4%) and co-infections with both G1 and G2 (7%); 
and P[8] (16%), P[4] (71%), and co-infections with both P[8] and P[4] (3%) to be associated 
with gastroenteritis.  The combinations most frequently found included G1P[8] and G2P[4], 
an unusual combination of G1P[4] was found to be responsible for 14% of cases.   During the 
2005 - 2007 seasons in Ecuador, the G9 strain was identified as the prevalent strain 
responsible for infections (Hasing et al. 2009).   
 
According to van Damme et al. (2007a), hospitalisation due to rotavirus infections in the 
European Union is approximately one in 54 children younger than five years of age.  Thus, it 
was estimated that approximately 87 000 children younger than five years of age were 
hospitalised in Europe due to rotavirus gastroenteritis annually (van Effelterre et al. 2009; 
Rodrigo et al. 2010); or approximately 30-50% hospitalisations (Adler et al. 2005), and 
approximately 700 000 out-patient visits annually (van Effelterre et al. 2009).  A study 
conducted during the winter season of 2007 in northwest Portugal showed a rotavirus 
infection incidence of 55.2%, the mean age for patients included was determined to 13 
months of age and the highest incidence occurrence was found among boys (58.7%) (Antunes 
et al. 2009). 
 
Atchison et al. (2009) estimated that ~13 000 rotavirus cases were treated in England and 
Wales annually.  Rotavirus occurrence usually peaks during winter and early spring 
(Atchison et al. 2009). 
 
In India it is estimated that rotavirus infections are responsible for 122 000 – 153 000 deaths, 
457 000 – 884 000 hospitalisations and 2 million outpatient visits annually (Tate et al. 2009).  
In a study conducted by Samajdar et al. (2006), G1 was identified as the most predominant 
strain (53.8%), followed by G2 (22.5%) and emerging strains G9 (2.1%) and G12 (17.1%) as 
determined from samples analysed in eastern India between 2003 and 2005.   
 
In Iran, a study conducted by Kargar et al. (2011) observed that G1 was the most common 
circulating strain, and the study also showed a high percentage of non-typeable strains.  The 
high percentage of non-typeable strains identified was explained as resulting from false-
positive EIA results, novel strains; not using primers for rare strains, including G5, G6 and 
G11, or the failure of the RT-PCR method.  Similar to findings in other countries, 79.54% of 
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the hospitalisations due to rotavirus infections occurred in children younger than two years of 
age. 
 
Rotavirus infections are associated with between 32% and 50% of hospitalisations in China 
(Wang et al. 2009; Fu et al. 2012).  In Japan, from June 2006 until July 2007, the G1 strain 
was found to be the most common circulating G-type, at 61%, followed by G9 at 20.3%, G2 
at 11.4% and G3 at 7.3%.  P-types circulating in Japan during this time-period were identified 
as P[8] at 84.6%, P[4] at 13.8% and P[6] at 1.6%.  The combination strain G1P[8] at 58.5% 
was found to be predominant, followed by G9P[8] at 18.7%, G2P[4] at 11.4%, G3P[8] at 
7.3%, G1P[4] at 2.5% (Dey et al. 2009).   
 
Shim et al. (2010) indicated that rotavirus is the most common cause of diarrhoea in children 
six to 24 months of age in South Korea.  The most predominant strains observed in South 
Korea shifted from G1-G4, in studies conducted between 1987 and 1999, to G2-G4 and G9, 
in studies conducted between 1998 and 2004.   
 
A study conducted by Moe et al. (2009) in Myanmar during 2004-2005, showed the age 
distribution to be 53% observed in 7-12 month old infants, 23% in 13-24 month old infants, 
20% in 0-6 month old infants, 3% in 25-36 month old infants, 1% in 37-48 month old infants 
and 0% in infants aged 49-60 months.  The predominant strains were identified as G3 (41%), 
G1 was identified in 10% of patients, G2 in 2%, G4 in 3% and G9 in 1%. 
 
2.4.2 Rotavirus in Africa 
It is estimated that the strains G1, G3, G4 and G9 are responsible for ~70% of diagnosed 
cases of rotavirus gastroenteritis in Africa, and the P[6] genotype being associated with a 
third of these cases (Sanchez-Padilla et al. 2009).  The human G8 strain has been identified as 
one of the most commonly found strains in Africa (Chouikha et al. 2009).  Esona et al. (2009) 
identified G8 as one of the more predominant strains in a Malawian study.   
 
Sanchez-Padilla et al. (2009) performed a meta-analysis of 35 articles relating to the burden 
of rotavirus disease and 31 articles relating to G and P types circulating in African 
communities.  These studies were conducted between 1984 and 2007.  The most frequent G 
types were summarised to be G1 (34.9%), G2 (9,1%), G3 (8.6%), G8 (3.3%), G9 (2.6%) and 
G4 (1.9%) and the most frequent P types as P[8] (35.5%), P[6] (27.5%) and P[4] (7.3%).   
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In Nigeria during January 1996 – December 1997 the circulating strains included G1 as well 
as G3 with the G1P[6] and G3P[6] strains being commonly observed (Audu et al. 2002a).  
Nigeria is estimated to have one of the highest mortality rates (approximately 160 000 deaths 
annually), with rotavirus-related mortality estimated to be approximately 20% of the annual 
mortality rate (Aminu et al. 2010).  During a two year study (2002 – 2004) in Nigeria the G1 
– G4, G8 and G9 were reported as the strains particularly associated with rotavirus 
gastroenteritis.  
 
A study conducted by Cunliffe et al. (2009) in Malawi found the most commonly detected 
strains from July 2005 through June 2007 included: G1P[8] (47%), G8P[8] (12%), G1P[6] 
(10%), G8P[6] (7%), G8P[4] (6%), and G12P[6] (4%).   
 
Studies conducted in Ghana determined rotavirus to be responsible for over 20% of 
diarrhoeal occurrences in children younger than 18 months, and present 10 months of the 
year, with seasonal peaks between September and February (Asmah et al. 2001). Rotavirus is 
responsible for the majority of severe childhood diarrhoeal cases in Ghana.  Samples 
collected in Ghana between January and April 1999 showed the G2P[6] strain to be the 
dominant strain circulating in the Upper East Region during the study period (Armah et al. 
2001).   
 
During 2001/2002, samples collected from Botswana were analysed for viral agents including 
rotavirus, non-enteric adenovirus, enteric adenovirus and astrovirus.  Of all samples analysed, 
rotavirus showed the highest incidence at 9.2%.  Rotavirus-related incidences were observed 
all year round but showed distinct peaks during June to August (autumn and winter).  The 
mean age occurrence for rotavirus infection was determined to be 9.7 months of age and the 
age group in infants showing the most frequent occurrence of rotavirus infection was less 
than 12 months of age (Basu et al. 2003).   
 
In Tunisia, rotavirus infections were mainly observed during the cooler season, i.e. November 
to February and the majority of children infected were younger than two years of age 
(Trabelsi et al. 2000).   
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Pan African rotavirus surveillance indicated, from June 2006 through December 2008, that 
2200 (40%) of 5461 stool samples collected from children enrolled in 8 countries (Uganda, 
Ghana, Kenya, Zambia, Zimbabwe, Cameroon, Ethiopia and Tanzania) tested positive for 
rotavirus.  Of these children, 90% of all rotavirus hospitalisations occurred in young children 
between three and 18 months of age.  Commonly occurring rotavirus types included G1P[8] 
(22%), G2P[4] (7%), and G9P[8] (7%); however, unusual types were also detected, including 
G8P[6] (5%), G8P[8] (2%), G12P[6] (1%), and G12P[8] (1%) (Mwenda et al. 2010).     
 
In a review study conducted by Todd et al. (2010) on samples analysed in 16 studies between 
1997 and 2006 in 10 African countries (Botswana, Egypt, Ghana, Guinea-Bissau, Kenya, 
Libya, Malawi, Nigeria, Tunisia and Zambia), the following common G/P combinations 
identified included; G1P[8] (17.4%), G2P[6] (9.6%), G8P[6] (9.4%), and G3P[8] (7%), 
unusual strains identified during this period included G8P[14], G9P[10], G8P[2], G3P[9], 
G4P[9], G8P[1], and G6P[6].  In this review Todd et al. (2010) also showed the shift in 
strains associated with infections with G1 as the most prevalent strain observed, together with 
G2, G3, G4, and a high number (approximately 25%) of non-typeable strains being 
responsible for infections before 2007.  However, studies reviewed post 2007 showed a 
decrease in the number of infections associated with the more common strains and the 
emergence of uncommon strains, including G8, G12 and P[6] as being more commonly 
associated with rotavirus infections, especially on the African continent. 
  
2.4.3 Rotavirus in South Africa 
In stool samples from Ga-Rankuwa, South Africa, analysed between 1984 and 1993, P[8] 
was identified as the most common genotype circulating at 63.7%, followed by P[4] at 
22.3%, P[6] at 8.3%, P[12] at 3.8% and P[9] at 1.9% (Mphahlele and Steele 1995).  Rotavirus 
strains circulating in South Africa during the 1988 and 1989 seasons were identified as G1 in 
44% of patients, G4 in 24% of patients and G2 in 23% of patients, the G3 strain was not very 
common during the 1988 and 1989 season, but was found to be more common in 
Johannesburg and Cape Town.  Various regional differences were observed in the 
predominant strains responsible for infection, e.g. G2 was predominant in Port Elizabeth and 
Transkei, and during the same period G4 was identified as being the predominant strain in 
Johannesburg, Pretoria and Ga-Rankuwa.  During this study period (1988 and 1989), P[8] 
was identified in approximately 67% of patients, P[4] in 22% and P[6] in 10% (Steele et al. 
2003).  The 1988 and 1989 season data were compared to data for 1998 and 1999 and showed 
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G1 to be the most commonly observed strain, followed by G2.  The G3 strain was also more 
commonly observed compared to the 1988 and 1989 season (Steele et al. 2003). 
 
In samples analysed by Potgieter et al. (2010), from the Vhembe region in the Limpopo 
province from June 1998 through June 2000, showed the G1 strain to be most predominant 
(73.9%), followed by G8 (13.5%), G9 (4.5%) and G2 (2.7%).  The G and P combinations 
observed during this time included, G1P[6] (32.4%), G1P[8] (13.5%), G9P[6] (4.5%), 
G8P[4] (3.6%), G1P[4] (3.6%), G8P[6] (3.6%) and G2P[6] (2.7%).  
 
In samples analysed between 2003 and 2006, collected from the North of Pretoria, Gauteng, 
G1 was observed in 36%, G3 in 27%, G2 in 14%, G9 in 8% and G8 in 5%  and various 
unusual G and P combinations were observed, including: G1P[6], G1P[4], G2P[6], G3P[6], 
G3P[4], G8P[8], G8P[6], G8P[4], G9P[4], G9P[6] and G12P[6].  These unusual strains were 
responsible for 22-33% of rotavirus infections observed.  In addition, the unusual strain 
G12P[6] with a long electropherotype was detected for the first time in South African patients 
late in 2004, and early 2005, prior to the rotavirus season (Seheri et al. 2010b). 
 
In 2009 the National Institute for Communicable Diseases (NICD) implemented an active 
surveillance of rotavirus infections in South Africa to estimate the incidence of rotavirus 
infections and determination of the prevalent strains following the introduction of the Rotarix 
vaccine.  During the 2009 surveillance, strains observed included G1P[8] (40%), G2P[6] 
(14%), G2P[4] (11%), G12P[8] (8%), G12P[4] (6%), G1P[6] (5%), G9P[8] (4%), G2P[8] 
(3%), G1P[4] (2%), G3P[4] (>1%), G9P[6] (>1%), G12P[6] (>1%) and G4P8] (1%) (NICD 
2010). 
 
From the various studies conducted in South Africa, it can be concluded that the most 
commonly found serotypes were; G1, G2, G3, G4, G8, G9 and G12, and the most commonly 
found genotypes; P[4], P[6] and P[8]. 
 
2.5 Rotavirus Epidemiology 
Armah et al. (2003) indicated various differences between developing and developed 
countries with regards to rotavirus infections as including the age of primary infection and the 
level of co-infections.  Thus, in developing countries primary infections tend to occur at an 
earlier childhood age and there is also a high level of co-infections with other pathogens. 
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2.5.1 Age and gender of children susceptible to rotavirus infection 
Studies have shown that approximately 30% of infants have been affected with rotavirus by 
the age of 9 months and 90% during the first 18 months (Wang et al. 2009) and the most 
susceptible individuals are children aged between six months and two years of age (Donelli 
and Superti 1994; Percival et al. 2004; King 2006; van Damme et al. 2007a; Heymann 2008; 
Linhares et al. 2008; Atchison et al. 2009; Wang et al. 2009; van Doorn et al. 2009; Atchison 
et al. 2010; Potgieter et al. 2010; Kargar et al. 2011; Sherchand et al. 2012).  Studies indicate 
that rotavirus has a lower pathogenicity in children older than two years of age (Seheri et al. 
2010a), and newborns (Donelli and Superti 1994; Lundgren and Svensson 2001; WHO 2002) 
and adults generally experience asymptomatic infections (Donelli and Superti 1994; Linhares 
et al. 2002; WHO 2002).  Steele and Ivanoff (2003) indicated that rotavirus infects African 
children at younger ages compared to children in Europe or America.  Uchida et al. (2006) 
indicated that while the majority of diarrhoea cases caused by rotavirus are observed in 
children younger than five years of age, approximately 5-7% of diarrhoeal cases in older 
children and adults in Nepal were caused by rotavirus.  Thus, the severity of rotavirus 
gastroenteritis is significantly greater during the first year of life compared to the second or 
third years of life (Perez-Schael et al. 2009). 
 
Studies have been done to determine the effect of season of birth on the burden and incidence 
of the disease.  Children are at the highest risk of infection during their first year after birth 
and are thereby also more likely to be infectious to other individuals.  Atchison et al. (2009), 
therefore, estimate that children born during spring and summer play an important role in 
spreading rotavirus infections, as these children will be more susceptible to infection in 
temperate countries where rotavirus peaks during winter months.  Likewise, children born 
during winter months would experience less severe incidences of infection, as infection in 
children born during winter months will only occur at an older age. 
 
The results from ten different global studies (Bishop et al. 2001; van Man et al. 2001; 
Linhares et al. 2002; Sanchez-Fauquier et al. 2004; Mascharenhas et al. 2006; Lin et al. 2008; 
Atchison et al. 2009; Dey et al. 2009; Perez-Schael et al. 2009; Shim et al. 2010) indicated a 
slight increase in the incidence of rotavirus infection in males compared to females. In these 
comparative studies, only three of the studies showed a higher incidence rate in young 
females compared to young males. 
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2.5.2 Seasonality of rotavirus infections 
In temperate countries, the cooler winter to early spring months is associated with the typical 
peak season for rotavirus infections (Bos et al. 1992; Percival et al. 2004; Page 2006; Perez-
Vargas et al. 2006; Farkas and Jiang 2007; Heymann 2008; Atchison et al. 2009; McCormack 
and Keam 2009; Atchison et al. 2010; Kargar et al. 2011).  No seasonality has to date been 
observed in group B infections (Barman et al. 2006).  Epidemiological studies also indicated 
that there is an increase in rotavirus incidence as humidity decreases (Steele et al. 1986a).  
Rotavirus-related infections show an increase in cold and dry weather periods (D’Souza et al. 
2008).  Rainfall may be included under the environmental factors affecting the incidences of 
rotavirus infections in Morocco, Algeria, Egypt, Bangladesh, India and Costa Rica where it 
was found that rotavirus infection decreased during wet seasons compared with dry seasons 
(D’Souza et al. 2008).  Various studies identified that rotavirus gastroenteritis can vary within 
a country or region as seen in Australia, Venezuela, Latin America and Africa (Perez-Schael 
et al. 2009). 
 
The characteristic seasonality pattern for rotavirus infections in South Africa has been 
determined in previously conducted studies as starting to peak in autumn (March – June), 
before declining in numbers and then showing a second peak in late winter (August) (Steele 
et al. 1986a; Steele et al. 1986b).  This appears to be consistent as Bos et al. (1992) and Page 
(2006) indicated the rotavirus season in South Africa to be from late March, or early April to 
July or August.  Monitoring of the seasonality of rotavirus infections in the Johannesburg and 
Pretoria regions indicated that the rotavirus season started late in April and ended early in 
September (Page et al. 2009).  In a study conducted by Seheri et al. (2010a) from 2003 to 
2005 in Gauteng and the North West Province, it was observed that diarrhoea caused by 
rotavirus infections occurred throughout the year but had distinct peaks during the winter 
season (March/April to September/October).  Data indicate that the incidence of rotavirus 
infection during the summer months was <5% and during the winter peaks could exceed 
50%.  From the various studies conducted in South Africa, it can be concluded that rotavirus 
gastroenteritis is present throughout the year, but that there is a definite peak period observed 
starting in March lasting until September and, in some cases October.   
 
2.5.3 Immunity to rotavirus infection 
Various factors play a role in immunity against rotavirus infections.  These include maternal 
antibodies contributing to some protection for newborns so that children up to the age of 
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three months are at relatively low risk for infection. This age group is also at lower risk due 
to limited contact with infected individuals.  Children that are breastfed also show a lower 
risk of being infected, as do children who had previous infections (previous infections reduce 
a child’s risk of further infections).  The reasons provided for children older than six months 
being more susceptible to infection include maternal antibody titres decreasing as 
breastfeeding ceases and there is an increase in the interactions with other individuals thereby 
increasing the possibility of oral-faecal contact (Atchison et al. 2009).  The IgG maternal 
antibodies transmitted across the placenta do not appear to protect a newborn baby from 
rotavirus infections but IgA antibodies in the colostrum does offer some protection for 
newborns (White and Fenner 1994).  Van Damme et al. (2007b) indicated that local intestinal 
immunity may present to give some protection against succeeding rotavirus infections.  Most 
studies have shown the first rotavirus infection to be the most severe, the severity of rotavirus 
infections generally declines after the first infection (Page 2006), with the second and any 
future infections as being less severe or asymptomatic.  Studies have indicated that three 
infections generally reduce the risk of serious rotavirus infections with approximately 100% 
(van Damme et al. 2007b), and early research conducted by Offit et al. (1986a) and Offit et 
al. (1986b) indicated that monoclonal antibodies specific for the neutralization proteins, when 
administered orally during experiments on mice, showed neutralizing characteristics against 
rotavirus serotypes. 
 
2.5.4 Transmission of rotaviruses 
Rotaviruses are mainly transmitted via the faecal-oral route to infect, as indicated above, the 
small intestine (Donelli and Superti 1994; Percival et al. 2004; Desselberger et al. 2005; 
Murray et al. 2005; Page 2006; Perez-Vargas et al. 2006; van Zyl et al. 2006; Farkas and 
Jiang 2007; Heymann 2008; CDC 2009; Atchison et al. 2010; Salvadori and le Saux 2010).  
Rotaviruses can also be transmitted by direct person-person contact or by the ingestion of 
contaminated food or water sources (Donelli and Superti 1994; Desselberger et al. 2005; 
Murray et al. 2005; Page 2006; CDC 2009; Atchison et al. 2010), and also through fomites 
(CDC 2009; Salvadori and le Saux 2010).  Perez-Vargas et al. (2006) suggested that 
respiratory transmission of rotaviruses could also be possible and Donelli and Superti (1994) 
observed rotavirus infections of the oropharynx and respiratory tract.  Various worldwide 
waterborne and food-borne outbreaks have been linked to rotavirus infection and this could 
be due to high numbers of virus particles that may contaminate surface water, ground water, 
drinking water and food (van Zyl et al. 2006).   
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The CDC noted in the Morbidity and Mortality Weekly Report for 2009 that animal-to-human 
transmissions are uncommon, however, due to genetic reassortment characteristic of 
rotavirus, natural reassortant animal-human rotavirus strains have been identified in humans 
and some of these have been used during vaccine preparation (CDC 2009).  There have been 
several sporadic cases and epidemics of animal-like rotavirus infections reported since 
identification of rotavirus in humans.  In an epidemic during the 1987 to 1988 season in India 
G9P[19] was identified as the causative agent, with the P[14] strain of porcine origin,  these 
strains are still observed in the community in low occurrences (2.1%).  Porcine-like P[6] 
strains have also been found to be responsible for human rotavirus infections in Europe, 
Africa and Asia.  Bovine-like strains found to be responsible for illness in humans include 
G6, G8, G10, P[1], P[2], P[4], P[6], P[8], P[9], P[11] and P[14]  (Martella et al. 2010).  
Unusual or animal-like strains identified sporadically in humans include G3P[3], G3P[9], 
G5P[6], G6P[14], G10P[14], G11P[25] and G12P[8] (Khamrin et al. 2009), and Martella et 
al. (2010) indicated the possibility of the emergence of the G9 and G12 strains in humans 
may have been due to interspecies infections, and that these infections occur more frequently 
due to the close interactions between animals and humans.  
 
Rotaviruses are found to be viable outside a host for several hours to days in certain 
environmental situations, including low temperatures (4 - 20°C), a low pH, low humidity and 
where protected from ultraviolet light (D’Souza et al. 2008).  Thus, rotavirus particles are 
relatively stable at ambient temperatures and during repeated freezing and thawing (Murray 
et al. 2005). 
 
2.6 Methods of rotavirus Detection 
The most important parameters when selecting diagnostic assays include the specificity and 
sensitivity of these tests.  Detection methods for rotavirus in stool samples or rectal swabs 
include electron microscopy techniques, latex agglutination and other immunological 
techniques for which commercial kits are available (Heymann 2008).  White and Fenner 
(1994), Fischer and Gentsch (2004), and Farkas and Jiang (2007) listed detection methods of 
rotavirus in stool samples or rectal swabs to include: electron microscopic analysis of 
negatively stained virions, antigen detection by enzyme immunoassays such as enzyme 
immunoassay (EIA), passive particle agglutination tests or lateral-flow immunoassays, 
polyacrylamide gel electrophoresis (PAGE), silver nitrate or ethidium bromide staining 
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(ethidium bromide staining is, however, generally not used due to the low sensitivity of the 
test, as per Murray et al. 2005), deoxyribonucleic acid-agarose gel electrophoresis, dot blot 
hybridization assays, nucleic acid sequence-based amplification (NASBA), reverse 
transcription-polymerase chain reaction (RT-PCR) with RT-PCR identified as the preferred 
choice of strain typing (as per Fischer and Gentsch 2004) or virus isolation in cell cultures.  
Cell cultures of rotaviruses are not reliable for diagnostic analysis of infections as culturing of 
rotaviruses are difficult (Murray et al. 2005).   
 
When the levels of virus shedding are very high electron microscopy, EIA and PAGE are 
suitable for diagnostic purposes and when high-titred monoclonal antibodies are used, antigen 
detection assays can show a high sensitivity and specificity (Farkas and Jiang 2007; 
Arguelles et al. 2000).  When samples are collected at a late phase of the illness, or collected 
from alternative sources, including throat swabs, cerebrospinal fluid, or respiratory 
secretions, or when the number of viral particles are expected to be low, then more sensitive 
methods, such as RT-PCR, should be used (Arguelles et al. 2000).  Serological studies are 
mainly used for research and epidemiological purposes.  Many people have rotavirus-specific 
antibodies and, therefore, a fourfold rise in the antibody titre is classified as an indication of a 
recent infection or active disease (Murray et al. 2005).  A reason for the inability to type 
strains includes the age of the sample, which could lead to degradation of the rotavirus 
antigen or RNA (Steele et al. 2003). 
 
It is important to note that group B and group C rotaviruses excrete in very low numbers and 
these rotaviruses can, therefore, be better detected using a highly sensitive technique such as 
RT-PCR (Barman et al. 2006). 
 
Iturriza-Gomara et al. (2004) indicated that due to the high probability of point mutations 
observed in rotavirus strains, and the possibility of these mutations occurring in the region 
coding for the VP4 and VP7 proteins, methods of typing should be continuously and 
constantly monitored.  This especially due to the possibility of interspecies transmission 
between animals and humans, where reassortment could lead to the emergence of novel 
strains as well as the introduction of zoonotic strains into the human population. 
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2.6.1 Electron microscopic analysis 
Electron microscopic detection is the most rapid detection method used to identify rotaviruses 
in samples, but is less sensitive compared to immunoassays, as the sample analysed requires 
at least 106 to 108 virions per millilitre to be detectable (White and Fenner 1994; Arguelles et 
al. 2000; Logan et al. 2006; Farkas and Jiang 2007).  The electron microscope can detect 
negatively stained virions (Fischer and Gentsch 2004).  
 
2.6.2 Latex Agglutination Assays 
Latex Agglutination Assays are based on the agglutination of latex beads, coated with virus-
specific immunoglobulins, by antigens present in samples tested (Murray et al. 2005).   
 
Latex Agglutination Assays are generally less sensitive compared to rotavirus 
immunochromatographic tests (Dewar et al. 2005) and EIA (Arguelles et al. 2000; Farkas and 
Jiang 2007).  False negative results are generally found unless large numbers of virions are 
present in the samples, resulting in a low sensitivity and low specificity of Latex 
Agglutination Assays (White and Fenner 1994).  Latex Agglutination Assays are still used by 
some pathology laboratories as a routine diagnostic tool even though these latex agglutination 
assays resulted in a specificity of 93% and a sensitivity of only 57% when compared to EIA 
analysis (Dewar et al. 2005). 
 
2.6.3 Enzyme immunoassay (EIA) 
The standard rotavirus diagnosis is generally based on the detection of the rotavirus Group A 
antigen in stool samples by using EIA (Beards et al. 1984).  This technique makes use of 
labelled antibody molecules to detect antigen-antibody reactions (Atlas 1997).  A sandwich 
EIA consists of a plate coated with a capture antibody to which the diluted stool sample 
solution is added in order to determine the presence of a specific antigen.  Adler et al. (2005) 
noted that empty rotavirus particles can be detected using the VP6-EIA.  This technique was 
initially used to identify different G serotypes, however 20 – 30% of all samples tested failed 
to provide serotyping results leading to the development of alternative characterisation 
techniques, included RT-PCR (Page et al. 2009).  The overall sensitivity of EIA has a range 
of 105 to 106 viral particles per millilitre (Arguelles et al. 2000) and these authors indicated 
that EIA resulted in a specificity of 100% and sensitivity of 98.4% when compared to RT-
PCR analysis. 
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2.6.4 Rapid Healthcare Practice analysis methods 
Test kits, e.g. the Combi-test strips, are used by Healthcare Practices for rapid diagnosis for 
identification of rotaviruses in faecal samples.  The rapid test kits specificity is based on 
monoclonal antibody directed against specific rotavirus protein and use a homogeneous 
membrane system with colloidal gold particles.  Samples to be tested are diluted in a dilution 
buffer included in the kit.  The test strip has a nitrocellulose membrane sensitized with 
antibodies directed against the virus tested for in the sample.  The diluted sample is allowed 
to interact with the test strip and rotaviruses then bond to the colloidal gold.   
 
During analysis the test strip is dipped into the liquid phase of a faecal suspension, the 
solubilised conjugates migrate with the sample by passive diffusion and the conjugate and 
sample come in contact with the monoclonal antibody directed against the specific virus 
protein.  A test line will appear on the test strip if the sample analysed tests positive for 
rotavirus after approximately ten minutes. 
 
Dewar et al. (2005) indicated that the Coris RotaStrip resulted in a sensitivity of 88% and a 
specificity of 100% when compared to EIA analysis. 
 
2.6.5 PAGE 
In the molecular characterisation of rotavirus dsRNA, polyacrylamide gel electrophoresis 
(PAGE) allows these negatively charged macromolecules to separate through the gel 
according to size.  Resulting migration patterns can then be visualized by staining the gel 
with silver nitrate (Herring et al. 1982; Laird et al. 2003; Desselberger et al. 2005; WHO 
2009b).  Electropherotypes provide information on the genetic diversity of rotavirus 
circulating in a population (Fischer and Gentsch 2004; Uchida et al. 2006; Dzikwi et al. 
2008).  The overall sensitivity of PAGE has a range of 108 to 109 viral particles per millilitre 
(Arguelles et al. 2000).   Samples that test PAGE negative after testing EIA positive could 
indicate degradation of virus particles (Fischer and Gentsch 2004). 
 
2.6.6 Conventional RT-PCR 
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of viral RNA is a process 
during which the RNA is converted to complementary deoxyribonucleic acid (cDNA) which 
is then amplified to detectable levels by PCR.  The PCR is a method in which DNA 
fragments are amplified to detect the presence or absence of a specific gene sequence (Atlas 
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1997).  Such RT-PCR assays are used in the G and P typing of Group A rotaviruses by using 
type-specific primers which target specific regions of the VP4 and VP7 genes (Farkas and 
Jiang 2007).  Using RT-PCR as an analysis tool has reduced the number of non-typeable 
strains, but strains containing spontaneous mutations at the primer binding sites, however, 
remain non-typeable by RT-PCR (Santos and Hoshino 2005).  Several sensitive conventional 
RT-PCT methods based on primers specific to several different rotavirus genes have been 
developed to date (WHO 2009b).  As a detection method, RT-PCR improves Group A 
rotavirus detection compared to enzyme immunoassay or electron microscopy (Logan et al. 
2006).  Due to a lack of appropriate reagents for serotyping of rotaviruses, such as type-
specific high-titer polyconal antisera and G- and P-specific monoclonal antibodies, 
serotyping cannot be considered as a typing method, and genotyping using RT-PCR should 
be considered as a generally used typing method (Honma et al. 2007). 
 
2.6.7 Real time RT-PCR 
Real time RT-PCR of rotavirus genes allows for amplification and fluorescent detection 
phases to be performed in one test tube by a single instrument.  The product for the real time 
RT-PCR is plotted in the form of an amplification curve, consisting of an early background 
phase, log phase indicating the presence of the tested organism, and the end-point (WHO 
2009b).  Zeng et al. (2008) indicated that real time RT-PCR is a more rapid and more 
sensitive method of detection and quantitation of rotavirus compared to the conventional RT-
PCR method.  Several sensitive real time RT-PCR methods based on primers specific to 
several different rotavirus genes have been developed to date (WHO 2009b).  A study 
conducted by Logan et al. (2006) showed a 111% increased rate of detection by real time RT-
PCR compared to latex agglutination, and a 186% increase rate of detection compared to 
electron microscopy.   
 
2.7 Methods of rotavirus control 
Methods for rotavirus control as indicated by Heymann (2008) included preventive measures 
such as vaccination, disinfecting surfaces with chlorine (as rotaviruses have shown resistance 
to commonly used disinfectants), dressing infants in overalls to cover diapers to reduce the 
chances of leakage, sanitary disposal of diapers and frequent washing of their hands by 
parents or caretakers to reduce the risk of other children being infected.  Disinfectants which 
can inactivate rotavirus include ethanol, phenol and formalin (Donelli and Superti 1994). 
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2.8 Rotavirus Vaccines 
In countries that show a high mortality rate of ≥10%, it is highly recommended that children 
should be vaccinated.  Rotavirus infections trigger a serum and intestinal antibody response 
in the body which leads to protection against severe gastroenteritis when a patient is re-
infected (Jiang et al. 2002).   
 
Reasons noted by Armah et al. (2001) for the development of vaccines include the fact that 
natural immunity to initial rotavirus infection is generally homotypic and that immunity will 
broaden after subsequent infections.  These factors led to research involving protective 
immunity against antigenic types so that if children were exposed at an earlier stage in life the 
children would not then develop severe, life-threatening infection following exposure to 
rotaviruses.  In a study conducted by Velazquez et al. (1996) in Mexico, results showed the 
role that initial and subsequent infections play in natural immunity against rotavirus 
infections.  Results showed that repeated infections with the same G type is not very likely to 
occur, a 77% efficacy against any rotavirus-associated diarrhoeal infections after one 
infection, 83% after two infections and 92% after three infections; an 87% efficacy against 
moderate to severe diarrhoea after one infection and up to 100% after two infections; a 73% 
efficacy against mild diarrhoea after one infection, 75% after two infections and 99% after 
three infections, and 38% asymptomatic diarrhoea after one infection, 62% after two 
infections and 74% after three infections.  Therefore, vaccines mimicking the initial infection 
by rotaviruses should induce immunity in young children.  The protection due to natural 
infections are generally lower in developing countries,  with only 43% after the first infection 
and 79% as seen in India after three infections compared to 100% after two infections as seen 
in Mexico (Babji and Kang 2012).  Rotavirus vaccine development has been largely based on 
the most prevalent VP7 serotypes (G1 - G4) (Woods et al. 1992; Trabelsi et al. 2000).   
 
A vaccine should form part of a diarrhoea disease control strategy that also includes 
improvement of hygiene and sanitation, zinc supplementation and community-based 
administration of oral-rehydration solutions (WHO 2009a).  A comprehensive analysis of all 
circulating rotavirus geno/serotypes is important in order to fully evaluate the suitability of 
vaccines worldwide (AnnaRita et al. 2010).  Atchison et al. (2010) indicated that the expected 
long-term effectiveness of rotavirus vaccination would be similar to that of the diphtheria, 
tetanus and polio (DTP) vaccine, which is approximately 91% at the child’s first birthday in 
the United Kingdom.  These authors, however, predicted that during the first two years post 
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vaccination introduction there will be an increasing decline in the number of rotavirus 
incidences requiring medical treatment and that this will be followed by the third year where 
a large epidemic of rotavirus infections will be experienced before the disease incidence will 
stabilize at long-term, post-vaccination levels.  Chang et al. (2010) determined that an 
approximate 27% drop in hospitalisation due to rotavirus infections post-vaccination will also 
lead to a decrease in hospitalisation costs. 
 
Malnutrition and poor access to treatment could play an important role in the effectiveness of 
vaccines, leading to the vaccine being less effective in reducing the burden of the disease in 
some countries.  Other health conditions that could possibly impact on the efficiency of the 
vaccine could include HIV infections, infections with other enteropathogens and the 
epidemiology of the rotavirus in a specific region (Parashar et al. 2006; Ciarlet and Schödel 
2009; Rodrigo et al. 2010).  Rodrigo et al. (2010) also indicated that the maternal antibodies 
in breast milk and/or maternal transplacental antibodies might potentially reduce the efficacy 
of rotavirus vaccines.  
 
For rotavirus vaccines to be effective it might be significant for pharmaceutical companies to 
include the not so common strains, which have shown to be the major cause of infections as 
in Brazil and Malawi (Armah et al. 2001). 
 
The first rotavirus vaccines were based on non-human rotavirus strains, including the bovine 
rotavirus vaccines RIT4237 and WC3, the rhesus rotavirus vaccine MMU188006 and the 
Lanzhou lamb rotavirus vaccine (Parashar et al. 2006).  The emphasis of vaccine production 
thereafter shifted to the development of multivalent animal-human reassortant vaccines and 
these vaccines were based on quadrivalent rhesus rotavirus/rhesus-human reassortant 
vaccines such as RotaShield and BIOVIRx (Parashar et al. 2006; Ward et al. 2008). 
 
2.8.1 Bovine rotavirus vaccines RIT4237 and WC3 
The RIT4237 and WC3 vaccines were both bovine rotavirus vaccines (based on the G6P[6] 
strain for RIT4237 and G6P[7] strains for WC3).  During initial clinical trials, both the 
vaccines showed promising results with regard to efficacy, but a lower efficacy was observed 
in trials conducted in developing countries, leading to the vaccines being withdrawn and 
further development being discontinued (Laird et al. 2003; Parashar et al. 2006; Perez-Vargas 
et al. 2006).  The RIT4237 vaccine was, for example, effective in preventing severe diarrhoea 
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in Finland (>80%) but showed a low efficacy in Africa and Latin America (Greenberg and 
Estes 2009). 
 
2.8.2 Rhesus vaccine (MMU18006) 
The MMU18006 vaccine was a rhesus rotavirus vaccine (based on the G3P[5] strain).  
However, the efficacy of the vaccine was inconsistent (0% to 85%) when assessed in clinical 
trials and the development of the vaccines was stopped (Parashar et al. 2006; Perez-Vargas et 
al. 2006). 
 
2.8.3 Lanzhou lamb vaccine (LLR vaccine) 
The LLR vaccine is a monovalent, lamb strain vaccine (based on the G10P[12] strain) and is 
produced in China.  This vaccine is currently still available for use in some areas in China 
(Parashar et al. 2006; Perez-Vargas et al. 2006; Farkas and Jiang 2007; Mirzayeva et al. 
2009).  The vaccine is very expensive resulting in many patients not completing the 
recommended program of three doses (Fu et al. 2012).  The LLR vaccine showed an overall 
efficacy of approximately 73% against rotavirus gastroenteritis (Mirzayeva et al. 2009).  An 
efficacy study conducted by Fu et al. (2012) from 2009 to 2011 in Guangzhou, showed 
partial protection against rotavirus-associated diarrhoea when this vaccine was given to 
children 9 to 35 months of age.  The small cohort of children included in the study who 
received the LLR vaccine showed a 43.8% efficacy after one dose and 44.6% after two doses.  
These researchers suggested that, for vaccine administration, infants should receive their first 
dose during their first year and the second dose when aged between 12 and 23 months and the 
third dose between 24 and 35 months.    
 
2.8.4 Rotashield 
Rotashield was a quadrivalent human-rhesus reassortant vaccine and was based on the G3 
strain (Parashar et al. 2006).  Rotashield was designed as a vaccine to protect against the four 
most predominant rotavirus types identified at the time of production - G1 to G4 (Asmah et 
al. 2001; Santos and Hoshino 2005; Perez-Vargas et al. 2006; Gurgel et al. 2008).  Rotashield 
was withdrawn in October 1999 after it was reported that the vaccine appeared to be 
responsible for intussusception, a bowel obstruction where one segment of the bowel 
becomes enfolded in another segment (Barnes et al. 2002; Bernstein et al. 2002; WHO 2002; 
Santos and Hoshino 2005; Parashar et al. 2006; Perez-Vargas et al. 2006; Farkas and Jiang 
2007; van Damme et al. 2007b; Gurgel et al. 2008; CDC 2009; Ciarlet and Schödel 2009; 
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McCormack and Keam 2009; Mirzayeva et al. 2009; Salvadori and le Saux 2010).  
Rotashield was also associated with increased occurrences of fever, vomiting, diarrhoea, 
abdominal pain and bloody stools (Vesikari et al. 2006).  In 2004, the license for the 
Rotashield vaccine was transferred to BIOVIRx and BIOVIRx is currently being re-evaluated 
as a rotavirus vaccine (Parashar et al. 2006). 
 
2.8.5 Rotarix 
Rotarix contains the live, attenuated human rotavirus RIX4414 strain (Ruiz-Palacios et al. 
2006; McCormack and Keam 2009; Mirzayeva et al. 2009; Salvadori and le Saux 2010) and 
is a human infant rotavirus strain, based on the G1P[8] rotavirus strain 89-12 (Parashar et al. 
2006; Perez-Vargas et al. 2006; Ruiz-Palacios et al. 2006; McCormack and Keam 2009; 
Mirzayeva et al. 2009; van Effelterre et al. 2009; Atchison et al. 2010; Tate et al. 2010; 
Gagneur et al. 2011; Hauber et al. 2011; Lopman et al. 2012).  This strain was isolated in 
Cincinnati and cloned and attenuated by serial passage in African green monkey kidney cell 
tissue culture (CDC 2009; Ward et al. 2008; McCormack and Keam 2009).  The dosing 
schedule in the U.S.A. was set as two, four and six months of age, with the first dose to be 
administered between six and 15 weeks of age, the last dose before eight months of age, with 
at least four weeks elapsing between doses (Lopman et al. 2012).   
 
Rotarix has been identified as being effective in preventing serious rotavirus gastroenteritis 
caused by G1P[8], G3P[8], G4P[8] and G9P[8] (Sanchez-Padilla et al. 2009).  McCormack 
and Keam (2009) used data from various clinical trials to indicate a protective efficacy of 
Rotarix against rotavirus gastroenteritis of any severity to be 90-96% against G1P[8], 73-90% 
against non-G1, P[8] rotaviruses, 58-62% against G2P[4]; and protective efficacy against 
severe rotavirus gastroenteritis of 83-100% caused by G1P[8], 82-100% caused by non-G1, 
P[8], and 44-86% caused by G2P[4].  Linhares et al. (2008) determined the protective 
efficacy of Rotarix to be 90.4-99.1% (average 96.4%) against G1, 24.0-98.5% (average 
85.5%) against G2, 52.8-99.9% (average 93.7%) against G3, 68.3-99.9% (average 95.4%) 
against G4 and 71.7-92.6% (average 85.0%) against G9. 
 
A safety and efficacy trial conducted in 11 Latin American countries and Finland showed the 
efficacy against severe rotavirus-associated diarrhoea as 84.7% and against hospitalisation as 
85%.  The occurrence of diarrhoea, vomiting and dehydration was lower in infants who 
received the vaccine compared to infants who received a placebo, and the incidence of 
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hospitalisation was also lower in vaccinees (Ruiz-Palacios et al. 2006). Double-blinded, 
placebo-controlled protective efficacy trials for Rotarix were conducted in Europe, Latin 
America, Finland, Asia and South Africa, and the combined results for clinical trials 
conducted in Europe, Latin America, Asia and South Africa indicated a protective efficacy of 
Rotarix to be 82-96% against severe rotavirus diarrhoea, 85-100% effective against severe 
rotavirus gastroenteritis requiring hospitalisation following the first year of vaccination 
(McCormack and Keam 2009).  Clinical trials which followed participants to two years of 
age of the end of the second rotavirus season (McCormack and Keam 2009) prior to vaccine 
introduction showed the efficacy of Rotarix to be 81-96% against severe rotavirus 
gastroenteritis and 83-96% against severe rotavirus gastroenteritis requiring hospitalisation.  
Clinical trials conducted in Finland, Latin America and Asia indicated that Rotarix was 
effective against severe rotavirus gastroenteritis in 68-90% of cases, 56-73% against any type 
of rotavirus diarrhoea (Page 2006).  The introduction of vaccination with Rotarix showed a 
reduction in the hospitalisation of infants due to diarrhoea by 42% during the first year of the 
Latin American and Finland clinical trials and a reduction of 29% following two years of a 
clinical trial conducted in Asia (Ruiz-Palacios et al. 2006; McCormack and Keam 2009).  
Clinical trials conducted in Mexico, Venezuela, Brazil (Latin America) and Singapore (Asia) 
indicated Rotarix to be effective against severe rotavirus gastroenteritis in 85-93% of cases, 
70-85% against any type of rotavirus gastroenteritis (Parashar et al. 2006).  During a phase III 
clinical trial in European countries, the protective efficacy during the first two year of life of 
infants against severe rotavirus gastroenteritis was determined to be 85.1-94.1% and against 
hospitalisation 83.3-99.5% (Linhares et al. 2008).  In studies conducted in South Africa, a 
high efficacy against severe rotavirus infections was demonstrated by Rotarix in patients with 
HIV (Rodrigo et al. 2010).  Data from a phase III placebo-controlled efficacy study in 
Singapore, Hong Kong and Taiwan indicated that Rotarix showed a >95% efficacy against 
severe rotavirus gastroenteritis, 100% against wild type G1 and 94% against non-G1 types, 
an overall reduction of 29% was observed in hospitalisation due to rotavirus associated 
gastroenteritis (Mirzayeva et al. 2009).  In Asia, Rotarix showed a 96.1% efficacy in Taiwan, 
in Singapore a 85.1% efficacy and in Hong Kong a 96.1% efficacy against rotavirus-
associated diarrhoea in post licensure trails (Babji and Kang 2012). 
 
A placebo-controlled, multicentre trial conducted in South Africa and Malawi showed the 
rotavirus vaccine efficacy to be 61.2%, with a reduction of 30.2% in all-cause severe 
gastroenteritis.  The study showed the efficacy of the vaccine in South Africa and Malawi 
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(61.2%) to be lower compared to studies performed in Europe (96.4%) and Latin America 
(84.8%).  These findings are consistent with other vaccine efficacies in lower income, 
developing countries involving poliomyelitis vaccine, oral typhoid vaccine and other 
rotavirus vaccines.  Possible explanations for the lowered efficacy of vaccines in developing 
countries include poor nutrition, enteric co-infections, the levels of anti-rotavirus antibodies 
in breast milk, interference of maternal antibodies or interference by co-administration of oral 
polio vaccine (Madhi et al. 2010).  The efficacy of Rotarix in South Africa was found to be 
76.9% and in Malawi 49.4%, as determined during post-licensure efficacy trials (Babji and 
Kang 2012). 
 
Steele et al. (2008) determined that administrating two doses of Rotarix to infants at age six 
and ten weeks yielded the development of anti-rotavirus IgA in 36% in infants who received 
Rotarix together with oral poliovirus vaccine (OPV) and 43% in infants who received Rotarix 
together with inactivated poliovirus vaccine (IPV).  The anti-rotavirus IgA development 
increased after adaption of the schedule to administration of the vaccine at 10 and 14 weeks 
in 61% of children who received Rotarix with OPV and in 55% in children who received 
Rotarix with IPV.  The increase of anti-rotavirus IgA seen after the adaption of the schedule 
could be due to immature gut or immune systems in younger infants, the presence of other 
enteric pathogens or the presence of rotavirus-specific maternal antibodies.  These studies 
showed that it was safe to administer Rotarix together with routine infant vaccines such as 
IPV or OPV (Steele et al. 2008).   
 
Lopman et al. (2012) indicated that as of 2011 Rotarix had been introduced as part of 27 
programs nationally or regionally within the Americas, Europe and Australia.  Rotarix was 
registered in July 2006 in South Africa and is available in a two dose schedule (Page 2006).   
 
2.8.6 RotaTeq 
RotaTeq is a live, oral, pentavalent human-bovine reassortant vaccine (Perez-Vargas et al. 
2006; Vesikari et al. 2006; Farkas and Jiang 2007; Salvadori and le Saux 2010), and contains 
five reassortant rotaviruses that were developed using human and bovine parent strains (CDC 
2009).  RotaTeq is composed of reassortants expressing the human G1, G2, G3, G4 and P[8] 
strains (Gurgel et al. 2008; Ciarlet and Schödel 2009; Atchison et al. 2010; Salvadori and le 
Saux 2010; Tate et al. 2010; Gagneur et al. 2011; Hauber et al. 2011).  The strains used for 
development of RotaTeq include G1P[5], G2P[5], G3P[5], G4P[5] and G6P[8] (van 
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Effelterre et al. 2009).  The parent bovine strain, WC3, was derived from a calf in 
Pennsylvania and cloned and attenuated by serial passage in African green monkey kidney 
cells (CDC 2009).  The dosing schedule in the U.S.A. was set as two and four months of age, 
with the first dose to be administered between six and 15 weeks of age, the last dose before 
eight months of age, with at least four weeks elapsing between doses (Lopman et al. 2012). 
 
RotaTeq was proven to be 75% efficacious against all rotavirus gastroenteritis and 100% 
efficacious against severe disease in the United States (Ciarlet and Schödel 2009; Atchison et 
al. 2010).  The safety and efficacy of RotaTeq was evaluated during the Rotavirus Efficacy 
and Safety Trial (REST) which was conducted in America and Finland and included 70 000 
infants (Parashar et al. 2006; Vesikari et al. 2006; CDC 2009).  The REST was conducted in 
11 countries, form 2001 to 2004, and enrolled healthy infants between the ages of six and 12 
weeks.  Results showed that RotaTeq reduced the rate of hospitalisation and emergency room 
visits caused by G1 by 95%, G2 by 87.6%, G3 by 93.4%, G4 by 89.1%, and G9 and G12 
by 100% (Vesikari et al. 2006).  Sanchez-Padilla et al. (2009) indicated a reduction in 
hospitalisation and visits to the emergency room due to infections caused by rotavirus strains 
G1, G3, G4 and G9 after introduction of RotaTeq, with limited data being available with 
regards to effectiveness of RotaTeq on rotavirus strain G2.  Results from the REST showed 
the efficacy against rotavirus-associated diarrhoea of any severity to be 74.9% against G1, 
63.4% against G2, 82.7% against G3, 48.1% against G4 and 65.4% against G9 (Vesikari et 
al. 2006).  Sub-studies of the REST was performed to determine the efficiency of RotaTeq 
and showed it to reduce rotavirus-related hospitalisation and emergency room visits by 95% 
in both Europe and the United States and by 90% in the Latin American/Caribbean region 
(Ciarlet and Schödel 2009).  Clinical trials conducted in the United States, Belgium, Costa 
Rica, Germany, Guatemala, Italy, Jamaica, Mexico, Sweden and Taiwan indicated that 
RotaTeq is effective against severe rotavirus diarrhoea in 98% of cases, 74% against any type 
of rotavirus diarrhoea (Vesikari et al. 2006).  Parashar et al. (2006) indicated RotaTeq to be 
74% effective against any G1-G4 rotavirus infections and 98% effective against severe G1-
G4 infections in the first season of administration.  In Asia RotaTeq showed a 42.7% 
efficacy, in Bangladesh and a 63.9% efficacy in Vietnam; and in Africa a 55.5% efficacy in 
Ghana, a 63.9% efficacy in Kenya and in Mali a 17.6% efficacy against rotavirus-associated 
diarrhoea in post licensure trails conducted (Babji and Kang 2012). 
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The REST also showed similar results for infants receiving a vaccine and those receiving a 
placebo for deaths, the occurrences of fever, vomiting and diarrhoea and adverse effects were 
also similar in infants receiving the vaccine and those receiving a placebo (Vesikari et al. 
2006).  
 
In a study by Donato et al. (2012), results showed that RotaTeq could cause disease in some 
individuals, including patients with medical conditions associated with immunosuppression.  
However, these patients represent a small percentage of vaccinated children, and the risk 
associated with rare events of vaccine-associated disease is minor compared to the risk 
associated with wild-type infections. 
 
RotaTeq was licensed and recommended for use in the United States in 2006 and data 
gathered from various population-based surveillances in North America indicated a reduction 
in hospitalisations due to rotavirus infections of 46% in 2008 compared to data from 2006 
(Curns et al. 2010).  Lopman et al. (2012) indicated that as of 2011 RotaTeq had been 
introduced as part of seven programs nationally or regionally within the Americas, Europe 
and Australia. 
 
2.8.7 Rotarix and RotaTeq – associated risk of intussusception 
As a risk of intussusception was associated with and led to the withdrawal of Rotashield, the 
Rotarix and RotaTeq vaccines were intensively surveyed in large safety and efficacy trials.  
Post-marketing surveillance was also performed on these two vaccines (Greenberg and Estes 
2009; WHO 2011b).  Whilst no increased risk of intussusception was reported in two clinical 
trials conducted each with between 60 000 and 70 000 subjects, post-marketing surveillance 
identified a slight risk of intussusception when 1 – 2 / 100 000 patients were diagnosed with 
intussusceptions.  This reduced risk is significantly lower than the risk observed with 
Rotashield that indicated an incidence five and ten times higher in some populations (WHO 
2011b), or 18 to 56 / 100 000, with the greatest risk  observed 3-14 days after the first dose 
and 3-7 days after the second dose (Vesikari et al. 2006). 
 
Patel et al. (2011) conducted safety trials in Brazil that started in March 2006 and in Mexico 
May 2007, on infants receiving the Rotarix vaccine and followed these patients for five years.  
The researchers found an association between intussusception and the first dose of Rotarix in 
infects in the Mexican trial, but no risk after the first dose was observed among infants in the 
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Brazilian trial, with no increase in risk after the second dose.  No increased risk of 
intussusception was identified in various initial trials conducted between infants receiving the 
vaccine and those in the placebo study group (Greenberg and Estes 2009; Salvadori and le 
Saux 2010; Hagbom et al. 2012). 
 
A safety trial, REST, was conducted in which 70 000 infants were enrolled to evaluate the 
risk of intussusceptions.  During the trial no sign of intussusception was observed within 42 
days after a dose of RotaTeq (Vesikari et al. 2006; Tate et al. 2010).  The risk of 
intussusception was checked during follow-up visits with the patients on days 7, 14, 60 and 
365 after receiving the first dose (Vesikari et al. 2006).  No increased risk of intussusception 
was identified in various initial trials conducted between infants receiving the vaccine and 
those in the placebo study group (Greenberg and Estes 2009; Salvadori and le Saux 2010; 
Hagbom et al. 2012).   
 
The benefits of the vaccines, therefore, outweigh the risks and support the WHO 
recommendation that these vaccines should form part of an immunisation program.   
 
2.8.8 Additional Vaccine Research 
Currently, additional research is being conducted in India on human neonatal rotavirus strain 
vaccines, including 116E (based on the G9P[11] strain) (Parashar et al. 2006; Babji and Kang 
2012) and 1321 (based on the G10P[11] strain) (Parashar et al. 2006).  The 116E vaccine is a 
naturally reassortant responsible for asymptomatic disease, isolated from an Indian strain, and 
is currently in phase III clinical trials (Babji and Kang 2012).  The RV3 vaccine (based on the 
G3P[6] strain) was isolated from newborns in Melbourne, Australia (Barnes et al. 2002; 
Parashar et al. 2006), and is currently undergoing development in Indonesia (Babji and Kang 
2012).  Barnes et al. (2002) indicated that neonates who were infected with RV3 (G3) were 
protected against infection for the first three years of life, and were also protected against 
severe infections due to community strains of the virus, including serotypes G1 and G2.  
Todd et al. (2010) indicated that the National Institutes of Health has developed a bovine-
human tetravalent reassortant vaccine (G1-G4), which could be modified to include emerging 
serotypes such as G8 and G9, making this vaccine ideal for developing countries where high 
numbers of uncommon strains are observed.   
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2.8.9 Summary 
After monitoring the trends of rotavirus infections over a seven year period, Gagneur et al. 
(2011) reported a two-fold decrease in the number of hospitalisations due to severe rotavirus 
diarrhoea in children younger than two years of age.  Note that this research period included 
five years prior to vaccine introduction and two years post vaccine introduction.  After the 
introduction of Rotarix and RotaTeq in France, Gagneur et al. (2011) observed no significant 
changes in the distribution of rotavirus genotypes and no emergent rotavirus genotypes were 
identified.  However, it remains important to identify circulating rotavirus strains to monitor 
vaccine effectiveness.  Ramani et al. (2007) raised the concern that current vaccines will not 
be effective in protecting children from the G12 strain, as this strain was observed in patients 
who presented with severe symptomatic diarrhoea, and who had previous rotavirus 
infections.   
 
South Africa was the first African country which introduced rotavirus vaccines as part of 
their immunisation programme, starting in the Eastern Cape region with a roll out to the rest 
of the country during 2009 (Neuzil et al. 2010).   
 
As seen with natural infections, protection is lower after subsequent infections in developing 
countries, the same is observed during vaccinations with a lower efficacy observed in 
developing countries compared to developed countries.  Lopman et al. (2012) indicated that 
the Rotarix and RotaTeq provide protection against a range of circulating homotypic and 
heterotypic rotavirus strains, however in lower income countries where greater strain 
diversity is observed, the emergence of new or novel rotavirus strains may reduce the 
immunogenicity and efficacy of the vaccines. 
 
In conclusion, based on the data from the various efficacy studies performed on the two 
vaccines currently available in South Africa, Rotarix and RotaTeq, it is recommended that 
these vaccines form part of an immunisation programme in South Africa, and that research to 
determine the predominant circulating rotavirus strains continue so as to determine the 
continued efficacy of these vaccines. 
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CHAPTER 3 
 
METHODOLOGY 
 
Research is conducted to solve specific problems and to increase understanding of a specific 
phenomenon or topic of interest.  This can be achieved by following a systematic process of 
collecting, analysing, interpreting and discussing data (Leedy and Ormrod 2005).  The 
research methodology of a project is concerned with the research processes and the 
procedures used to gather and analyse data (Mouton 2001). 
 
The research design for this study was based on a quantitative research design.  A 
quantitative research design project can be used to statistically explain, confirm, validate and 
test research questions (Leedy and Ormrod 2005).  The quantitative research design type used 
for this study was an experimental or empirical study and included a natural experimental 
design study and a methodological study (Mouton 2001).  Experimental studies are 
concerned with cause and effect relationships, expressed in different variables (Leedy and 
Ormrod 2005). 
 
The referencing style used in the dissertation was based on the Name-date (Harvard) style as 
described by Neville (2010). 
 
The objectives, hypotheses, sampling and analysis methodologies were specified prior to 
commencement of data collection, and a literature study was conducted on all factors relating 
to the variables examined during the research project.   
 
Results obtained from the experimental processes and data gathered from literature was used 
and integrated to formulate conclusions, answer the research questions and support 
recommendations made. 
  
3.1 Quantitative Research Design 
The quantitative research design can be subdivided into three phases, a conceptual phase, an 
empirical phase, and an analytical phase.  The conceptual phase consisted of the research 
proposal and literature review, during which all aspects and variables of the study problem 
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were reviewed; the empirical phase consisted of the selection and collection of samples, data 
collection, and the methodologies used for sample analysis; and the analysis phase during 
which all results, technical data and literature data were collated. 
The quantitative research design was used for this project to determine: 
• the effectiveness (sensitivity and specificity) of rapid-test kits used by diagnostic 
laboratories to determine the presence of rotaviruses in stool samples, 
• the geographical distribution of rotavirus infections in Gauteng and selected regions 
within the North West and Limpopo provinces,  
• the seasonality of rotavirus infections during the 2010/2011 seasons,  
• the age and gender of children with rotavirus infections, 
• the circulating strain/strains responsible for rotavirus disease in Trichardt, Middelburg 
and Rustenburg during the 2010/2011 seasons, and 
• the potential effectiveness of rotavirus vaccines within the study community. 
 
The study results were also compared with finding from studies conducted locally and 
internationally and similarities and differences identified and discussed. 
 
3.2 Sample and Demographic Data Collection 
Stool samples were collected from a Private Pathology Practice in Pretoria, and screened to 
determine the age and gender of the patients, sample collection date, location of sample 
origins and if samples were rotavirus positive or negative as determined by rapid test kits 
upon receipt. Data were analysed to determine the burden, molecular epidemiology and 
geographical distribution of rotavirus infections during the 2010 and 2011 seasons in Gauteng 
and selected regions within the North West and Limpopo provinces, to estimate the potential 
impact and expected effectiveness of the introduction of rotavirus vaccines, and to evaluate 
the effectiveness of rapid test-strips used by diagnostic laboratories.  The stool samples were 
received from private hospitals, clinics and general practitioners using the Pathology Practice 
as a diagnostic laboratory.  Data on the vaccination status of children included in the study 
were not known, as samples were received from the Pathology Practice and there was no 
direct contact with the patients.  It can, however, be assumed that the majority of patients did 
receive a rotavirus vaccination as most patients would have been a member of a medical aid. 
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3.2.1 Sample Selection  
Only stool samples were studied in this research and these samples were collected from a 
Private Pathology Practice in Pretoria from March 2010 to August 2011.  Verbal permission 
was received from the Pathologist in charge of the Microbiology Department to collect all 
stool samples prior to the department discarding the samples, and a letter indicating 
objectives of study was delivered to the Pathologist in Charge for their records (Please see 
Appendix A).   
 
Stool samples were kept in a 2° - 8°C refrigerator in the Microbiology Department of the 
Private Pathology Practice from the receiving date in the laboratory to the date when the 
samples were collected for study purposes – generally seven days following the collection 
date and prior to their being discarded from the Microbiology Laboratory.  Data from all stool 
samples were screened to determine the date of birth of the patient, in order to evaluate if the 
sample would be included or excluded from the study.  Inclusion criteria for the study were 
based only on the date of birth of the patient, i.e. only stool samples for children younger than 
five years of age were retained for inclusion in the research study.  As the reason for the 
patient’s visit to a doctor or emergency room was not known, it was not used as an inclusion 
or an exclusion criterion.  All samples selected for inclusion were then kept in a -20°C freezer 
prior to transporting to the Medunsa Campus of the University of Limpopo.  Samples were 
stored in freezers at the University of Limpopo until analysis. 
 
3.2.2 Equipment used for the collection and storage of samples 
The equipment used for sample collection and storage included; protective clothing, i.e. 
laboratory coats and gloves, sample containers and  boxes, refrigerators and freezers, a log to 
document demographic data, and study sample numbers which was allocated to all included 
samples. 
 
3.2.3 Study Area 
Samples included in the study were received from suburbs within Pretoria, Centurion, 
Cullinan, Bronkhorstspruit, Rustenburg, Brits, Witbank, Middelburg, Groblersdal, Secunda, 
Trichardt, Standerton, Ermelo, Bethal, Phalaborwa, Laudium, Makopane, Tzaneen, Witbank, 
Mafikeng and Thabazimbi.  From November 2010, samples were also received from suburbs 
within Johannesburg, the East Rand, West Rand, Potchefstroom and Klerskdorp.  Rotavirus 
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negative samples were also sent to the Pathology laboratory for additional analysis from 
Pietermaritzburg, Polokwane, Nelspruit, Louis Trichart, Newcastle and Ellisras. 
 
3.2.4 Other data collection methods used 
Documentation, including journals, text books and reports was collected from the databases 
on the UNISA library, and the information was integrated with the data obtained through 
observation and analysis to confirm and gain additional information during the research 
project. 
 
3.3 Data Analysis methods 
Analysis procedures for the study included macroscopic analysis, EIA, PAGE, and RT-PCR 
analysis. 
 
3.3.1 Macroscopic analysis 
A macroscopic analysis was performed on all samples included in the study to determine if 
the sample could be characterised as a symptomatic or an asymptomatic diarrheal sample.  A 
macroscopic analysis can be defined as a visible evaluation of the sample to determine if the 
diarrheal sample is classified as symptomatic (e.g. watery or loose) or asymptomatic (e.g. 
regular stool sample). 
 
3.3.2 Enzyme immunoassay (EIA) 
An EIA was used to confirm and identify rotavirus positive samples.  This assay is based on 
labelled enzymes attached to either antigens in the detection of antibodies, during an indirect 
EIA, or antibodies in the detection of antigens, during a direct EIA (Atlas 1997).   
 
3.3.2.1 Sample selection for analysis: 
For the purpose of this study 752 samples, negative and positive as determined by rapid test 
strip analysis, were selected and subjected to EIA analysis to identify the positive samples.  
Samples analysed included all samples viable for EIA analysis received from Trichardt, 
Middelburg and Rustenburg, as well as 327 additional samples selected randomly from other 
sites.  The majority of these additional samples were selected from the expected peak periods 
for rotavirus infections (May to August).  The selection was also based on the age of the 
children, and the majority included symptomatic samples collected from children between the 
ages of six to 24 months. 
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3.3.2.2 Principle of the method 
Standard rotavirus diagnosis is generally based on the detection of the rotavirus Group A 
antigen in stool samples by using EIA, as described by Beards et al. (1984).  The ProSpecTTM 
Rotavirus EIA kit was used during the research study.  This rotavirus test uses a polyclonal 
antibody that is in a solid-phase sandwich enzyme immunoassay to detect the specific antigen 
present in Group A rotaviruses (ProSpecTTM Rotavirus package insert 2010).   
 
3.3.2.3 Procedure 
This procedure was adapted from the ProSpecTTM Rotavirus package insert 2010 
A 10% suspension or dilution was prepared for each faecal sample selected for analysis, by 
mixing approximately 0.1 g or 100 µl of sample with 1 ml of distilled water (dH2O).  Each 
sample per well was identified by labelling the corresponding well on an EIA worksheet.  
Two drops (equal to 100 µl) of the positive control, supplied with the ProSpecTTM Rotavirus 
EIA kit, was added to the first micro-well.  An aliquot of 100 µl of distilled water (dH2O) 
was added to the second micro-well as a negative control.  Distilled water was used as the 
negative control as it was used to prepare the stool suspensions or dilution of the stool.  An 
aliquot of 100 µl of the stool suspensions or dilution was added to each of the remaining 94 
micro-wells.  Two drops of conjugate (an enzyme linked capture antibody) was then added to 
each micro-well, the plate was covered and sealed it in its original packet and incubated for 
60 minutes in a 37°C incubator.  After incubation, the contents of the micro-wells were 
discarded into a waste dish and freshly prepared Wash Buffer (X10) was poured into the 
micro-wells.  The Wash buffer was prepared by adding 900 ml of dH2O to 100 ml of Wash 
Buffer supplied in the ProSpecTTM kit.  The washing step was repeated an additional four 
times.  This involved shaking all fluid from the wells after each wash, before the plate was 
inverted and tapped on absorbent paper to remove all traces of the Wash Buffer.  Two drops 
of the enzyme substrate was added to each well, the plate was covered and sealed in its 
original packet and incubated for 10 minutes in a 37°C incubator.  After this incubation step, 
two drops of stop solution were added to each micro-well to stop the substrate reaction, and 
the colour change was visually observed after the second incubation and noted on the EIA 
worksheet.  The plate was read spectrophotometrically at a setting of 454 nm and the 
spectrometer printout collected to validate visually observed results. 
(Please also see Standard Operating Procedure - Appendix B). 
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3.3.2.4 Quality Control 
This procedure was adapted from the ProSpecTTM Rotavirus package insert 2010 
To ensure the validity of the test, a positive (supplied in EIA kit) and negative control (dH2O) 
was included in the first and second micro-wells, respectively, of each EIA performed.  The 
controls acted as a basis for identifying any possible contamination or errors (e.g. excessive 
light or heat exposure) that could have occurred.  When spectrophotometrically read, the 
negative control value should be <0.150 nm and the positive control value >0.500 nm. 
 
3.3.2.5 Calculations 
The cut-off value is determined for each EIA by taking the negative control value as read by 
the spectrophotometer and adding 0.200 (ProSpecTTM Rotavirus package insert 2010). 
 
3.3.2.6 Results 
Micro-wells were visually observed after the second incubation period for a colour change, 
and these changes were noted.  The plate was then read spectrophotometrically after the Stop 
Solution had been added and the spectrophotometer printout collected as validation of all 
results.  Results from EIA analysis were compared with results from the Private Pathology 
Practice to evaluate the effectiveness of the rapid test-strips used for diagnosis. 
 
3.3.3 Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide Gel Electrophoresis (PAGE) analysis was used to determine the rotavirus 
electropherotypes present in stool samples collected during the 2010 and 2011 seasons in 
Trichardt, Middelburg and Rustenburg.  
 
Polyacrylamide Gel Electrophoresis was originally developed as a method to determine the 
molecular weight of proteins in a sample (Laemmli, 1970; Walker 1986).  This method is 
used to separate rotavirus dsRNA fragments and following gel staining of the gene fragments 
in the gel, an electropherotype migration pattern is produced that is used to characterise 
rotaviruses.  During the PAGE process the negatively charged macromolecules separate 
according to size through the gel, these migration patterns can then be visualized by staining 
the gel with silver nitrate (Herring et al. 1982; Laird et al. 2003; WHO 2009b).     
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3.3.3.1 Sample selection for analysis 
Polyacrylamide Gel Electrophoresis analysis was performed on 30 of the positive samples as 
identified by the Private Pathology Practice.  The selection was also based on the age of the 
children, and included symptomatic samples collected from children between the ages of six 
to 24 months, as these ages are identified in literature as the ages where infection most 
frequently occur. 
 
3.3.3.2 Principle of the method 
The PAGE and silver staining procedure can be divided into three main processes; RNA 
extraction, PAGE and silver staining, as described in the “World Health Organizations 
Manual of Rotavirus detection and characterisation methods” (WHO 2009b). 
 
3.3.3.3 Procedure 
This procedure was adapted from the 11th African Rotavirus Surveillance Workshop, 2011.  
  
RNA Extraction Process  
The same suspension prepared for EIA was used for PAGE analysis, a 10% suspension was 
prepared for each faecal sample selected for analysis, by mixing approximately 0.1 g or 100 
µl of sample with 1 ml of dH2O.  An aliquot of 450 µl of the 10% suspension was added to an 
eppendorf tube and 50 µl of a pre-warmed solution of 1 M Sodium Acetate with 1% SDS was 
added to the suspension.   The mixture was vortexed for 10 seconds and then incubated in a 
37°C water bath for 15 minutes.  After incubation 500 µl of phenol-chloroform was added to 
the eppendorf tube, the mixture was vortexed for one minute and incubated in a 56°C water 
bath for 15 minutes.  After incubation the tube was opened and immediately resealed, before 
vortexing for one minute, and centrifuging at 16 000 g for 5 minutes.  The upper aqueous 
phase was transferred to a clean eppendorf tube using a micro pipette.  An aliquot of 40 µl of 
3 M sodium acetate (pH 5.0) was added to the eppendorf tube and the tube filled by adding 
ice-cold absolute ethanol to the dsRNA solution, the tube was gently inverted 4-6 times and 
incubated overnight (two hours to overnight) at -20°C.  After incubation, the solution was 
centrifuged at 16 000 g for 15 minutes at 4°C, and the ethanol immediately decanted.  The 
tube was inverted and placed on an absorbent towel to air dry.  The dsRNA pellet was re-
suspended in 30 µl of PAGE sample running dye (Please see section 3.7 for complete 
composition of reagent).   
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PAGE 
The glass plates were cleaned with soap and water and wiped with 96% ethanol before use.  
The glass plates were assembled according to the manufacturer’s instructions.  The top level 
of the resolving gel was marked on the plate, leaving enough room for the stacking gel.  The 
resolving gel was prepared using a standard recipe (Please see section 3.7 for complete 
composition of reagent).  The acrylamide gel solution was poured in-between the glass plates 
to the mark and gently overlayed with distilled water to prevent meniscus effects.  The gel 
was allowed to set for 2 hours (until the interface between the gel and overlay was visible).  
The water overlay was poured from the top of the gel and draining into a paper towel.  The 
gel apparatus was placed in an upright position whilst the stacking gel was prepared (Please 
see section 3.7 for complete composition of reagent).  The stacking gel was added on top of 
the resolving gel and the comb was placed in immediately.  The gel was allowed to 
polymerise for one hour (45 minutes to one hour).  The comb was removed and the glass 
plates assembled in the electrophoresis apparatus.  A 1xTris-running buffer (Please see 
section 3.7 for complete composition of reagent) was added to the bottom reservoir and the 
glass plates were inserted into the electrophoresis tank.   The 1xTris-running buffer was 
added to the front and back upper tanks, and the tanks were checked for any leakage before 
filling the tanks to the top.  The wells were also filled with electrophoresis buffer (this is 
important to remove any air that might be present under the gel bottom).  The dsRNA 
samples in PAGE buffer was loaded into the designated gel wells and the gel electrophoresed 
100V for 20 hours (16 – 20 hours). 
 
Silver staining 
After electrophoresis the running buffer was poured out and the gel removed from between 
the glass plates.  The bottom right corner of each gel was cut for orientation purposes, the 
stacking gels discarded and resolving gels placed into 200ml of fixing solution (Please see 
section 3.7 for complete composition of reagent) in a clean glass dishes, and rotated at room 
temperature for 30 minutes on an orbital shaker.  After rotation fixing solution one was 
removed by aspiration, and 200ml of fixing solution two (Please see section 3.7 for complete 
composition of reagent) was added to each gel and rotated at room temperature for 30 
minutes on an orbital shaker.  The silver nitrate staining solution was prepared using the 
standard recipe just prior to use (Please see section 3.7 for complete composition of reagent).  
Fixing solution two was removed by aspiration, and 200ml of the silver nitrate staining 
solution was added to each gel and rotated for 30 minutes on an orbital shaker.  The 
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developing solution was prepared, just prior to using, by adding sodium hydroxide to a 
previously prepared formaldehyde and water solution (Please see section 3.7 for complete 
composition of reagent).  The silver nitrate staining solution was removed by aspiration, and 
each gel was washed twice with 200 ml dH2O, allowing 2 minutes for each wash.  
Approximately 50 ml of the developing solution was added to each gel, and shook for 30 
seconds to ensure removal of any black precipitate.  The developing solution was removed by 
aspiration and the remaining developing solution added and rotated at room temperature on 
an orbital shaker for approximately five minutes until the RNA bands were visible.  The 
developing solution was removed by aspiration and the stopping solution (Please see section 
3.7 for complete composition of reagent) was added to prevent any further colouring reaction.  
The gel was rotated for five to 10 minutes in stopping solution at room temperature on an 
orbital shaker before removing the stopping solution by aspiration.  The gels were rinsed in 
dH2O, and dried in a vacuum gel dryer according to the manufacturer’s instructions. 
(Please also see Standard Operating Procedure - Appendix C). 
 
3.3.3.4 Quality Control 
Not applicable. 
 
3.3.3.5 Calculations 
g = 1.12 x radius in mm x (rpm/1000)^2 
 
3.3.3.6 Results 
During the electrophoresis process the negatively charged macromolecules separated 
according to size through the gel, and the migration patterns were visualized by staining the 
gel with silver nitrate (WHO 2009b).  Migration patterns present on the gel can represent a 
super-short, short or long electropherotype.   
 
3.3.4 RT-PCR 
RT-PCR assays were used in the G and P typing of Group A rotaviruses by using type-
specific primers which targeted specific regions of the VP4 (P types) and VP7 (G types) 
genes.  RT-PCR analysis of viral RNA is a process during which the RNA is converted to 
cDNA which is then amplified to detectable levels using PCR (Atlas 1997).  As RNA cannot 
serve as a template during PCR analysis, the RNA must first be converted into cDNA by 
reverse transcriptase. 
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3.3.4.1 Sample selection for analysis 
Conventional RT-PCR analysis was performed on all samples subjected to PAGE analysis.   
 
3.3.4.2 Principle of the method 
The RT-PCT procedure can be divided into three main processes: RNA extraction, reverse 
transcription of dsRNA, and genotype amplification of cDNA as described in the World 
Health Organizations Manual of Rotavirus detection and characterisation methods (WHO 
2009b). 
 
3.3.4.3 Procedure 
This procedure was adapted from the 11th African Rotavirus Surveillance Workshop, 2011. 
 
RNA Extraction (using the QIAamp method) 
An aliquot of 560 µl of the AVL buffer (from the QIAgen kit) and 140 µl of a 10% faecal 
suspension (the same suspension prepared for EIA was used for the RNA Extraction step) 
was added to a 1.5 ml eppendorf tube and mixed by vortexing and then incubated at room 
temperature for 10 minutes.  The AVL buffer was prepared by adding 1 ml of the Buffer 
AVL to one tube of lyophilized carrier RNA.  The tube was briefly centrifuge to sediment 
droplets from the lid.  An aliquot of 560 µl of absolute ethanol was added to the solution, and 
the briefly mixed by vortexing and centrifugation.  An aliquot of 630 µl of the solution was 
transferred to a QIAamp mini spin column (with a 2 ml collection tube) and centrifuged at 7 
200 g for one minute.  After centrifugation, the collection tube containing the filtrate was 
discarded and the QIAamp spin column placed in a clean collection tube.  The remaining 630 
µl of the solution was transferred to the QIAamp mini spin column and centrifuged at 7 200 g 
for one minute.  After centrifugation the QIAamp mini spin column was opened and 500 µl 
of Wash buffer one (AW1) was added to the column.  The AW1 was prepared by adding 125 
ml absolute ethanol to 95 ml of concentrated Wash buffer supplied in the Qiagen kit.  The 
column was centrifuged at 7 200 g for one minute.  After centrifugation the collection tube 
containing the filtrate was discarded and the QIAamp spin column placed in a clean 
collection tube.  An aliquot of 500 µl of Wash buffer two (AW2) was added to the QIAamp 
mini spin column and centrifuged at 16 000 g for three minute.  The AW2 was prepared by 
adding 160 ml absolute ethanol to 66 ml of concentrated Wash buffer supplied in the Qiagen 
kit.  After centrifugation the collection tube containing the filtrate was discarded and the 
QIAamp spin column placed in a clean collection tube.  The QIAamp spin column was 
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centrifuged at 16 000 g for 1 minute.  After centrifugation the collection tube was discarded 
and the spin column placed in a clean 1.5 ml Eppendorf tube.  An aliquot of 60 µl of the AVE 
buffer was added to the spin column and incubated at room temperature for one to five 
minutes.  The AVE buffer is RNase-free water that reduces contamination with RNase and it 
also contains 0.04% of sodium azide used to prevent microbial growth. After incubation the 
spin column was centrifuged at 7 200 g for one minute.  After centrifugation the QIAamp 
spin column was discarded and the 1.5 ml Eppendorf tube was stored at -20°C or -70°C. 
 
RT-PCR 
The RT-master mix was prepared in a 1.5 ml Eppendorf tube according to calculations as 
indicated on the RT-PCR worksheet (Please see section 3.3.4.5 and Appendix D) and placed 
on cold beads, the AMV enzyme was added prior to use.  The amplification master mix was 
prepared in a 1.5 ml Eppendorf tube according to calculations as indicated on the RT-PCR 
worksheet (Please see section 3.3.4.5 and Appendix D) and placed on cold beads, the Taq 
Polymerase was added prior to use.  The 5’ (sBeg9 for VP7 and Con2 for VP4) and 3’ (End9 
for VP7 and Con3 for VP4) primers and dsRNA (Please see section 3.3.4.5) was added to a 
0.5 ml amplification tube and mixed by pipetting.  The primers and dsRNA were denatured 
on a 94°C heating block for five minutes and transferred immediately to the cold beads.  An 
aliquot of 3.2 µl of the RT-master mix was added to each tube and mixed by pipetting, it is 
important to note that the RT-master mix must be added within five minutes from removing 
tubes from heating block.  The samples were incubated on a 42°C heating block for five 
minutes and immediately transferred to the cold beads.  An aliquot of 40 µl of the 
amplification master mix was added to each tube, and mixed by pipetting and placed on cold 
beads.  The samples were placed in a master cycler for synthesis of cDNA.  The master 
cycler was set to the following settings: 
o One cycle set at 94°C for 2 minutes, 
o 30 cycles set at 94°C for one minutes (denaturation), 42°C for one minute 
(annealing), 72°C for one minute (extension), 
o One cycle set at 72°C for eight minutes, and cooled and held at 4°C. 
After synthesis of cDNA, 3 μl of the cDNA samples and 5μl of a molecular weight marker 
were loaded and ran on 1% agarose at 90 V for approximately 15 minutes to determine 
concentration to be used in genotype amplification. 
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Genotype amplification 
The Genotype-master mix was prepared in a 1.5 ml Eppendorf tube according to calculations 
as indicated on the Genotype worksheet (Please see section 3.3.4.5 and Appendix D) and 
placed on cold beads.  The cDNA was added to a PCR (Eppendorf) tube (0.1 to 6 μl as 
determined by cDNA concentration of RT-PCR amplicons).  The master mix was added to 
the cDNA, and mixed by pipetting.  The samples were placed in a master cycler.  The master 
cycler was set to the following settings: 
o One cycle set at 94°C for 2 minutes, 
o 30 cycles set at 94°C for one minutes (denaturation), 42°C for one minute 
(annealing), 72°C for one minute (extension), 
o One cycle set at 72°C for eight minutes, and cooled and held at 4°C. 
After synthesis of cDNA, 5 μl of the cDNA samples and molecular weight marker were 
loaded and ran on 1% agarose at 90V for one hour to determine genotype. 
(Please also see Standard Operating Procedure - Appendix D). 
 
3.3.4.4 Quality Control 
To ensure the validity of the test, a negative control was included.  The negative control used 
for the electrophoresis of the RT-PCR and genotype amplification samples was the master 
mix prepared for each step. 
 
3.3.4.5 Calculations 
• g = 1.12 x radius in mm x (rpm/1000)^2 
 
• Denature solution: 
8 μl dsRNA 
1 μl Primer 1 (sBeg9 for VP7 and Con2 for VP4) 
1 μl Primer 2 (End9 for VP7 and Con3 for VP4) 
6-10 μl in total 
 
• RT-PCR master mix: 
1X Reaction   11 X reactions (10 samples plus one negative control) 
0.25 μl 10 mM dATP    μl 
0.25 μl 10 mM dCTP   μl 
0.25 μl 10 mM dGTP  11 μl 
0.25 μl 10 mM dTTP    μl 
0.2 μl   AMV RTase  2.2 μl 
2.0 μl   AMV Buffer  2.2 μl 
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• Amplification master mix: 
1X Reaction  11 X reactions (10 samples plus one negative control) 
1 μl dATP    μl 
1 μl dCTP    μl 
1 μl dGTP   44 μl 
1 μl dTTP    μl 
5 μl 10 x Taq buffer 55 μl 
1.2 μl 50 mM MgCl2 13.2 μl 
30 μl PCR Water  330 μl 
0.3 μl Taq Polymerase 3.3 μl 
 
• Genotyping master mix: 
1 X Reaction      31 X reactions  
(30 samples plus one negative control) 
0.1-6 μl cDNA        0.1-6 μl 
1 μl 10 mM dATP       μl 
1 μl 10 mM dCTP       μl 
1 μl 10 mM dGTP      124 μl 
1 μl 10 mM dTTP       μl 
1 μl 10 pmol Anchor primer    31 μl  
(RVG9 for VP7 and Con3 for VP4) 
1 μl 10 pmol Gene specific primers (Cocktail)  31 μl of each primer  
(Please see Table 3.10 and 3.11) 
1.2 μl 50 mM MgCl2     37.2 μl 
26 μl PCR Water      806 μl 
0.3 μl Taq Polymerase     9.3 μl 
  
3.3.4.6 Results 
Agarose gel electrophoresis followed by ethidium bromide staining allowed comparison of 
the migration distance of rotavirus amplicons through the gel against a 100 bp molecular 
weight marker to identify the VP7 and VP4 genotypes. 
 
Details of the expected annealing positions of rotavirus-specific G (Gouvea et al. 
1990/Iturriza-Gomara et al. 2004) or P (Gentsch et al. 1992/Iturriza-Gomara et al. 2000b) 
genotyping primer pairs are as seen in Tables 3.1 and 3.2: 
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Table 3.1 P-type primer pairs 
Primer Position (bp) Genotype 
1T-1D 339-356 P[8] 
2T-1 474-494 P[4] 
3T-1 259-278 P[6] 
4T-1 385-402 P[9] 
5T-1 575-594 P[10] 
mP11 305-323 P[11] 
 
Table 3.2 G-type primer pairs 
Primer Position (bp) Genotype 
aAT8v 178 - 198 G8 
aBT1 314-335 G1 
aCT2 411-435 G2 
aDT4 480-498 G4 
mG3 250-269 G3 
mG9 757-776 G9 
mG10 666-687 G10 
newG12 504-524 G12 
 
The position of the fragment observed on an agarose gel may be compared with the above 
data to determine the VP7 and VP4 specific genotypes. 
 
3.4 Limitations of the study 
The research study offered findings and information with regard to rotavirus surveillance, but 
may have some limitations due to errors which occurred during sample collection, analytical 
miscalculations and errors. 
 
3.5 Ethical Consideration 
Research ethics takes the following four categories into consideration:  
• protection of the participant, researcher and environment against harm 
• informed consent from all participants 
• the right of privacy for all participants, and 
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• honesty from the researcher (Leedy and Ormrod 2005).   
To ensure that the research project is ethically acceptable and to adhere to the Ethics Policy 
of UNISA, the research proposal was approved by the Ethical Committee of the College of 
Agriculture and Environmental Sciences (For details of this application, please see Appendix 
E). 
 
3.6 Summary 
This chapter discussed the methodology and research design that was used for this research 
study.  The results gained from the analysis procedures used were organised and grouped into 
tables to allow for easy analysis of results and preparation of graphs which illustrated various 
features and trends of rotavirus infection in the communities under study.  The data were 
discuss and used to formulate the conclusions of the study. 
 
3.7 Composition of reagents 
• 5 x Tris-glycine running buffer 
o Dissolve 15.1 g of 25 mM Tris base and 94 g of 250 mM glycine in dH2O 
o Make up to 1000 ml with dH2O 
• 1 x Tris-glycine running buffer 
o Dilute 200 ml 5 x Tris-glycine running buffer with 800 ml dH2O 
• PAGE sample running dye 
o Dissolve 10 mg of bromophenol blue and 1 ml glycerol in 5 ml spacer gel buffer 
o Make up to 10 ml with dH2O 
• 10% resolving gel 
Table 3.3 PAGE Resolving gel formula 
Reagent 1.5 mm gel 
 1x 2x 
dH2O 15.8 ml 31.6 ml 
30% acryl stock 10.0 ml 20.0 ml 
Resolving buffer, pH 8.8 3.75 ml 7.5 ml 
TEMED 15 μl 30 μl 
10% APS 450 μl 900 μl 
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• 4% spacer gel 
Table 3.4 PAGE Spacer gel formula 
Reagent 1.5 mm gel 
 1x 2x 
dH2O 6.8 ml 13.6 ml 
30% acryl stock 1.6 ml 3.2 ml 
Stacking buffer, pH 6.8 1.25 ml 2.5  ml 
TEMED 5 μl 10 μl 
10% APS 150 μl 300 μl 
• Fixing solution 1 
Table 3.5 PAGE Fixing solution 1 formula 
Reagent 1x 2x 
Ethanol 80 ml 160 ml 
dH2O 110 ml 220 ml 
Acetic acid 10 ml 20 ml 
• Fixing solution 2 
Table 3.6 PAGE Fixing solution 2 formula 
Reagent 1x 2x 
Ethanol 20 ml 40 ml 
dH2O 180 ml 360 ml 
Acetic acid 1 ml 2 ml 
• Silver nitrate solution 
Table 3.7 PAGE Silver nitrate formula 
Reagent 1x 2x 
AgNO3 (added prior to use) 0.37 g 0.74 g 
dH2O 200 ml 400 ml 
• Developing solution 
Table 3.8 PAGE Developing solution formula 
Reagent 1x 2x 
36% Formaldehyde 2 ml 4 ml 
dH2O 250 ml 500 ml 
NaOH (added prior to use) 7.5 g 15 g 
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• Stopping solution 
Table 3.9 PAGE Stopping solution formula 
Reagent 1x 2x 
Acetic Acid 10 ml 20 ml 
dH2O 200 ml 400 ml 
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CHAPTER 4 
 
RESULTS AND DISCUSSION 
 
4.1  The overall incidence of rotavirus infections during 2010 and 2011 
The following aspects of rotavirus disease were determined during 2010 and 2011 for the 
sample area:  incidence, seasonality, age and gender of the patients as well as the 
geographical distribution of rotavirus infections (Please see Table F.1, Appendix F).   
 
During the 18 months of sample collection from March 2010 to August 2011, 6050 stool 
samples were collected from a Private Pathology Practice in Pretoria, of which a total of 664 
(10.98%) tested positive for rotavirus infections when using rapid test-strips.  The detection 
rate for rotavirus positive samples received for 2010 was 342 of 3299 (10.37%), and for 2011 
the total number was 322 of 2751 (11.7%).  This is depicted in Figure 4.1.  To ensure the 
accuracy of the incidence of rotavirus infection in samples received by the Private Pathology 
Practice, results were recorded for all samples (Please see Table F.1, Appendix F).   
 
 
Figure 4.1 Incidence of rotavirus positive samples for the 2010 and 2011 season. 
 
 
10.37 % 
11.70 % 
2010 
2011 
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Of the rotavirus-positive stool samples that were collected over the two year period, 52% 
(n=342) were detected in 2010 and 48% (n=322) were detected in 2011.  This is shown in 
Figure 4.2.   
 
 
Figure 4.2 The total number of rotavirus positive samples for the 2010 and 2011 season. 
 
As can be noted in Figure 4.1, the incidence rate for rotavirus infections was slightly higher 
in 2011 (11.70%), compared to 2010 (10.37%) although the total number of rotavirus 
infections for 2010 was slightly higher (52%) compared with 2011 (48%) (Figure 4.2).   
 
Factors that may have contributed to the difference in incidence rates include: 
• more samples were collected in 2010 (n=3299) compared to 2011 (n=2751) 
• a longer collection period in 2010 (44 weeks) compared to 2011 (34 weeks) 
• samples were not collected on at least 9 days during July and August 2011.  
 
4.1.1 Geographical distribution 
Samples positive for rotavirus were widespread and were identified from the following study 
areas: 
• Pretoria (Akasia, Faerie Glen, Groenkloof, Kloof, Les Marais, Montana, Pretoria 
Central, Pretoria West, Rietfontein and Wilgers) 
• Johannesburg (Johannesburg Central, Lenasia, Mulbarton, Randburg and Sandton),  
52% 
48% 2010 
2011 
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• The West Rand (Roodepoort and Krugersdorp) 
• The East Rand (Alberton, Benoni, Germiston and Springs) 
• Klerksdorp, Middelburg, Midrand, Potchefstroom, Bethal, Brits, Bronkhorstspruit, 
Centurion, Ermelo, Groblersdal, Secunda, Standerton, Thabazimbi, Trichardt, Vaal 
Triangle (Vanderbijlpark), Witbank, and Rustenburg  
 
Table 4.1 Geographical-specific rotavirus incidence 
  2010 2011  Combined 
Area 
Number 
of 
positive 
samples 
Total 
number 
of 
samples 
Incidence 
(%) 
Number 
of 
positive 
samples 
Total 
number 
of 
samples 
Incidence 
(%) 
Number 
of 
positive 
samples 
Total 
number 
of 
samples 
Incidence 
(%) 
Pretoria 217 2095 10.4 116 982 11.8 333 3077 10.82 
East Rand 1 7 14.3 14 75 18.7 15 82 18.29 
Bethal 2 18 11.1 0 10 0.0 2 28 7.14 
Brits 10 98 10.2 5 44 11.4 15 142 10.56 
Bronkhorstspruit 0 16 0.0 1 12 8.3 1 28 3.57 
Centrurion 43 402 10.7 32 255 12.5 75 657 11.42 
Ermelo 5 29 17.2 3 13 23.1 8 42 19.05 
Groblersdal 1 16 6.3 0 5 0.0 1 21 4.76 
Johannesburg 1 136 0.7 66 717 9.2 67 853 7.85 
Klerksdorp 0 2 0.0 4 14 28.6 4 16 25.00 
Middelburg 12 96 12.5 4 41 9.8 16 137 11.68 
Midrand 1 13 7.7 24 100 24.0 25 113 22.12 
Potchefstroom 0 1 0.0 1 9 11.1 1 10 10.00 
West Rand 2 69 2.9 28 274 10.2 30 343 8.75 
Secunda 3 31 9.7 2 14 14.3 5 45 11.11 
Standerton 6 22 27.3 1 11 9.1 7 33 21.21 
Thabazimbi 1 4 25.0 0 3 0.0 1 7 14.29 
Trichardt 33 194 17.0 11 102 10.8 44 296 14.86 
Vaal Triangle 0 0 0.0 4 14 28.6 4 14 28.57 
Witbank 0 16 0.0 1 12 8.3 1 28 3.57 
Rustenburg 4 16 25.0 5 32 15.6 9 48 18.75 
Rates highlighted in blue indicate rates higher than the average rate observed for all samples collected over the 
total study area.  Rates highlighted in green indicate rates lower than the average rate observed for all samples 
collected over the total study area 
 
The data relating to the incidence (%) of rotavirus infection in communities in the cities, 
towns and areas indicated in Table 4.1 are indicated graphically in Figure 4.3 below.  
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Figure 4.3 Geographical incidence rates of rotavirus infections for 2010 and 2011 
seasons. 
 
The number and detection rates (%) of rotavirus-positive samples per geographical region are 
illustrated in Figure 4.3 and Table 4.1.  The highest numbers of samples were received from 
the inner city areas, including Pretoria, Centurion, Johannesburg and Midrand, as these are 
the areas from which General Practitioners are expected to more commonly make use of the 
Private Pathology Practice for analysis, especially with regard to microbiological analysis, 
because of the close proximity of these laboratories to their offices/private hospitals 
compared to smaller/more rural areas.   
 
It is important to note that the relative low detection rate observed in Johannesburg, 
Klerksdorp, Potchefstroom, Vaal Triangle and the West Rand for 2010 is due to a reduced 
period of sample collection for two months in November and December, which fell outside 
the rotavirus season.  The incidence rate for the areas ranged between 3.57% and 28.57%, 
and it should be noted that the incidence rates may be ascribed to the number of samples 
received from each area.  The incidence rates observed in Middelburg was 11.68%, in 
Rustenburg 18.75% and Trichardt 14.86%.    
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The NICD reported a detection rate of 21% for rotavirus infections in 2010 and 2011 as 
observed in five hospitals in South Africa, viz. Chris Hani Baragwanath Hospital in Gauteng, 
Dr. George Mukhari Hospital in the North West Province, and Mapulaneng, Matikwana and 
Edendale Hospitals in KwaZulu Natal (NICD 2011; NICD 2012).  In addition, a detection 
rate of 22.8% was reported by Seheri et al. (2010a) over the period 2003 to 2005 in a study 
conducted at the Dr. George Mukhari Hospital in Gauteng/North West, and Brits hospital in 
the North West Province. 
 
These latter rotavirus surveillance studies performed by the NICD and Seheri et al. (2010a) 
were conducted on a hospital surveillance model in Government hospitals in South Africa.  
The lower detection rate observed in this study (average=10.98%) compared to a published 
detection rates of >20% may be ascribed to a difference in incidence of rotavirus infection in 
children seeking treatment in public healthcare facilities as opposed to the relative rotavirus 
incidence in children seeking treatment in private practice.  In the latter case, sample 
collection is largely dependent on the decision of a private General Practitioner to send 
samples for analysis to a Private Pathology Practice to determine cause of illness.  This may 
or may not contribute to an inaccurate reflection of the incidence of rotavirus disease as 
experienced by patients seeking private health treatment.  It should also be taken into 
consideration that samples for both private and medical aid patients are analysed by the 
Pathology Practice, private patients might also, therefore, be more hesitant to provide 
samples for testing due to the costs involved, particularly in microbiological testing.  Samples 
received for inclusion in this study did not form part of a specific surveillance study and 
would have been collected from all patients visiting a private health care practitioner. 
Another consideration that may influence the relative differences in rotavirus infection 
reflects possible differences as to the effectiveness of the introduction and uptake of rotavirus 
vaccines by different communities, leading to mild gastroenteritis symptoms observed in 
children who received the rotavirus vaccine and thus, their exclusion from sample collection 
and diagnosis at the Private Pathology Practice.  This raises speculation as to the involvement 
of other agents responsible for acute gastroenteritis within this study cohort, including viral, 
bacterial, protozoan or helminth agents commonly associated with gastroenteritis, and other 
agents such as members of the Picornaviridae (Knox et al. 2012).   
 
Nevertheless, these figures indicate a significant, high incidence of rotavirus infection in 
communities whose patients seek medical advice at either private care or at primary 
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healthcare facilities.  As such, both these patient groups as well as their respective healthcare 
facilities experience a significant burden associated with rotavirus gastroenteritis. 
 
Based on the macroscopic examination of all samples received in the present study, 79% 
(n=4222) were symptomatic and 21% (n=1122) asymptomatic.  The percentage symptomatic 
rotavirus positive samples were 93% (n=601) and asymptomatic samples 7% (n=48), as seen 
in Figure 4.4. 
 
 
Figure 4.4 Percentage symptomatic vs. asymptomatic rotavirus stool samples. 
 
4.1.2 Seasonality 
The WHO recommends when determining seasonality of rotavirus infection, that the weekly 
or monthly detection rates of rotavirus infections should be determined.  In temperate areas 
such as found in South Africa where rotavirus infection shows a distinct seasonal trend, the 
peak of rotavirus infections can be defined as two consecutive weeks with the greatest 
number of detection.  The onset of a rotavirus season can be determined by determining the 
mean number of rotavirus infections per week and the first week where detection exceeds the 
mean value signals the beginning of the rotavirus season.  The duration of a rotavirus season 
is represented by the number of weeks where detection exceeds the weekly mean (WHO 
2002).   
 
93% 
7% 
Symptomatic 
Asymptomatic 
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In South Africa rotavirus infection has previously been characterised as having a seasonal 
peak starting during the latter part of autumn and reaching a peak during the winter months.   
As recommended by the WHO, both a monthly and a weekly analysis on rotavirus positive 
samples were prepared, as seen in Figure 4.5 and Figure 4.6.   
 
As can be seen in Figure 4.5 and Figure 4.6, rotaviruses appear to be circulating in the study 
communities all year round.  However, the vast majority of rotavirus-positive samples 
collected during 2010 and 2011 were observed particularly in the period June to August 
(>20%).   
  
 
Figure 4.5 Seasonality of rotavirus infections during 2010 and 2011. 
 
From the data collected, it was determined that the rotavirus season for 2010 (mean value 
≥7.8) started in Week 22 and ended in Week 36.  Thus, for 2010 the rotavirus season was 
from the first week of June until the first week of September with a peak being observed in 
Week 29, as seen in Figure 4.6.  
  
The rotavirus season for 2011 (mean value ≥9.5) started in week 23 but was foreshortened 
(due to a reduced collection of stool samples as previously arranged with the Private 
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Pathology Firm) at the end of August 2011.  Thus, the last data for 2011 included week 34 
which still fell within the rotavirus season for 2011.  Only the start of the rotavirus season for 
2011 could be determined as starting in the second week of June.  The peak of the rotavirus 
season for 2011 was observed to correspond to week 30, as seen in Figure 4.6. 
 
 
Figure 4.6 Detection rate (%) of rotavirus positive samples per week for 2010 and 2011. 
 
The study data correlated with data published by the NICD, collected from the five hospitals 
in South Africa included in their surveillance area, which showed the rotavirus season for 
2010 to start in Week 20 and start to decrease in Week 36, with the peak observed in Week 
24 (NICD 2011), and for 2011, to start in Week 21 and start to decrease after Week 36, with 
the peak observed in Week 30 (NICD 2012).  The study data are also consistent with recently 
published results describing the seasonal incidence of South African rotavirus infection (Page 
et al (2009); Seheri et al (2010a). 
 
4.1.3 Age-specific incidence rates 
Data meta-analysis shows the occurrence of rotavirus infections to be high in children 
between six months and two years of age (Donelli and Superti 1994; Percival et al. 2004; 
King 2006; van Damme et al. 2007a; Heymann 2008; Linhares et al. 2008; Atchison et al. 
2009; Wang et al. 2009; van Doorn et al. 2009; Atchison et al. 2010; Kargar et al. 2011; 
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Sherchand et al. 2012), and Seheri et al. (2010a), who reported a high incidence of infection 
in children between two and eleven months of age.    
 
The WHO recommends that when determining the specific age groups of children infected 
with rotavirus, the age groups should be clustered into the following age groups (in months); 
0-2, 3-5, 6-8, 9-11, 12-17, 18-23, 24-35, 36-47 and 48-59 (or 60) months.  Figure 4.7 
represents data from a WHO study that correlates the age of children to rotavirus incidence 
(WHO 2002). 
  
 
Figure 4.7 Age-specific rotavirus infection incidence rates as recommended by the WHO 
(WHO 2002). 
 
As seen in Figure 4.8 and Table 4.2, comparing the age-specific incidence rate of rotavirus 
infection in children from Middelburg, Rustenburg and Trichardt, the current study for 2010 
and 2011 indicates that the incidence in rotavirus infections for 2010 follows the age-specific 
incidence generally observed in rotavirus infections, with the highest incidences observed in 
children younger than two years of age.  Exceptions were noted, however, where in 2010 a 
high incidence of rotavirus infection was observed in children aged between three and five 
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months of age and in 2011, an unexpectedly high peak was observed in children between 25 
and 29 months of age. 
 
Table 4.2 Age-specific incidence percentage of children infected with rotavirus for 2010 
and 2011 
  2010 2011 Combined  
Age in 
Month
s 
Number 
of 
positive 
samples 
Total 
Number 
of 
samples  % 
Number 
of 
positive 
samples 
Total 
Number 
of 
samples % 
Number 
of 
positive 
samples 
Total 
Number 
of 
samples % 
< 1 0 342 0 2 322 0.62 2 664 0.3 
1 3 342 0.88 1 322 0.31 4 664 0.6 
2 8 342 2.34 2 322 0.62 10 664 1.51 
3 13 342 3.8 3 322 0.93 16 664 2.41 
4 13 342 3.8 3 322 0.93 16 664 2.41 
5 11 342 3.22 6 322 1.86 17 664 2.56 
6 9 342 2.63 5 322 1.55 14 664 2.11 
7 14 342 4.09 12 322 3.73 26 664 3.92 
8 14 342 4.09 7 322 2.17 21 664 3.16 
9 9 342 2.63 8 322 2.48 17 664 2.56 
10 6 342 1.75 11 322 3.42 17 664 2.56 
11 10 342 2.92 9 322 2.8 19 664 2.86 
12 15 342 4.39 14 322 4.35 29 664 4.37 
13 10 342 2.92 9 322 2.8 19 664 2.86 
14 16 342 4.68 10 322 3.11 26 664 3.92 
15 16 342 4.68 20 322 6.21 36 664 5.42 
16 17 342 4.97 17 322 5.28 34 664 5.12 
17 14 342 4.09 5 322 1.55 18 664 2.71 
18 11 342 3.22 14 322 4.35 25 664 3.77 
19 13 342 3.8 12 322 3.73 25 664 3.77 
20 12 342 3.51 6 322 1.86 18 664 2.71 
21 7 342 2.05 8 322 2.48 15 664 2.26 
22 5 342 1.46 12 322 3.73 17 664 2.56 
23 7 342 2.05 9 322 2.8 16 664 2.41 
24 10 342 2.92 3 322 0.93 13 664 1.96 
25 12 342 3.51 10 322 3.11 22 664 3.31 
26 3 342 0.88 8 322 2.48 11 664 1.66 
27 8 342 2.34 13 322 4.04 21 664 3.16 
28 1 342 0.29 10 322 3.11 11 664 1.66 
29 6 342 1.75 12 322 3.73 19 664 2.86 
30 5 342 1.46 4 322 1.24 9 664 1.36 
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31 8 342 2.34 4 322 1.24 12 664 1.81 
32 3 342 0.88 4 322 1.24 7 664 1.05 
33 6 342 1.75 3 322 0.93 9 664 1.36 
34 2 342 0.58 3 322 0.93 5 664 0.75 
35 0 342 0 3 322 0.93 3 664 0.45 
36 4 342 1.17 2 322 0.62 6 664 0.9 
37 3 342 0.88 6 322 1.86 9 664 1.36 
38 2 342 0.58 3 322 0.93 5 664 0.75 
39 2 342 0.58 3 322 0.93 5 664 0.75 
40 1 342 0.29 2 322 0.62 3 664 0.45 
41 1 342 0.29 0 322 0 1 664 0.15 
42 1 342 0.29 1 322 0.31 2 664 0.3 
43 3 342 0.88 4 322 1.24 7 664 1.05 
44 0 342 0 3 322 0.93 3 664 0.45 
45 0 342 0 1 322 0.31 1 664 0.15 
46 0 342 0 0 322 0 0 664 0 
47 0 342 0 2 322 0.62 2 664 0.3 
48 3 342 0.88 0 322 0 3 664 0.45 
49 0 342 0 0 322 0 0 664 0 
50 0 342 0 1 322 0.31 1 664 0.15 
51 0 342 0 1 322 0.31 1 664 0.15 
52 1 342 0.29 1 322 0.31 2 664 0.3 
53 1 342 0.29 4 322 1.24 5 664 0.75 
54 0 342 0 0 322 0 0 664 0 
55 0 342 0 0 322 0 0 664 0 
56 1 342 0.29 1 322 0.31 2 664 0.3 
57 1 342 0.29 3 322 0.93 4 664 0.6 
58 0 342 0 0 322 0 0 664 0 
59 1 342 0.29 2 322 0.62 3 664 0.45 
60 0 342 0 0 322 0 0 664 0 
 
Based on the mean value (≥1.64%) the age-specific incidence for rotavirus infection noted 
during the study was between three and 29 months of age Table 4.2.  A high incidence 
(≥2.50%) was observed in children aged five, 7-19, 22, 25, 27 and 29 months, with the 
highest incidence rate (5.42%) observed in children 15 months of age. From a broad 
perspective, then, data from the study support published data that indicate that children 
younger than five years of age are most susceptible to rotavirus infections with the vast 
majority of these children being under the age of 24 months.   
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Figure 4.8 Age-specific rotavirus infection incidence rates per month for 2010 and 2011. 
 
Based on the expected age groups (six months to two years of age), suggested by the WHO as 
being particularly susceptible to rotavirus infection, the current study showed a contrasting 
relatively high incidence of rotavirus infection in children aged between 24 and 35 months.  
This relatively high incidence rate for this age group is mainly due to a high number (>2.8%) 
of positive samples collected from children aged 25 months (n=22), 27 months (n=21) and 29 
months (n=19).  As this increase in rotavirus infection in these children was also noted in 
communities from different areas, this feature may not be ascribed to mini rotavirus 
epidemics within the winter seasonal epidemic.  An alternative explanation may have been 
provided by Atchison et al. (2009) who suggested that children born in the winter months 
may show a delayed susceptibility to rotavirus infection and may skew surveillance results 
regarding the relationship between the age of the infant treated for gastroenteritis and 
susceptibility to rotavirus infection.  It should be noted that in the current study, 59% of the 
children in this age group were born between March and September.  Other factors that may 
influence age-apparent disparities regarding susceptibility to rotavirus infection may involve 
the recent introduction of a rotavirus vaccine within the study area, and/or the subsequent 
emergence of an altered rotavirus strain profile evident in the study children.  Thus, relatively 
uncommon rotavirus strains which may show varying tropism for villi cells according to the 
age and development of the children, as indicated by Ramani et al. (2007) who identified the 
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G12 strain as being responsible for severe symptomatic diarrhoea in children older than two 
years of age. 
 
4.1.4 Gender-specific incidence rate 
The gender-specific incidence rate observed indicated a slightly higher incidence rate of 52% 
in young males (n=348) compared to 48% in young females (n=316).  These figures are 
reflected in Figure 4.9.   
 
 
Figure 4.9 Gender-specific rotavirus infection incidence rates combined for both 2010 
and 2011. 
 
The observation made in this study correlates with an average, 53% in young males and 47% 
in young females, determined using the results from ten different global studies (Bishop et al. 
2001; van Man et al. 2001; Linhares et al. 2002; Sanchez-Fauquier et al. 2004; Mascharenhas 
et al. 2006; Lin et al. 2008; Atchison et al. 2009; Dey et al. 2009; Perez-Schael et al. 2009; 
Shim et al. 2010).  In these comparative studies, only three of the studies showed a higher 
incidence rate observed in young females (52.9%) compared to young males (47.1%)  and 
these rates were observed particularly in neonatal patients (Linhares et al. 2002; 
Mascharenhas et al. 2006; Shim et al. 2010). 
 
4.2  Effectiveness of the test-strips used for routine testing 
EIA analysis was used to evaluate the effectiveness, the sensitivity and the specificity of the 
rapid test-strips used by Pathology Practice during their routine testing for rotaviruses.   
52% 
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The principle of the EIA method is based on a colour change observed for positive samples, 
negative samples will remain colourless whereas positive samples can be identified by the 
liquid in the well changing to a yellow colour, thereby showing the presence or absence of 
the specific antigen in samples tested.  An example of such a plate can be seen in Figure 4.10. 
 
 
 
Figure 4.10 Example of a ProSpecT EIA plate 
 
A total of 752 stool samples were selected from the 6050 samples received (12%) and these 
were retested using the EIA method.  The selection included all samples from Trichardt, 
Middelburg and Rustenburg (areas from which samples for electropherotyping and 
genotyping analysis were selected), and 327 randomly selected samples from all areas 
included in the study area.  The samples retested included four (0.5%) samples which were 
not tested for the presence of rotavirus by the Private Pathology Practice, 538 (71.5%) 
samples reported as negative and 210 (28%) samples reported as positive.   
 
Results from EIA analysis included 529 negative samples and 223 positive samples (Please 
see Table G.1, Appendix G).  The high number of re-tested negative samples that still proved 
negative reflects the high specificity of the Coris immunochromatographic test kits.   While 
the vast majority of the EIA results corresponded to the Coris immunochromatographic test 
strip (ICT) results, however:  
• compared to samples that tested negative by the Coris ICT, a total of 14 samples 
tested positive using the EIA method.  These included sample numbers 2197, T36, 
T80, T131, T140, T204, T281, T426, T440, T850, T1983, T2040, T2041, T2442, 
T2445, T2449, T2650, T2784, and T2812. 
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• one sample tested negative using the EIA method and positive by Coris (sample 
number T2249).  This result may be a Coris ICT false positive as only the faintest ICT 
positive result was obtained and no results were obtained for that sample when tested 
by PAGE or RT-PCR.   
 
From the results of this study, the sensitivity of the rapid Coris ICT used by the Private 
Pathology Practice was calculated to be 93.7% (94%) when compared to the gold standard 
ProSpecT EIA, while the specificity of the Coris ICT when compared to the EIA was 99.8% 
(100%).  This is shown in Table 4.3. 
 
Table 4.3 Sensitivity and Specificity of the test-strips against EIA 
  
EIA 
  
Positive Negative Total 
Pathology 
test-strips 
(Coris) 
Positive 209 1 210 
Negative 14 524 538 
Total 223 525 748 
 
In comparison with data from 2005 (Dewar et al. 2005), the sensitivity of the Coris test strip 
showed a 6% higher sensitivity rate, and a similar, consistent specificity in detecting rotavirus 
in stool samples.  This underscores the need for consistent research and development on the 
part of ICT manufacturers so as to ensure the continued validity and reliability of their 
products, particularly when these products are used for diagnostic purposes.  
 
Using the Chi square (χ2) test, the following statement can be made with regard to the 
difference between the EIA and Coris testing methods: The χ2 statistic for comparison 
between the EIA and Coris is 0.4556, with one degrees of freedom (p=0.4997108), therefore 
there is no statistical significant difference between the two methods of testing.  Nonetheless, 
on a global scale, when testing for the presence of rotavirus in so many infection children, it 
is important to ensure that the most accurate diagnostic assay is used so that the most 
appropriate and effective treatment is provided to the children. 
 
4.3  Molecular characterisation of rotavirus strains during the 2010 and 2011 seasons 
The towns of Trichardt, Middelburg and Rustenburg were selected as sampling areas for the 
molecular characterization of rotavirus strains so as to compare data from outlying areas, 
from which little data are available, against data from hospitals/areas under constant 
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surveillance in South Africa by the NICD.  This distinction was selected so as to focus on any 
differences in results presented by this study in comparison to the massive surveillance 
studies undertaken by the NICD to determine and compare rotavirus strains circulating in 
various communities in South Africa during 2010 and 2011.  Techniques that were used in 
this study to determine the molecular characterisation of rotaviruses at these sites included 
electropherotyping of rotavirus dsRNA, using PAGE analysis, and rotavirus genotyping, 
using RT-PCR. 
 
Based on the results from the Private Pathology Practice, a total of 69 rotavirus-positive 
samples were received from Middelburg (n=16), from Rustenburg (n=9) and from Trichardt 
(n=44).  Sample selection for electropherotyping and genotyping was restricted to include 
only 30 samples for testing and this was done following specific inclusion criterian, i.e. 15 
samples were selected from each year, 2010 and 2011.   
These samples should: 
• be received during June, July and August of each year, focusing on the peak of the 
rotavirus seasons, 
• the patients should be aged between six months and two years of age, to focus on the 
ages based on literary data specifications on most commonly infected by rotavirus. 
 
 Of the original 69 samples collected from these towns during 2010 and 2011, a total of 45 
samples, eight from Rustenburg, 11 from Middelburg and 26 from Trichardt, were acceptable 
for analysis.  A random selection was then made from the samples to ensure that the samples 
tested were representative of each area.  The total number of samples selected included: 
• four samples from 2010 and two from 2011 from Middelburg 
• two samples from 2010 and five from 2011 from Rustenburg 
• nine samples from 2010 and eight from 2011 from Trichardt.   
 
4.3.1 Genotyping 
Published data have shown G1, G3, G4 and G9 rotavirus strains to be most often associated 
with P[8] and the G2 genotype to be most commonly associated with P[4] (Bos and Steele 
1995; Steele et al. 1995; Trabelsi et al. 2000; WHO 2002; Linhares et al. 2006; Esona et al. 
2010).  G12 has been observed as associating with various P genotypes, including P[4], P[6], 
P[8] and P[9] (Ramani et al. 2007).   
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As seen in Figures 4.11 to 4.14, the following genotypes were determined as circulating in 
the study communities in 2010 and 2011: 
• VP7 encoding genome segment specific genotyping showed four samples typing as 
G1, two as G2, 10 as G8, one as G9 and 12 as G12   
• VP4 encoding genome segment specific genotyping showed 12 samples as P[4] and 
17 samples as P[8] 
• one sample showed no type for each of VP4 and VP7. 
 
The RT-PCR results were collated as Table 4.4 below.  This table links the three study sites 
as rotavirus genotype per year. 
 
Table 4.4 Genotyping results for Middelburg, Rustenburg and Trichardt for 2010 and 
2011. 
 Middelburg Rustenburg Trichardt 
 2010 2011 2010 2011 2010 2011 
 n % n % n % n % n % n % 
G1P[8] 1 7 0 0 0 0 1 7 1 7 1 7 
G2P[4] 0 0 0 0 0 0 0 0 2 13 0 0 
G8P[4] 2 13 0 0 0 0 1 7 6 40 1 7 
G9P[8] 1 7 0 0 0 0 0 0 0 0 0 0 
G12P[8] 0 0 2 13 2 13 2 13 0 0 6 40 
Non typeable 0 0 0 0 0 0 1 7 0 0 0 0 
 
 
 
From Table 4.4, it can be noted that the rotavirus genotypes for 2010 included G1P[8] were 
observed in two of the samples, G2P[4] in two of the samples, G8P[4] in eight samples, 
G9P[8] in one sample and G12P[8] in two samples, as also noted Table J.1, Appendix J.  
Based on these results, the G8P[4] strain was the most predominant strain in the study area 
for 2010, being associated with 60% of the 15 samples analysed from these three towns.  
Apart from the relatively low incidence of the G1P[8] strains in the study samples, these 
results may be considered to be consistent with South African data published by the NICD 
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for 2010.  Here, national surveillance identified the G1P[8] and G8P[4] strains to be most 
commonly associated with rotavirus gastroenteritis in three of the five hospitals included in 
their surveillance and the G12P[8] strain showed an increase in association with rotavirus 
gastroenteritis and the most predominant strain of 2010 was identified as the G1P[8] strain 
(NICD 2011). 
 
Genotyping results from the study year 2011 indicated the predominant occurrence of 
G12P[8] - as noted in ten samples - and the equal, low distribution of G1P[8] and G8P[4] in 
each of another two samples.  One strain was non-typeable for either VP4 or VP7.  It should 
be mentioned that some non-specific amplification occurred in some of the VP7 strain PCR 
reactions.   For 2011, the national data published by the NICD identified the G12P[8] strain 
in all five hospitals included in their surveillance and, consequently, the G12P[8] strain as 
being the most predominant strain surveilled.  The G9P[8] strain was identified in two out of 
the five hospitals (NICD 2012).  Consistent with these South African G12P[8] data - but not 
for the G9P[8] data - the current study showed that the G12P[8] strain was the most 
predominant rotavirus strain circulating in these three towns during 2011, being associated 
with 66% (n=10) of the 15 samples analysed (NICD 2012). 
 
From the limited study data, it is difficult to extrapolate trends in rotavirus infection 
(including outbreaks and appearance and disappearance of rotavirus strains) regarding the 
incidence of these rotavirus strains in these towns during the study period.   
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Figure 4.11 RT-PCR Genotyping – Gel One.   
Lane 1 – 100 bp molecular weight marker; Lane 2 – T501 (VP7 – G1); Lane 3 – T664 (VP7 – G8); Lane 4 – T704 (VP7 – G9); Lane 5 – T729 
(VP7 – G12); Lane 6 – T734 (VP7 – G2); Lane 7 – T778 (VP7 – G8); Lane 8 – T991 (VP7 - G1); Lane 9 – T995 (VP7 – G8); Lane 10 – T1019 
(VP7 – G8); Lane 11 – T1198 (VP7 – G2); Lane 12 – T1248 (VP7 – G8); Lane 13 – T1351 (VP7 – G8); Lane 14 – T1369 (VP7 – G8); Lane 15 
– T1714 (VP7 – G12); Lane 16 – 100 bp molecular weight marker.  
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Figure 4.12 RT-PCR Genotyping – Gel Two.   
Lane 1 – 100 bp molecular weight marker; Lane 2 – T1833 (VP7 – G8); Lane 3 – T2249 (Non-specific amplification); Lane 4 – T2254 (VP7 – 
G12); Lane 5 – T2273 (VP7 – G12); Lane 6 – T2611 (VP7 – G12); Lane 7 – T2798 (VP7 – G12); Lane 8 – T2845 (VP7 - G12); Lane 9 – T2868 
(VP7 – G12); Lane 10 – T2880 (VP7 – G1); Lane 11 – T3018 (VP7 – G8); Lane 12 – T3213 (VP7 – G1); Lane 13 – T3239 (VP7 – G12); Lane 
14 – T3236 (VP7 – G12); Lane 15 – T3323 (VP7 – G8); Lane 16 – 100 bp molecular weight marker. 
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Figure 4.13 RT-PCR Genotyping – Gel Three.   
Lane 1 – 100 bp molecular weight marker; Lane 2 – T3378 (VP7 – G12); Lane 3 – T3415 (VP7 – G12); Lane 4 – VP7 Negative control; 
Lane 5 – 100 bp molecular weight marker; Lane 6 – T501 (VP4 – P[8]); Lane 7 – T664 (VP4 – P[4]); Lane 8 – T704 (VP4 – P[8]); Lane 
9 – T729 (VP4 – P[8]); Lane 10 – T734 (VP4 – P[4]); Lane 11 – T778 (VP4 – P[4]); Lane 12 – T991 (VP4 – P[8]). 
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Figure 4.14 RT-PCR Genotyping – Gel Four.   
Lane 1 – 100 bp molecular weight marker; Lane 2 – T995 (VP4 – P[4]); Lane 3 – T1019 (VP4 – P[4]); Lane 4 – T1198 (VP4 – P[4]); Lane 5 – 
T1248 (VP4 – P[4]); Lane 6 – T1351 (VP4 – P[4]); Lane 7 – T1369 (VP4 – P[4]); Lane 8 – T1714 (VP4 – P[8]); Lane 9 – T1833 (VP4 – P[4]); 
Lane 10 – T2249 (Non-specific amplification); Lane 11 – T2254 (VP4 – P[8]); Lane 12 – T2273 (VP4 – P[8]); Lane 13 – T2611 (VP4 – P[8]); 
Lane 14 – T2798 (VP4 – P[8]); Lane 15 – T2845 (VP4 – P[8]); Lane 16 – T2868 (VP4 – P[8]); Lane 17 – T2880 (VP4 – P[8]); Lane 18 – T3018 
(VP4 – P[4]); Lane 19 – T3213 (VP4 – P[8]); Lane 20 – 100 bp molecular weight marker. 
1 9 10 12 13 20 14 15 1
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However, the detection of rotavirus strains in these three towns indicates: 
• A low incidence of G1P[8] in all three towns during the study period. 
• A transient, low level occurrence in Trichardt only of G2P[4] during the 2010 season. 
• G8P[4] occurred at a similar incidence to that of G1P[8] but appeared to spike in 
Trichardt during 2010.  This may be associated with an isolated outbreak of G8P[4] 
rotavirus at this time but a review of data from the Trichardt samples showed that 
there were two samples collected each month from June to August  making an 
epidemic unlikely. 
• The rotavirus strain profile in Trichardt changed from particularly G8P[4] in 2010 to 
be replaced by G12P[8] in 2011. 
• G12P[8] occurred in Rustenburg in 2010 and in all three towns in 2011, particularly 
in Trichardt.  
• G9P[8] showed only a transient, low level occurrence in Middelburg in 2010. 
 
4.3.2 Electropherotyping 
Various researchers (O’Halloran et al. 2000; Chouikha et al. 2009; Cunliffe et al. 2009; WHO 
2009b) have reported on the association between particular G-types and long or short 
electropherotypes.  These authors indicate that the long electropherotypes is commonly 
associated with G1, G3 and G4 as well as G9 (Ramachandran et al. 2000), G10 (Volotao et 
al. 2006) and G12 (Page et al. 2009) while the short electropherotypes is commonly 
associated with G2, G8 (Volotao et al. 2006) and G12 (Page et al. 2009).   
 
The G9 strains may be associated with either a long or a short electropherotype.  
Ramachandran et al. (1998) indicated that G9P[8] is generally associated with a long 
electropherotype while the G9P[6] may be associated with a short electropherotype.   
 
In G12, as with G9, is has been found that either a long or a short electropherotype could be 
observed.  G12P[4], G12[P8] and G12P[9] have been associated with a long electropherotype 
(Page et al. 2009) while G12P[6] can be associated with either a long or a short 
electropherotype (Cunliffe et al. 2009; Page et al. 2009). 
 
O’Halloran et al. (2000) indicated that the uncommon G1P[4] strain is associated  with a 
short electropherotype and in samples where a mixed infection of G1 and G2 is found, a long 
91 
 
electropherotype is observed when P[8] is present and a short electropherotype when P[4] is 
present in the sample. 
 
 
Figure 4.15 PAGE Gel for 2010 samples.   
Lane 1 – T501 (long electropherotype); Lane 2 – T664 (short electropherotype); Lane 3 – 
T704 (long electropherotype); Lane 4 – T729 (long electropherotype); Lane 5 – T734 (no 
electropherotype visible); Lane 6 – T778 (short electropherotype); Lane 7 – T991 (long 
electropherotype); Lane 8 – T995 (no electropherotype visible); Lane 9 – T1019 (no 
electropherotype visible); Lane 10 – T1198 (short electropherotype); Lane 11 – T1248 (short 
electropherotype); Lane 12 – T1351 (short electropherotype); Lane 13 – T1369 (short 
electropherotype); Lane 14 – T1714 (long electropherotype); Lane 15 – T1833 (short 
electropherotype). 
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Gel 1 of the original PAGE included all the test samples from 2010 while the samples from 
2011 were loaded onto Gel 2.  A photograph of Gel 1 is presented in Figure 4.15.  Of the 30 
samples subjected to PAGE analysis, no electropherotype was observed in five samples, a 
long electropherotype was observed in 16 samples and a short electropherotype was observed 
in nine samples, as seen in Table 4.5. 
 
The association between VP4 and VP7 genotypes and observed electropherotype was 
consistent with published reports.  As observed from PAGE and PCR analysis, 
electropherotypes were associated with rotavirus strains as follows:  
• The G1, G9 and G12 genotypes associated with P[8] and these rotavirus strains were 
associated with  the long electropherotype.  
• The G2 and G8 genotypes associated with P[4], and the electropherotypes observed 
for these genotypes showed a short electropherotype. 
 
Table 4.5 Electropherotypes and Genotypes circulating in Middelburg, Rustenburg and 
Trichardt 
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T501 S 23 June 2009 16 August 2010 14 Trichardt G1 P8 Long 
T664 S 26 April 2009 20 July 2010 15 Trichardt G8 P4 Short 
T704 S 25 June 2009 02 August 2010 14 Middelburg G9 P8 Long 
T729 S 12 May 2009 29 July 2010 14 Rustenburg G12 P8 Long 
T734 S 26 January 2010 
27 July 
2010 6 Trichardt G2 P4 Not visible 
T778 S 26 May 2009 02 August 2010 15 Trichardt G8 P4 Short 
T991 S 13 March 2009 
09 July 
2010 16 Middelburg G1 P8 Long 
T995 S 12 June 2009 09 July 2010 13 Middelburg G8 P4 Not visible 
T1019 S 24 August 2009 
08 July 
2010 11 Trichardt G8 P4 Not visible 
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T1198 S 04 February 2009 
18 June 
2010 16 Trichardt G2 P4 Short 
T1248 S 18 November 2009 
12 June 
2010 7 Trichardt G8 P4 Short 
T1351 S 30 April 2009 04 June 2010 14 Trichardt G8 P4 Short 
T1369 S 19 July 2009 07 June 2010 11 Middelburg G8 P4 Short 
T1714 S 29 November 2009 
31 August 
2010 9 Rustenburg G12 P8 Long 
T1833 S 28 January 2009 
23 August 
2010 19 Trichardt G8 P4 Short 
T2249 S 23 February 2010 
17 June 
2011 16 Rustenburg 
Not 
specific None Not visible 
T2254 S 03 October 2009 
21 June 
2011 20 Trichardt G12 P8 Long 
T2273 S 29 July 2010 19 June 2011 11 Middelburg G12 P8 Long 
T2611 S 18 November 2010 
03 June 
2011 7 Trichardt G12 P8 Long 
T2798 S 22 June 2010 27 June 2011 12 Trichardt G12 P8 Long 
T2845 S 11 June 2010 29 June 2011 12 Trichardt G12 P8 Long 
T2868 S 13 December 2010 
28 June 
2011 6 Middelburg G12 P8 Long 
T2880 S 19 October 2010 
01 July 
2011 9 Trichardt G1 P8 Long 
T3018 S 23 July 2010 27 July 2011 12 Rustenburg G8 P4 Short 
T3213 S 15 December 2010 
15 July 
2011 7 Rustenburg G1 P8 Long 
T3239 S 15 September 2010 
12 July 
2011 10 Trichardt G12 P8 Not visible 
T3286 S 31 May 2010 15 July 2011 14 Rustenburg G12 P8 Long 
T3323 S 02 January 2010 
13 July 
2011 18 Trichardt G8 P4 Short 
T3378 S 11 February 2010 
22 August 
2011 18 Trichardt G12 P8 Long 
T3415 S 26 September 2009 
23 June 
2011 21 Rustenburg G12 P8 Long 
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CHAPTER 5 
 
CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
Since the discovery of rotavirus particles in the stool samples of young children in 1973, 
there have been many studies conducted to research the various aspects associated with this 
virus, including symptoms, characteristics and outcomes of the associated disease (Santos 
and Hoshino 2005; WHO 2008).   The question can, therefore, be asked, and is regularly 
asked in the Health and Scientific Communities: “Should rotaviruses and the associated 
disease still be monitored and researched almost 40 years after it was first identified as a 
causative diarrhoeal agent?”  The answer lies therein that rotaviruses are, to date, still 
associated in many developing countries with a high morbidity and mortality rate among 
young children and this is reflected in the determination to develop and test appropriate 
rotavirus vaccines and, subsequently, their recent introduction as part of vaccination 
programmes (WHO 2009a).  Causes and effects associated with rotavirus infection require 
continued rotavirus surveillance and molecular characterisation of rotavirus strains, to 
identify those strains circulating in communities and to determine the impact rotavirus 
infection has on morbidity and mortality in children in those communities.  Such knowledge 
provides insights into the effectiveness of rotavirus vaccination programmes (AnnaRita 
2010).  The WHO advised that rotavirus vaccines should form part of immunization 
programmes in countries, and vaccination was introduced in South Africa in 2009 (Steele and 
Glass 2011).  It is important to remember that, in addition to rotaviruses, there are many other 
viral agents responsible for acute gastroenteritis including members of the Picornaviridae.  
As the symptoms and pathology resulting from infection with such viruses is currently poorly 
understood, the relatively low incidence of rotavirus infection as shown in this study (as 
compared to the National average) in acute gastroenteritis cases may be ascribed to infection 
with other gastroenteritis-associated infectious agents (Knox et al. 2012).   
 
Rotaviruses may respond to a changing and challenging environment and such changes are 
due not only to genetic reassortment commonly observed in RNA viruses (Streicker et al. 
2012), but also to external factors, including environmental changes, such as climate change; 
and host population changes, such as population growth and changes in living habits.  Thus, 
various changes in rotavirus infections should anticipated prior to and following the 
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introduction of vaccines, including seasonality, age-specific incidences, and more 
importantly, circulating rotavirus genotypes that are responsible for infection.  The results for 
the current study confirmed the seasonality, age-specific and gender-specific occurrences, 
and geographical distribution of rotavirus infections within Gauteng and selected areas within 
the North West and Limpopo provinces.  Data obtained were compared with data from 
surveillance studies performed locally in South Africa on an annual basis by the NICD, and 
other South African scientists; as well as to international data provided by organisations such 
as the WHO, and other scientists.   
 
In South Africa the rotavirus season was generally identified as starting in late autumn, 
reaching its peak during the winter months and ending early in spring, corresponding to 
March/April to August/September (Steele et al. 1986a; Steele et al. 1986b; Bos et al. 1992; 
Page 2006; Page et al. 2009; Seheri et al. 2010a).  The study data and data by the NICD 
(NICD 2011; NICD 2012), over the 2010 and 2011 seasons, showed a shift in the start of the 
rotavirus season observed in South Africa, resulting in a slightly shorter rotavirus season. 
These trends were demonstrated in the current study.   
 
The WHO specifies that children younger than five years of age should be included when 
conducting a surveillance study (WHO 2002).  Various studies have shown the most 
susceptible age groups for rotavirus associated gastroenteritis to be between six months and 
two years of age.  This study has complemented published data indicating that rotavirus is 
responsible for gastroenteritis in children younger than five years, and particularly under the 
age of 29 months.  As theoretically speculated by Atchison et al. (2009), this result has also 
shown the occurrence of higher numbers than may generally be expected to be observed in 
patients falling within slightly older, more uncommon age groups, than is reflected in the 
literature.  As was shown in this study and other studies/surveillances performed in South 
Africa, geographically, rotaviruses are not associated with particular areas or selected 
communities and all South African children are at risk of succumbing to rotavirus infections.  
Geographically significant to South Africa, and to developing countries in general, are the 
different types of communities found not only within a rural or an urban area, but also the 
presence of various informal settlements found within both rural and urban communities. 
 
Data on the circulating strains plays an important role in evaluating the potential 
effectiveness of rotavirus vaccines introduced as part of immunization programmes in 
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countries.  Based on global studies and the identification of G1P[8] as the most prevalent 
strain responsible for rotavirus infection, many of the pharmaceutical companies focused on 
preparing a vaccine that would increase the immunity of young children against this strain.  
The two current vaccines forming part of the immunization programmes in South Africa and 
various other countries globally are effective in stimulating an immune response against 
many strains of rotavirus.  The Rotarix vaccine is based on the G1P[8] strain (Parashar et al. 
2006; McCormack and Keam 2009; Mirzayeva et al. 2009; van Effelterre et al. 2009; 
Atchison et al. 2010; Tate et al. 2010; Gagneur et al. 2011; Hauber et al. 2011), and RotaTeq 
vaccine is composed of reassortants of the human G1, G2, G3, G4 and P[8] strains (Gurgel et 
al. 2008; Ciarlet and Schödel 2009; Atchison et al. 2010; Salvadori and le Saux 2010; Tate et 
al. 2010; Gagneur et al. 2011; Hauber et al. 2011).  Clinical trials conducted in developing 
countries, including South Africa, showed positive results in decreasing the number of 
serious gastroenteritis cases.  Questions can, however, still be raised on the potential impact 
the vaccines will have on the more uncommon strains and the potential vaccine effectiveness 
when new rotavirus reassortants are formed.   
 
Rotaviruses are not associated with only one country or one community, and published data 
have shown a consistency as to the expected results involving most prevalent strains 
responsible for rotavirus infections globally, with G1P[8], G2P[4], G3P[8], G4P[8] and 
G9P[8] being considered the most common causes of gastroenteritis (Woods et al. 1992; 
Audu et al. 2002b; Iturriza-Gomara et al. 2000a; Pietruchinski et al. 2006; Linhares et al. 
2008; Antunes et al. 2009; Dey et al. 2009; McCormack and Keam 2009; van Doorn et al. 
2009; Aminu et al. 2010; AnnaRita et al. 2010; Aladin et al. 2010).  Data by the WHO have, 
however, shown that these strains are more commonly found in the American, European and 
Western Pacific regions, with uncommon strains more often being responsible for infections 
in the African, South East Asian, and Eastern Mediterranean Regions (WHO 2011a).     
 
Annualised globally, the predominant strains for rotavirus gastroenteritis in 2010 included 
G1P[8] (31%), G2P[4] (19%) and uncommon strains (20%) including the G8P[4] strain.  
Upon further analysis, the following observation were made for the European, American and 
Western Pacific Regions where the G1P[8] strain was the predominant strain and responsible 
for more than 30% of all rotavirus associated gastroenteritis cases.  However, in the African, 
South East Asian and Eastern Mediterranean Regions the uncommon strains (>30%) were 
responsible for the greatest number of rotavirus associated gastroenteritis cases.  During this 
97 
 
time period the G1P[8] strain was associated with 14% of infections in the African region, 
and G2P[4] and G9P[8] with 10% each.  Uncommon strains in the African region included 
G2P[6] (28%), G3P[6] (21%), G1P[6] (11%), G9P[6] (9%), G12P[6] (7%), G12P[8] (7%), 
and G8P[4] (5%) (WHO 2011a). 
 
Todd et al. (2010) highlighted the difference in strain prevalence globally compared to strains 
observed in African countries.  In this review, global strains was identified as including, 
G1P[8] (52%), G2P[4] (11%), G4P[8] (8%), G3P[8] (3%), G9P[6] (2%), G9P[8] (2%) and 
uncommon strains (6%).  These data compare to African countries where the following 
observations were made, G1P[8] (17%), G1P[6] (3%), G2P[4] (5%), G2P[6] (10%), G3P[4] 
(4%), G3P[6] (2%), G3P[8] (7%), G8P[4] (3%), G8P[6] (9%), G9P[8] (5%), and other 
uncommon strains (5%). 
 
Data from the current study showed a relatively minor presence of G1P[8] in samples 
analysed.  However, for 2010 and 2011, two relatively uncommon strains - G8P[4] and 
G12P[8] - were found to be predominant in the study areas.  Data from this study and various 
other studies show an increase in more uncommon strains including G8 and G12 and P[6], 
not included in current available rotavirus vaccines.  This raises the question as to whether 
the introduction of rotavirus vaccines may enhance immunity against the more common 
strains, but at the same time enhance the chances of uncommon or novel strains taking their 
place?  Results from the current study provide a qualified “yes” to this question but also 
underline the relevance of continuing rotavirus research and surveillance so that constant 
review of known characteristics of rotavirus gastroenteritis and identification of changes in 
rotavirus infection trends allows, particularly, primary healthcare practitioners and policy 
makers to act appropriately in updating testing protocols and/or immunization programmes.  
By using data from this study and many other similar studies conducted now and in the 
future, pharmaceutical companies can keep an eye on the changes in trends and 
predominance of rotavirus strains thereby ensuring that the most effective vaccines are 
produced and available to patients.   
 
An accurate diagnosis of rotavirus positive samples are important for treatment of infected 
children and EIA is one of the most specific and sensitive testing methods in detecting 
rotavirus positive samples.  However, as diagnostic laboratories receive large volumes of 
samples to test and as EIA is a relatively costly procedure, EIA analysis may not always be a 
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viable option, not only because of the cost for the test, but also due to time constraints 
associated with EIA analysis when testing large volumes of samples.  Therefore, rapid test-
strips are used by commercial diagnostic laboratories to identify positive rotavirus samples.  
These test-strips should thus have a high specificity and sensitivity towards the antigens 
tested.  This study, as a follow-up to a previous study (Dewar et al in 2005), serves as support 
that the rapid test-strip (Coris) is an appropriate testing method for diagnostic laboratories as 
it shows a high sensitivity and specificity towards rotavirus antigens. 
 
5.2 Recommendations 
Recommendation that can be made from results and observations made during the study 
include: 
• The number of samples subjected to PAGE and RT-PCR analysis for Middelburg, 
Rustenburg and Trichardt, should be increased to include all the positive samples, and 
samples from one or more additional small towns should also be included to increase 
the number of samples analysed to validate data to be published in articles. 
• As information on the vaccination status of the children from whom the samples were 
collected was not known, data should be included and investigated in future studies to 
determine if the changes observed in the age-specific incidence rates are due to the 
introduction of vaccines, and to also determine the potential effect of herd immunity 
on the health of unvaccinated children. 
• Performing genotyping and electropherotyping on rotavirus-positive samples in 
children younger than six months and older than two years of age.  This is to identify 
the responsible strain and thereby determine if a specific/novel strain is responsible 
for a rotavirus infection peaks observed in children who may be at an age where they 
might be expected to have lower susceptibility to rotavirus infection. 
• Performing follow-up analysis such as genotyping and electropherotyping on samples 
that test negative using diagnostic assays such as the rapid test strips (Coris) and 
positive using EIA, so as to more accurately identify strains responsible for 
gastroenteritis and to identify any possible trends in strains that could affect the Coris 
test. 
• Performing regular genotyping and electropherotyping will assist in identifying 
uncommon rotavirus strains thereby evaluating the effectiveness and impact of 
rotavirus vaccines, by providing information on new or novel strains, including the 
99 
 
identification of zoonotic strains, which are of extreme importance to pharmaceutical 
companies in ensuring that vaccines in circulation remain relevant and current. 
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Determination of the burden / occurrence of Rotavirus Infections 
 
 
Dear Health Care Practitioner, 
 
Thank you for agreeing to participate in the confidential research study that is being conducted by 
UNISA to determine the burden and impact of rotavirus infections  in children younger than five 
years of age.  It is hoped that the results of this study can be used to promote vaccination of children 
against rotavirus infections. 
 
In agreeing to participate in this research project the University will guarantee confidentiality.  No 
personal information/details about yourself, the Pathology Practice or personal patient information 
will be made public and only generalised results will be published, thus, ensuring your privacy and 
anonymity.  There is no physical, social or psychological danger associated with this study nor will 
you incur any financial costs if you participate in this study.  This research will adhere to the 
UNISA’s Policy on Research Ethics that states that: UNISA is committed to undertake and promote 
research that will be beneficial to society and contribute to knowledge and understanding of the 
subject; research should respect the independence, rights, dignity, privacy and confidentiality of all 
participants.   
 
As part of the research project, stool samples will be collected from the Pathology Practice to 
determine if rotavirus is present within the stool samples and then to determine the strains of rotavirus 
circulating within the different geographical areas for which the Pathology Practice acts as reference 
laboratory.  Samples will be collected from the Practice, starting from March 2010.  Only data relating 
to the date of birth and gender of the patients and collection date and geographical origin of samples 
will be collected.  No other personal information of the patient will be recorded during the research 
project and all samples will be identified only by a sample number.  Samples diagnosed as rotavirus 
positive will be marked separately and re-tested as part of the research project using ELISA analysis.  
Data will also be made available to you on the effectiveness of rapid rotavirus test-strips compared to 
ELISA analysis. 
 
Your participation is voluntary. If at any time during this study you wish to withdraw from 
participating, you are free to do so without any consequences. If you have any questions prior or 
during the time of the study, do not hesitate to contact us. 
 
 
 
 
_________________________                                  __________________________ 
Ms. Liza Theron                     Prof. John Dewar 
Researcher                       Research Supervisor 
UNISA                       UNISA 
Contact Details: 076 880 8574                          Contact Details: 011 471 3112 
Email: theronl@ampath.co.za                                Email: dewarj@unisa.ac.za 
 
 
_______________________        __________________________ 
 
Date           Date 
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1. INTRODUCTION 
A sandwich EIA consists of a plate coated with a capture antibody to which the 
diluted stool specimen solution is added in order to determine the presence of a 
specific antigen.  The standard rotavirus diagnosis is generally based on the detection 
of the rotavirus Group A antigen in stool samples by using EIA (Beards et al. 1984, 
cited by Zeng et al. 2008).  EIA makes use of labels attached to antibody molecules to 
detect antigen-antibody reactions (Atlas, 1997).  Adler et al. (2005) noted that empty 
particles of rotavirus can be detected during the VP6-EIA, enhancing the sensitivity of 
the EIA assay in detecting the virus.  The overall sensitivity of EIA has a range of 105 
to 106 viral particles per millilitre (Brandt et al. 1981, cited by Arguelles et al. 2000; 
Wilde et al. 1990, cited by Arguelles et al. 2000; Estes, 1996, cited by Arguelles et al. 
2000).  Arguelles et al. (2000), indicated that EIA resulted in a specificity of 100% 
and sensitivity of 98.4% when compared to RT-PCR analysis. 
 
2. SCOPE 
This procedure applies to all laboratory staff and researchers performing ELISA 
analysis. 
 
3. DEFINITIONS AND ABBREVIATIONS 
Distilled Water   dH2O 
Enzyme immunoassay  EIA  
 
4. RESPONSIBILITY 
Supervisor: To ensure that this procedure is implemented 
and that the staff is trained and fully conversant 
in its application. 
 
Laboratory Staff and researchers: To follow the procedure as set out in this SOP. 
 
5. DOCUMENTATION 
EIA Worksheet 
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6. SAFETY 
• The use of broken glassware can cause serious injuries, discard broken glassware 
when chipped or broken;  
• All reagents should be treated as potentially harmful; 
• Always wear protective clothing (latex gloves, protective spectacles and acid 
resistant lab coat) when performing analysis. 
  
7. MATERIAL AND EQUIPMENT 
• Protective clothing, i.e. laboratory coats and gloves 
• Refrigerators and freezers for storage 
• Plastic Test tubes - Storage tubes for back-up samples and test tubes used to 
prepare dilutions 
• Cryo-boxes for storage of storage tubes and tests tubes 
• Labels and sample numbers for the identification of test and storage tubes per 
sample 
• ProSpecTTM EIA kits 
• Transfer pipettes / 3mm round wooden transfer sticks 
• Micropipettor with disposable tips 
• Timer 
• Vortex mixer 
• 1000 ml Measuring cylinder 
• Absorbent paper for tap-drying of micro-wells after washing 
• Incubator (37°C) 
• Spectrometer set at 454 nm - ELx800 Universal micro plate reader (Bio-Tek 
Instruments, Inc., USA) 
 
8. REAGENTS 
• Distilled water (dH2O) 
• Positive Control (supplied in EIA kit) 
• Conjugate (supplied in EIA kit) 
• Wash buffer (supplied in EIA kit) 
• Substrate (supplied in EIA kit) 
• Stop Solution (supplied in EIA kit) 
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9. ACTIONS AND METHODS 
Principle of Procedure: 
A sandwich ELISA consists of a plate coated with a capture antibody (polyclonal 
antibody) to which is added diluted stool specimen solution.  The antigen, if present, 
will then bind to the capture antibody and a conjugate (an enzyme linked capture 
antibody) is also added to each well which attaches to any bound antigen.  The plate is 
incubated for one hour before the wells are washed with Wash Buffer to remove 
excess specimen and any unbound enzymes and antibodies.  A substrate is then added 
to the micro-wells and incubated for 10 minutes which results in a colour change 
where the enzyme- labelled antibodies are present.  A Stop Solution is added to the 
micro-wells after the 10 minute incubation period to stop the Substrate reaction.  A 
change in substrate colour indicates a positive reaction.  Micro-wells can then be read 
spectrophotometrically. 
 
Procedure:  
• Prepare a 10% suspension or dilution of each faecal specimen to be analysed, 
approximately 0.1 g or 100 µl of specimen is mixed with 1ml of dH2O (or 
diluent) to prepare the dilution. 
• Identify each specimen per well by labelling corresponding wells on an EIA 
worksheet. 
• Add two drops (equal to 100 µl positive control) of the positive control to the 
first micro-well 
• Add 100 µl dH2O or diluent into the second micro-well as a negative control.   
Distilled water or diluent is used as the negative control as dH2O or diluent is 
used to prepare the stool suspensions or dilution of the stool 
• Add 100 µl of each stool suspensions or dilution to each of the remaining 94 
micro-wells 
• After adding specimen to each micro-wells, add two drops of Conjugate to each 
micro-well, cover the plate and seal it in its original packet and incubate the plate 
for 60 minutes in a 37°C incubator 
• After incubation, shake out all content of the micro-wells into a waste dish and 
then carefully pour freshly prepared Wash Buffer into the micro-wells. 
• Repeat this washing step once more using the Wash Buffer, and shaking out all 
fluid after each wash 
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• Repeat the washing step three times using the automated EIA plate washer, if no 
automated plate washer is used, manual washing should be done five times 
• After all traces of the Wash Buffer have been removed from the micro-wells, add 
two drops of the Substrate to each well 
• Replace the covered plate inside its packet and incubate the covered plate for 10 
minutes in a 37°C incubator 
• After incubation add two drops of the Stop Solution to each micro-well to stop 
the Substrate reaction. 
• Visually observe the colour change after the second incubation and note the 
changes on your worksheet. 
• Read the plate spectrophotometrically at a setting of 454 nm and collect the 
spectrometer printout collected to validate all results. 
• File the completed EIA worksheet. 
 
Quality control 
To ensure the validity of the test, a positive (supplied in EIA kit) and negative control 
(dH2O) was included in the first and second micro-wells, respectively, of each EIA 
performed.  The controls acted as a basis for identifying any possible contamination 
or errors (e.g. excessive light or heat exposure) that could have occurred.  When 
spectrophotometrically read, the negative control value should be <0.150 nm and the 
positive control value >0.500 nm. 
 
Calculation  
The cut-off value is determined for each EIA by taking the negative control value as 
read by the spectrophotometer and adding 0.200 
 
10. TROUBLESHOOTING 
Refer to Manufacturer’s instructions. 
 
11. MAINTENANCE OF ANALYSERS 
• Spectrometer – Refer to MP-001 
• ELISA Plate Washer – Refer to MP-002 
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Figure B.1 EIA Flowchart 
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EIA Worksheet          LF-001 
                 Edition 1 
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1. INTRODUCTION 
During the polyacrylamide gel electrophoresis (PAGE) process the negatively 
charged macromolecules separate according to size through the gel, these migration 
patterns can then be visualized by staining the gel with silver nitrate (Herring et al. 
1982, cited by Desselberger et al. 2005; Kapikian et al. 2001, cited by Laird et al. 
2003; WHO, 2009).  The human Group A rotavirus electropherotype consists of a 
pattern of gene fragments grouped as four large fragments, followed by two 
fragments, three fragments and two small fragments (Dzikwi et al. 2008; Chouikha et 
al. 2009).  Electropherotypes provide information on the genetic diversity of rotavirus 
circulating in a population (Nakagomi et al. 1988, cited by Fischer & Gentsch, 2004 
and Uchida et al. 2006; Dunn et al. 1993, cited by Uchida et al. 2006; Koshimura et 
al. 2000, cited by Uchida et al. 2006; Kapikian et al. 2001, cited by Dzikwi et al. 
2008; Nakagomi et al. 2002, cited by Uchida et al. 2006).  The overall sensitivity of 
PAGE has a range of 108 to 109 viral particles per millilitre (Brandt et al. 1981, cited 
by Arguelles et al. 2000; Wilde et al. 1990, cited by Arguelles et al. 2000; Estes, 
1996, cited by Arguelles et al. 2000).    
 
The human Group A rotavirus electropherotype consists of a pattern of gene 
fragments grouped as four large fragments, followed by two fragments, three 
fragments and two small fragments (Chouikha et al. 2009).  Group A rotaviruses 
display either a long electropherotype or a short electropherotype (Chouikha et al. 
2009; Cunliffe et al. 2009; Page et al. 2009; WHO, 2009). Donelli & Superti (1994) 
indicated that a super short electropherotype could also be observed, the observation 
of a long, short or super short electropherotype is based on the mobility of the last two 
dsRNA segments. 
 
2. SCOPE 
This procedure applies to all laboratory staff and researchers performing SDS-PAGE 
analysis. 
 
3. DEFINITIONS AND ABBREVIATIONS 
Ammonium persulphate   APS 
Distilled Water    dH2O 
Hydrochloric Acid    HCl 
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N,N,N’,N’-tetramethylenediamine  TEMED 
Polyacrylamide gel electrophoresis  PAGE  
Silver nitrate     AgNO3 
Sodium dodecyl sulphate   SDS 
Sodium hydroxide    NaOH 
 
4. RESPONSIBILITY 
Supervisor: To ensure that this procedure is implemented 
and that the staff is trained and fully conversant 
in its application. 
 
Laboratory Staff and researchers: To follow the procedure as set out in this SOP. 
 
5. DOCUMENTATION 
None 
 
6. SAFETY 
• The use of broken glassware can cause serious injuries, discard broken glassware 
when chipped or broken;  
• All reagents should be treated as potentially harmful – acrylamide is a neurotoxin; 
• Always wear protective clothing (latex gloves, protective spectacles and acid 
resistant lab coat) when performing analysis. 
  
7. MATERIAL AND EQUIPMENT 
• Protective clothing, i.e. laboratory coats and gloves  
• Cryo-boxes for storage of storage tubes and tests tubes  
• Labels and sample numbers for the identification of test and storage tubes per 
sample 
• Eppendorf tubes 
• Pipettes with disposable tips 
• Timer 
• Vortex mixer 
• Water bath (37°C) 
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• Water bath (56°C) 
• Electrophoresis apparatus 
• Vacuum pump 
• Filter paper 
• Laboratory balance 
• Spatula 
• Gel dryer 
• Orbital rotator 
• Freezer (-20°C) and/or Freezer (-70°C) 
• Centrifuge 
• Cooled Centrifuge (4°C) 
• 1000 ml Measuring cylinder 
• 100 ml Measuring cylinder 
 
8. REAGENTS 
• Distilled water (dH2O)  
• 10% SDS stock 
o Add 1g of SDS to 10ml dH2O, dissolve in a 65°C water bath 
• 1 M Sodium acetate containing 1% SDS 
o Dissolve 8.2 g sodium acetate in 60ml dH2O 
o Add 10 ml of the 10% SDS stock and mix 
o Adjust the pH to 5.0 with glacial acetic acid, and make up to 100 ml with sterile 
dH2O 
• Phenol-chloroform (1:1) 
o Mix equal volumes of citrate-saturated phenol (pH 4.3) and chloroform 
o Place in a dark or foil-covered bottle and store at 4°C 
• 3 M Sodium acetate (pH 5.0) 
o Dissolve 4.92 g sodium acetate in 10 ml dH2O 
o Make up to 20 ml with dH2O 
• 30% acrylamide stock 
o Dissolve 30 g of acrylamide and 0.8 g of N,N’methylene bis-acrylamide in 100 
ml dH2O 
o Filter before use 
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o Place in a dark or foil-covered bottle and store at 4°C 
• 1N Hydrochloric acid 
o Add 8.6 ml concentrated HCl to 91.4 ml of sterile dH2O 
• Resolving gel buffer (1.5 M, pH 8.9) 
o Dissolve 36.3 g of Tris base in 48 ml dH2O 
o Adjust pH to 8.9 with 1 N HCl or 3 M NaOH 
o Make up to 100 ml with dH2O 
• Stacking gel buffer (0.5 M, pH 6.7) 
o Dissolve 5.98 g of Tris base in 50 ml dH2O 
o Adjust pH to 6.7 with 1 N HCl 
o Make up to 100 ml with dH2O 
• 10% ammonium persulphate (APS) 
o Dissolve 0.1 g APS in 1 ml dH2O prior to use 
o Store at 4°C for a maximum of three days 
• 5 x Tris-glycine running buffer 
o Dissolve 15.1 g of 25 mM Tris base and 94 g of 250 mM glycine in dH2O 
o Make up to 1000 ml with dH2O 
• 1 x Tris-glycine running buffer 
o Dilute 200 ml 5 x Tris-glycine running buffer with 800 ml dH2O 
• PAGE sample running dye 
o Dissolve 10 mg of bromophenol blue and 1 ml glycerol in 5 ml spacer gel buffer 
o Make up to 10 ml with dH2O 
• 10% resolving gel 
Table C.1 PAGE Resolving gel formula 
Reagent 1.5 mm gel 
 1x 2x 
dH2O 15.8 ml 31.6 ml 
30% acryl stock 10.0 ml 20.0 ml 
Resolving buffer, pH 8.8 3.75 ml 7.5 ml 
TEMED 15 μl 30 μl 
10% APS 450 μl 900 μl 
 
 
 145 
 
• 4% spacer gel 
Table C.2 PAGE Spacer gel formula 
Reagent 1.5 mm gel 
 1x 2x 
dH2O 6.8 ml 13.6 ml 
30% acryl stock 1.6 ml 3.2 ml 
Stacking buffer, pH 6.8 1.25 ml 2.5  ml 
TEMED 5 μl 10 μl 
10% APS 150 μl 300 μl 
• Absolute Ethanol 
• Fixing solution 1 
Table C.3 PAGE Fixing solution 1 formula 
Reagent 1x 2x 
Ethanol 80 ml 160 ml 
dH2O 110 ml 220 ml 
Acetic acid 10 ml 20 ml 
• Fixing solution 2 
Table C.4 PAGE Fixing solution 2 formula 
Reagent 1x 2x 
Ethanol 20 ml 40 ml 
dH2O 180 ml 360 ml 
Acetic acid 1 ml 2 ml 
• Silver nitrate solution 
Table C.5 PAGE Silver nitrate formula 
Reagent 1x 2x 
AgNO3 (added prior to use) 0.37 g 0.74 g 
dH2O 200 ml 400 ml 
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• Developing solution 
Table C.6 PAGE Developing solution formula 
Reagent 1x 2x 
36% Formaldehyde 2 ml 4 ml 
dH2O 250 ml 500 ml 
NaOH (added prior to use) 7.5 g 15 g 
• Stopping solution 
Table C.7 PAGE Stopping solution formula 
Reagent 1x 2x 
Acetic Acid 10 ml 20 ml 
dH2O 200 ml 400 ml 
 
9. ACTIONS AND METHODS 
Principle of Procedure: 
Polyacrylamide gel electrophoresis (PAGE) and gel staining of rotavirus gene 
fragments produce an electropherotype migration pattern that will be used in the 
characterisation of rotaviruses.  
 
The sodium acetate reduces the disulphide bridges holding the protein in the tertiary 
structure, the SDS binds strongly to, and denatures, the protein.  The protein is 
therefore fully denatured and is opened up into a rod-shaped structure with a series of 
negatively charged SDS molecules along the length of the protein chain.  The purpose 
of the stacking gel is to concentrate the protein sample into a sharp band before it 
enters the main separating gel, this is achieved by using the differences in ionic 
strength and pH between the electrophoresis buffer and the stacking gel buffer.  The 
stacking gel has a very large pore size, allowing the proteins to move freely and 
concentrate under the effect of the electric field (Wilson and Walker, 2010).   
 
During the electrophoresis process the negatively charged macromolecules separate 
according to size through the gel, these migration patterns can then be visualized by 
staining the gel with silver nitrate (WHO, 2009). 
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Procedure: 
RNA Extraction Process  
• Prepare a 10% suspension or dilution for each faecal sample selected for analysis, 
mix approximately 0.1 g or 100 µl of sample with 1 ml of dH2O to prepare the 
dilution (The same suspension prepared for EIA can be used for PAGE analysis). 
• Add 450 µl of the 10% suspension to an eppendorf tube. 
• Add 50 µl of a pre-warmed solution of 1 M Sodium Acetate with 1% SDS to the 
suspension.  
• Vortex the mixture for 10 seconds and incubate in a 37°C water bath for 15 
minutes. 
• After incubation add an equal volume (500 µl) of phenol-chloroform to the 
eppendorf tube. 
• Vortex the mixture for one minute and incubated in a 56°C water bath for 15 
minutes. 
• After incubation open the tube and immediately reseal, before vortexing for one 
minute. 
• After vortexing the tube, centrifuge the tube at 16 000 g for 5 minutes. 
• Transfer the upper aqueous phase to a clean eppendorf tube using a micro pipette. 
• Add 40 µl 3 M sodium acetate (pH 5.0) to the eppendorf tube and fill the tube by 
adding ice-cold absolute ethanol to the dsRNA solution, gently invert the tube 4-6 
times and incubated for 2 hours to overnight at -20°C. 
• After incubation, centrifuge the solution at 16 000 g for 15 minutes at 4°C, and 
immediately decant the ethanol. 
• Inverted and place the tube on an absorbent towel to air dry. 
• Re-suspend the dsRNA pellet was in 30 µl of PAGE loading buffer. 
 
PAGE 
• Clean the glass plates with soap and water and wipe with 96% ethanol before use. 
• Assemble the glass plates according to the manufacturer’s instructions.  Mark the 
top level of the resolving gel on the plate, leaving enough room for the stacking 
gel. 
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• Prepare the resolving gel using a standard recipe.  Pour the acrylamide gel 
solution in-between the glass plates to the mark and gently overlay with distilled 
water to prevent meniscus effects. 
• Allow the gel to set for 2 hours (until the interface between the gel and overlay is 
visible). 
• Pour the water overlay from the top of the gel and drain into a paper towel. 
• Place the gel apparatus in an upright position and prepare the stacking gel. 
• Add the stacking gel on top of the resolving gel and place the comb in 
immediately, ensuring that no bubbles are trapped beneath the comb. 
• Allow the gel was to polymerise for 45 minutes to 1 hour.  
• Remove the comb and assemble the glass plates in the electrophoresis apparatus. 
• Add the Tris-running buffer to the bottom reservoir and insert the glass plates into 
the electrophoresis tank.   
• Add the Tris-running buffer the front and back upper tanks, check these tanks 
were checked for any leakage and fill to the top. 
• Fill the wells with electrophoresis buffer (It is important to remove air that might 
be present under the gel bottom). 
• Load the dsRNA samples in PAGE buffer into the designated gel wells and 
electrophorese the gel 100V for 20 hours (16 – 20 hours). 
 
Silver staining 
• After electrophoresis pour the running buffer out and remove the gel from 
between the glass plates. 
• Cut the bottom right corner of the gel for orientation purposes, discard the 
stacking gel and place the resolving gel was placed into the fixing solution in a 
clean glass dish. 
• Allow each gel to rotate at room temperature for 30 minutes on an orbital shaker 
in 200 ml Fixing solution one. 
• Aspirate Fixing solution one. 
• Add 200 ml of Fixing solution two to each gel and rotate at room temperature for 
30 minutes on an orbital shaker. 
• Prepare the silver nitrate staining solution using the standard recipe. 
• Aspirate Fixing solution. 
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• Add 200 ml of the silver nitrate staining solution and rotate for 30 minutes on an 
orbital shaker. 
• Prepare the developing solution by adding sodium hydroxide to a previously 
prepared formaldehyde and water solution. 
• Aspirate the silver nitrate staining solution.  
• Wash each gel twice with 200 ml dH2O, allowing 2 minutes for each wash. 
• Add approximately 50 ml of the developing solution to each gel, and shake for 30 
seconds to ensure removal of any black precipitate. 
• Aspirate the developing solution, add the remaining developing solution and rotate 
at room temperature on an orbital shaker for approximately five minutes until the 
RNA bands are visible. 
• Aspirate the developing solution and add the stopping solution to prevent a further 
colouring reaction. 
• Rotate the gel for five to 10 minutes in stopping solution at room temperature on 
an orbital shaker before removing the stopping solution by aspiration. 
• Rinse the gel in dH2O. 
• Dry the gel in a vacuum gel dryer according to the manufacturer’s instructions. 
 
Quality control 
Not applicable. 
 
Calculation  
g = 1.12 x radius in mm x (rpm/1000)^2 
 
10. TROUBLESHOOTING 
Refer to Manufacturer’s instructions. 
 
11. MAINTENANCE OF ANALYSERS 
• Water Bath – Refer to MP-003 
• Vacuum Pump – Refer to MP-004 
• Centrifuge – Refer to MP-005 
• Electrophoresis Apparatus – Refer to MP-006 
• Laboratory Scale – Refer to MP-007 
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• Orbital Rotator (and Glass Dishes) – Refer to  MP-008 
• Gel Dryer – Refer to MP-009 
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Figure C.1 PAGE Flowchart (RNA Extraction) 
Please note – highlighted section is an additional step only when required 
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Figure C.2 PAGE Flowchart (PAGE) 
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Figure C.3 PAGE Flowchart (Silver Staining) 
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1. INTRODUCTION 
RT-PCR assays were used in the G and P typing of Group A rotaviruses by using 
type-specific primers which targeted specific regions of the VP4 (P types) and VP7 
(G types) genes.  RT-PCR analysis of viral RNA is a process during which the RNA 
is converted to cDNA which is then amplified to detectable levels using PCR (Atlas 
1997).  As RNA cannot serve as a template during PCR analysis, the RNA must first 
be converted into cDNA by reverse transcriptase (WHO 2009). 
 
2. SCOPE 
This procedure applies to all laboratory staff and researchers performing Real-time 
PCR analysis. 
 
3. DEFINITIONS AND ABBREVIATIONS 
Complementary DNA    cDNA 
Distilled Water    dH2O 
Polymerase chain reaction   PCR 
Sodium Chloride    NaCl 
 
4. RESPONSIBILITY 
Supervisor: To ensure that this procedure is implemented 
and that the staff is trained and fully conversant 
in its application. 
 
Laboratory Staff and researchers: To follow the procedure as set out in this SOP. 
 
5. DOCUMENTATION 
None 
 
6. SAFETY 
• The use of broken glassware can cause serious injuries, discard broken glassware 
when chipped or broken;  
• All reagents should be treated as potentially harmful; 
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• Always wear protective clothing (latex gloves, protective spectacles and acid 
resistant lab coat) when performing analysis. 
  
7. MATERIAL AND EQUIPMENT 
• Protective clothing, i.e. laboratory coats and gloves  
• Refrigerators and freezers 
• 1.5 ml and 0.5 μl Eppendorf tubes 
• QIAamp spin columns 
• Collection tubes 
• Cryo-boxes for storage of storage tubes and tests tubes  
• Labels and sample numbers for the identification of test and storage tubes per 
sample 
• Micropipettor with disposable tips (filtered, RNase free) 
• Timer 
• Vortex mixer 
• Heating block (94°C) 
• Heating block (42°C) 
• Cold beads 
• Absorbent paper 
• Centrifuge 
• Master Cycler - Perkin Elmer Model 4800 synthesiser 
• Electrophoresis apparatus. 
 
8. REAGENTS 
• Distilled water (dH2O)  
• Absolute ethanol 
• AVL Buffer for RNA extraction, Wash buffer (AW1) for RNA extraction, Wash 
buffer (AW2) for RNA extraction, AVE buffer for RNA extraction (all supplied in 
the QIAamp RNA extraction kit). 
• RT-PCR primers: 
o VP7 (Gouvea et al. 1990; Iturriza-Gomara et al. 2004) 
 sBeg9 (5’) 
 End9 (3’) 
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o VP4 (Gentsch et al. 1992; Iturriza-Gomara et al. 2000) 
 Con2 (3’) 
 Con3 (5’) 
• RT-PCR Reverse transcription Master mix: 
o Deoxynucleotides 
o AMV RTase (enzyme) 
o AMV Buffer 
• RT-PCR PCR amplification Master mix: 
o Deoxynucleotides 
o Taq buffer 
o Magnesium Chloride (MgCl2) 
o PCR water 
o Taq Polymerase 
• Genotyping of cDNA Master mix (VP7) (Gouvea et al. 1990; Iturriza-Gomara et 
al. 2004): 
o Deoxynucleotides 
o Anchor primer (RVG9) 
o Strain specific primers 
 aAT8v (G8), aBT1 (G1), aCT2 (G2), aDT4 (G4), mG3 (G3), mG9 (G9), 
mG10 (G10) and newG12 (G12). 
o Taq Buffer 
o MgCl2 
o PCR Water 
o Taq Polymerase 
• Genotyping of cDNA Master mix (VP4) (Gentsch et al. 1992; Iturriza-Gomara et 
al. 2000): 
o Deoxynucleotides 
o Anchor primer (Con3) 
o Strain specific primers 
 1T-1D/dP8 (P[8]), 1T1-VN/p8Vn (P[8]), 1T-1Wa/P8Wa (P[8]), 2T-1 (P[4]), 
3T-1 (P[6]), 4T-1 (P[9]), 5T-1 (P[10]), mP11 (P[11]) and P14 (P[14]). 
o Taq Buffer 
o MgCl2 
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o PCR Water 
o Taq Polymerase 
• 1% Agarose gel 
o Dissolve one agarose tablet (1 g)  in 100 ml 0.5 x TBE, after cooling mixture add 
2 μl Ethidium bromide  
• 0.5M EDTA (pH 8.0) 
Table D.1 RT-PCR EDTA formula 
Reagent  
EDTA 18.61 g 
dH2O 70 ml 
Adjust pH and make the final volume to 100 ml with dH2O 
• 5xTris-Borate EDTA (TBE) Buffer 
Table D.2 RT-PCR TBE formula 
Reagent  
Trisma Base 54 g 
Boric acid 27.5 g 
dH2O 800 ml 
0.5 M EDTA  20 l 
• 0.5 x TBE for agarose gel electrophoresis 
o Add 100 ml 5 x TBE to 900 ml dH2O 
 
9. ACTIONS AND METHODS 
Principle of Procedure: 
The RT-PCT procedure can be divided into three main processes: RNA extraction, 
reverse transcription of dsRNA, and genotype amplification of cDNA as described in 
the World Health Organizations Manual of Rotavirus detection and characterisation 
methods (WHO 2009). 
 
Procedure:  
RNA Extraction (using the QIAamp method) 
• Add 560 µl AVL buffer and 140 µl of a 10% faecal suspension to a 1.5 ml 
eppendorf tube and mix by vortexing. 
• Incubate the solution at room temperature for 10 minutes. 
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• Briefly centrifuge the too sediment droplets from the lid. 
• Add 560 µl absolute ethanol to the solution and mix the solution by brief 
vortexing and centrifugation. 
• Transfer 630 µl of the solution to a QIAamp mini spin column (with a 2 ml 
collection tube) and centrifuge at 7 200 g for one minute.  After centrifugation 
discard the collection tube containing the filtrate and place the QIAamp spin 
column in a clean collection tube. 
• Transfer the remaining 630 µl of the solution to the QIAamp mini spin column 
and centrifuge at 7 200 g for one minute. 
• After centrifugation the QIAamp mini spin column open and add 500 µl of Wash 
buffer one (AW1) to the column.  Centrifuge the column at 7 200 g for one 
minute.  After centrifugation discard the collection tube containing the filtrate and 
place the QIAamp spin column in a clean collection tube. 
• Add 500 µl of Wash buffer two (AW2) to the QIAamp mini spin column and 
centrifuge at 16 000 g for three minute.  After centrifugation discard the collection 
tube containing the filtrate and place the QIAamp spin column in a clean 
collection tube. 
• Centrifuge the QIAamp spin column was at 16 000 g for 1 minute.  After 
centrifugation discard the collection tube and place the spin column in a clean 1.5 
ml Eppendorf tube. 
• Add 60 µl of the AVE buffer to the spin column and incubate at room temperature 
for one to five minutes.  After incubation centrifuge the spin column at 7 200 g for 
one minute.  
• After centrifugation discard the QIAamp spin column and store the 1.5 ml 
Eppendorf tube at -20°C or -70°C. 
 
RT-PCR 
• Prepare the RT-master mix 1.5 ml Eppendorf tube according to calculations as 
indicated on the RT-PCR worksheet and place on cold beads.  The AMV enzyme 
must be added prior to use. 
• Prepare the amplification master mix in a 1.5 ml Eppendorf tube according to 
calculations as indicated on the RT-PCR worksheet and place on cold beads.  The 
Taq Polymerase must be added prior to use. 
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• Add the 5’ and 3’ primers and dsRNA to a 0.5 ml amplification tube and mix by 
pipetting. 
• Denature the primers and dsRNA on a 94°C heating block for five minutes and 
transfer immediately to the cold beads. 
• Add 3.2 µl of the RT-master mix to each tube and mix by pipetting.   
(The RT-master mix must be added within five minutes from removing tubes from 
heating block). 
• Incubate the samples on a 42°C heating block for five minutes and immediately 
transfer to the cold beads. 
• Add 40 µl of the amplification master mix to each tube, mix by pipetting and 
place on cold beads. 
• Place the samples in a master cycler for synthesis of cDNA.  The master cycler 
must be set to the following settings: 
o One cycle set at 94°C for 2 minutes, 
o 30 cycles set at 94°C for one minutes (denaturation), 42°C for one minute 
(annealing), 72°C for one minute (extension), 
o One cycle set at 72°C for eight minutes, and cooled and held at 4°C. 
• After synthesis of cDNA, load 3 μl of the cDNA sample and 5μl of a molecular 
weight marker and run on 1% agarose at 90 V for approximately 15 minutes to 
determine concentration to be used in genotype amplification. 
 
Genotype amplification 
• Prepare the Genotype-master mix in a 1.5 ml Eppendorf tube according to 
calculations as indicated on the Genotype worksheet and place on cold beads.   
• Add the cDNA to a PCR (Eppendorf) tube (0.1 to 6 μl as determined by cDNA 
concentration of RT-PCR amplicons). 
• Add the master mix to the cDNA, and mix by pipetting. 
• Place the samples in a master cycler.  The master cycler must set to the following 
settings: 
o One cycle set at 94°C for 2 minutes, 
o 30 cycles set at 94°C for one minutes (denaturation), 42°C for one minute 
(annealing), 72°C for one minute (extension), 
o One cycle set at 72°C for eight minutes, and cooled and held at 4°C. 
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• After synthesis of cDNA, load 5 μl of the cDNA sample molecular weight marker 
and run on 1% agarose at 90V for one hour to determine genotype. 
 
Quality control 
To ensure the validity of the test, a negative control was included.  The negative 
control used for the electrophoresis of the RT-PCR and genotype amplification 
samples was the master mix prepared for each step. 
 
Calculation  
• g = 1.12 x radius in mm x (rpm/1000)˄ 2 
 
• Denature solution: 
___________μl dsRNA 
___________μl Primer 1 
___________μl Primer 2 
6-10 μl in total 
 
• RT-PCR master mix: 
(Do not exceed 10 reactions plus a negative control) 
1X Reaction    ________________ X reactions 
0.25 μl 10 mM dATP  ________________μl 
0.25 μl 10 mM dCTP  ________________μl 
0.25 μl 10 mM dGTP  ________________μl 
0.25 μl 10 mM dTTP  ________________μl 
0.2 μl   AMV RTase   ________________μl 
2.0 μl   AMV Buffer   ________________μl 
 
• Amplification master mix: 
(Do not exceed 10 reactions plus a negative control) 
1X Reaction   ________________ X reactions 
1 μl dATP   ________________μl 
1 μl dCTP   ________________μl 
1 μl dGTP   ________________μl 
1 μl dTTP   ________________μl 
5 μl 10 x Taq buffer  ________________μl 
1.2 μl 50 mM MgCl2  ________________μl 
  30 μl PCR Water  ________________μl 
  0.3 μl Taq Polymerase ________________μl 
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• Genotyping master mix: 
1 X Reaction       ___________ X reactions 
1 μl 0.1-6 μl cDNA        ________________μl 
1 μl 10 mM dATP      ________________μl 
1 μl 10 mM dCTP      ________________μl 
1 μl 10 mM dGTP      ________________μl 
1 μl 10 mM dTTP      ________________μl 
1 μl 10 pmol Anchor primer     ________________μl 
1 μl 10 pmol Gene specific primers (Cocktail)  ________________μl 
1.2 μl 50 mM MgCl2     ________________μl 
26 μl PCR Water      ________________μl 
        0.3 μl Taq Polymerase     ________________μl 
 
10. TROUBLESHOOTING 
Refer to Manufacturer’s instructions. 
 
11. MAINTENANCE OF ANALYSERS  
• Centrifuge – Refer to MP-005 
• Master Cycler - PCR – Refer to MP-010 
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Figure D.1 RT-PCR Flowchart (RNA Extraction) 
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Figure D.2 RT-PCR Flowchart (RT-PCR) 
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Figure D.3 RT-PCR Flowchart (Genotyping) 
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RT-PCR Worksheet    LF-003 
                             Edition 1 
Test Date:     ______________________________________________________________ 
Name:           ______________________________________________________________ 
Signature:     ______________________________________________________________ 
 
Denature solution: 
___________μl dsRNA 
___________μl Primer 1 
___________μl Primer 2 
6-10 μl in total 
 
RT-PCR master mix: 
(Do not exceed 10 reactions plus a negative control) 
Work on cold beads 
 
1X Reaction   ________________ X reactions 
0.25 μl 10 mM dATP  ________________μl 
0.25 μl 10 mM dCTP  ________________μl 
0.25 μl 10 mM dGTP  ________________μl 
0.25 μl 10 mM dTTP  ________________μl 
0.2 μl   AMV RTase  ________________μl 
2.0 μl   AMV Buffer  ________________μl 
 
Amplification master mix: 
(Do not exceed 10 reactions plus a negative control) 
Work on cold beads 
 
1X Reaction   ________________ X reactions 
1 μl dATP   ________________μl 
1 μl dCTP   ________________μl 
1 μl dGTP   ________________μl 
1 μl dTTP   ________________μl 
5 μl 10 x Taq buffer  ________________μl 
1.2 μl 50 mM MgCl2  ________________μl 
30 μl PCR Water  ________________μl 
0.3 μl Taq Polymerase  ________________μl 
 
Amplification Cycles: 
_____°C ______min 
_____°C ______min _____°C ______min _____°C ______min x 30 cycles 
_____°C ______min 
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 College: Agriculture and Environmental Sciences 
 
School: Agriculture and Life Sciences 
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Genotyping Worksheet    LF-004 
                     Edition 1 
 
 
 
Test Date:     ______________________________________________________________ 
Primers:        ______________________________________________________________ 
Name:           ______________________________________________________________ 
Signature:     ______________________________________________________________ 
 
Genotyping master mix: 
Work on cold beads 
 
1 X Reaction       ________________ X reactions 
1 μl 0.1-6 μl cDNA        ________________μl 
1 μl 10 mM dATP      ________________μl 
1 μl 10 mM dCTP      ________________μl 
1 μl 10 mM dGTP      ________________μl 
1 μl 10 mM dTTP      ________________μl 
1 μl 10 pmol Anchor primer     ________________μl 
1 μl  10 pmol Gene specific primers (Cocktail)  ________________μl 
1.2 μl 50 mM MgCl2      ________________μl 
26 μl PCR Water      ________________μl 
0.3 μl Taq Polymerase     ________________μl 
 
 
Amplification Cycles: 
_____°C ______min 
_____°C ______min _____°C ______min _____°C ______min x 30 cycles 
_____°C ______min 
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APPENDIX F (Pathology results – Positive Results only) 
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Table F.1   Pathology Practice results        
MRC / UNISA # 
SENSITIVITY 
S – Symptomatic 
A - Asymptomatic 
DATE OF BIRTH  COLLECTION DATE AGE IN MONTHS 
RAPID TEST 
STRIP 
RESULT 
P = Present 
GENDER LOCATION 
Samples misplaced at Medunsa   06 January 2008 09 March 2010 26 P M Trichardt 
T1947 S 22 August 2007 22 March 2010 31 P M PTA East 
T1958 S 21 January 2009 03 April 2010 15 P M PTA East 
1732 S 15 December 2009 24 April 2010 4 P M Akasia 
1739 S 01 October 2008 25 April 2010 18 P F Les Marais 
1744 S 18 September 2007 27 April 2010 31 P F PTA Central 
1678 S 18 September 2008 29 April 2010 19 P M Les Marais 
1688 S 13 March 2008 30 April 2010 25 P M PTA East 
1779 S 27 May 2009 03 May 2010 12 P M Les Marais 
1782 S 09 July 2007 04 May 2010 34 P F Akasia 
1854 A 07 November 2008 11 May 2010 18 P F Centurion 
1910 S 09 December 2007 18 May 2010 29 P M Centurion 
1952 S 19 November 2007 21 May 2010 30 P M Akasia 
T1325 S 11 December 2007 27 May 2010 29 P M Centurion 
T1360 S 12 March 2009 27 May 2010 14 P F PTA Central 
T1278 S 27 September 2008 31 May 2010 20 P M PTA Central 
T1254 S 08 May 2009 31 May 2010 12 P M PTA Central 
T1207 S 30 May 2009 31 May 2010 12 P F PTA Central 
T1242 S 29 March 2009 01 June 2010 15 P M Centurion 
T1401 S 15 October 2008 02 June 2010 20 P M Centurion 
T1363 S 25 March 2008 02 June 2010 27 P M PTA Central 
T1319 S 29 October 2008 02 June 2010 20 P M PTA Central 
T1410 S 09 March 2009 02 June 2010 15 P M Wilgers 
T1351 S 30 April 2009 04 June 2010 14 P M Trichardt 
T1364 S 11 February 2009 04 June 2010 16 P F Wilgers 
T1318 S 09 March 2010 05 June 2010 3 P M Groenkloof 
T1333 A 22 December 2008 06 June 2010 18 P F PTA Central 
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T1316 S 23 November 2009 07 June 2010 7 P M Centurion 
T1369 S 19 July 2009 07 June 2010 11 P M Middelburg 
T1323 S 21 August 2008 07 June 2010 22 P F PTA Central 
T1353 S 10 July 2008 07 June 2010 23 P M PTA Central 
T1306 S 01 October 2009 07 June 2010 8 P F Wilgers 
T1276 S 27 April 2009 08 June 2010 14 P F Akasia 
T1277 S 23 September 2008 08 June 2010 21 P M PTA Central 
T1370 S 17 May 2010 08 June 2010 1 P F PTA Central 
T1358 S 25 November 2009 08 June 2010 7 P F Trichardt 
T1308 S 29 January 2010 09 June 2010 5 P M Akasia 
T1343 A 06 October 2009 09 June 2010 8 P F PTA Central 
T1223 S 30 June 2009 09 June 2010 12 P F PTA Central 
T1322 S 26 November 2009 09 June 2010 7 P M PTA Central 
T1248 S 18 November 2009 12 June 2010 7 P M Trichardt 
T1288 S 06 November 2008 13 June 2010 19 P M Centurion 
T1282 S 16 February 2010 13 June 2010 4 P M PTA Central 
T1235 S 20 February 2009 13 June 2010 16 P F Wilgers 
Sample dried out   21 May 2009 15 June 2010 13 P F Secunda 
T1227 S 01 June 2007 16 June 2010 36 P F PTA East 
T1200 A 22 January 2009 17 June 2010 17 P F Brits 
T1221 S 08 December 2009 17 June 2010 6 P M PTA Central 
T1234 S 15 February 2010 17 June 2010 4 P F Trichardt 
T1245 S 03 June 2009 18 June 2010 12 P F PTA Central 
T1198 S 04 February 2009 18 June 2010 16 P F Trichardt 
T1211 S 17 November 2008 18 June 2010 19 P F Wilgers 
T1172 S 15 September 2009 19 June 2010 9 P M PTA Central 
T1199 S 15 February 2010 19 June 2010 4 P F Trichardt 
T1217 S 04 March 2009 20 June 2010 15 P F Akasia 
T1257 S 06 December 2008 20 June 2010 18 P F PTA East 
T1185 A 30 October 2008 20 June 2010 20 P F Trichardt 
T1166 S 23 November 2009 21 June 2010 7 P M Centurion 
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T1183 S 02 September 2007 21 June 2010 33 P M Centurion 
T1165 S 22 June 2009 21 June 2010 12 P F Centurion 
T1224 S 19 October 2009 21 June 2010 8 P F Montana 
T1209 S 17 May 2010 21 June 2010 1 P F Wilgers 
T1106 S 03 August 2008 22 June 2010 22 P M Akasia 
T1060 S 02 September 2007 22 June 2010 33 P M Centurion 
T1131 S 17 February 2009 22 June 2010 16 P M Centurion 
T1081 S 16 October 2008 22 June 2010 20 P F Centurion 
T1042 S 19 September 2007 22 June 2010 33 P F Montana 
T1114 A 15 July 2009 23 June 2010 11 P F Montana 
T1152 S 14 May 2008 23 June 2010 25 P F PTA Central 
T1130 S 01 May 2009 23 June 2010 13 P F PTA Central 
T1096 S 16 October 2009 23 June 2010 8 P F PTA East 
T1091 S 29 June 2009 23 June 2010 12 P F Trichardt 
T1134 S 21 May 2009 23 June 2010 13 P M Trichardt 
T1145 A 25 February 2007 24 June 2010 40 P M Wilgers 
T1127 S 08 March 2010 25 June 2010 3 P M Les Marais 
T1148 A 10 October 2008 25 June 2010 20 P F Montana 
T1140 S 08 July 2005 25 June 2010 59 P F Montana 
T1102 S 03 May 2010 25 June 2010 1 P M PTA Central 
T1139 S 31 March 2009 26 June 2010 15 P F PTA Central 
T1125 A 29 June 2008 26 June 2010 24 P M PTA East 
T1110 S 06 September 2008 27 June 2010 21 P M PTA East 
T1132 S 02 January 2008 28 June 2010 29 P M Akasia 
T1129 S 13 November 2009 28 June 2010 7 P M Les Marais 
T1029 S 09 October 2009 29 June 2010 8 P M Centurion 
T1062 S 23 September 2008 29 June 2010 21 P M Faerie Glen 
T1083 S 19 July 2008 29 June 2010 23 P M PTA Central 
T1027 S 13 February 2009 29 June 2010 16 P M Wilgers 
T1036 S 21 February 2008 30 June 2010 28 P M Montana 
T1112 S 30 September 2009 30 June 2010 9 P M Montana 
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T961 S 03 January 2010 30 June 2010 5 P F PTA Central 
T1004 S 23 October 2009 30 June 2010 8 P F PTA Central 
T1030 A 29 June 2009 30 June 2010 12 P F PTA Central 
T1071 S 04 August 2008 01 July 2010 23 P F Montana 
T997 S 07 January 2010 01 July 2010 6 P F PTA Central 
T1043 S 11 November 2005 01 July 2010 56 P M PTA Central 
T1028 S 07 July 2006 01 July 2010 48 P F PTA East 
T1007 S 10 September 2008 01 July 2010 22 P M PTA East 
T1022 S 02 July 2009 02 July 2010 12 P M Brits 
T1069 S 21 March 2009 02 July 2010 16 P M PTA Central 
T1003 S 03 April 2007 03 July 2010 39 P M Centurion 
T1146 S 28 July 2009 03 July 2010 12 P M Montana 
T1033 S 31 May 2010 03 July 2010 2 P M Montana 
T1066 S 21 July 2009 03 July 2010 12 P M PTA Central 
T989 S 30 April 2010 03 July 2010 3 P M Trichardt 
T1142 A 11 August 2009 04 July 2010 11 P F Montana 
T1107 S 06 July 2009 04 July 2010 12 P F Montana 
T1087 A 13 December 2007 04 July 2010 31 P F PTA Central 
T1045 S 19 February 2009 05 July 2010 17 P M Akasia 
T954 A 03 December 2009 06 July 2010 7 P M Akasia 
T979 S 30 May 2007 06 July 2010 38 P F Groenkloof 
T938 S 18 May 2009 06 July 2010 14 P M Secunda 
T965 S 25 August 2008 06 July 2010 23 P F Standerton 
T935 S 11 February 2010 06 July 2010 5 P M Trichardt 
T1011 S 15 May 2009 07 July 2010 14 P M Montana 
T924 S 01 December 2008 07 July 2010 19 P F Montana 
T983 S 16 November 2009 08 July 2010 8 P M Akasia 
Sample dried out and too little to analyse   20 November 2008 08 July 2010 20 P M Middelburg 
T1000 S 14 February 2009 08 July 2010 17 P F PTA Central 
T962 S 27 December 2007 08 July 2010 31 P M PTA East 
T974 S 15 January 2008 08 July 2010 30 P M Trichardt 
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T1019 S 24 August 2009 08 July 2010 11 P M Trichardt 
T995 S 12 June 2009 09 July 2010 13 P M Middelburg 
T991 S 13 March 2009 09 July 2010 16 P M Middelburg 
T956 S 11 February 2009 09 July 2010 17 P M PTA Central 
T951 S 21 April 2009 09 July 2010 15 P M PTA East 
T1068 S 03 May 2009 10 July 2010 14 P F Brits 
T923 S 06 October 2009 10 July 2010 9 P M Rietfontein 
T1034 A 02 January 2009 11 July 2010 18 P M Montana 
T967 A 18 December 2009 11 July 2010 7 P M PTA Central 
T950 A 02 February 2010 12 July 2010 5 P F Akasia 
T940 S 18 November 2008 12 July 2010 20 P M Middelburg 
T1015 S 04 July 2008 12 July 2010 24 P F Middelburg 
T1017 A 08 June 2009 12 July 2010 13 P M Montana 
T897 A 20 April 2010 12 July 2010 3 P F PTA East 
T982 S 16 April 2009 12 July 2010 15 P F Wilgers 
T1160 S 16 October 2008 13 July 2010 21 P M Akasia 
T914 S 21 August 2009 13 July 2010 11 P M Brits 
T896 S 11 June 2009 13 July 2010 13 P M Centurion 
T1161 S 20 May 2010 13 July 2010 2 P F Centurion 
T895 S 01 March 2010 13 July 2010 4 P F Middelburg 
T884 A 07 May 2009 13 July 2010 14 P M PTA Central 
T1159 S 06 June 2009 14 July 2010 13 P M PTA Central 
T889 S 17 March 2009 14 July 2010 16 P M Standerton 
T1157 S 08 April 2009 15 July 2010 15 P M Akasia 
T887 S 10 July 2008 15 July 2010 24 P F Ermelo 
Overgrown with fungi - not transfered   14 November 2008 15 July 2010 20 P F PTA Central 
T900 S 26 March 2009 15 July 2010 16 P F PTA East 
Sample dried out and too little to analyse   10 July 2008 16 July 2010 24 P F Ermelo 
Sample dried out and too little to analyse   10 February 2009 16 July 2010 17 P F PTA Central 
T1162 A 11 February 2009 16 July 2010 17 P F PTA Central 
T903 S 11 March 2010 17 July 2010 4 P M PTA Central 
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T1153 S 03 October 2008 17 July 2010 21 P F PTA Central 
T936 S 26 January 2009 17 July 2010 18 P M Standerton 
T898 A 31 March 2009 18 July 2010 16 P M Montana 
Sample dried out and too little to analyse   25 January 2009 18 July 2010 18 P M PTA Central 
T917 S 24 September 2009 19 July 2010 10 P F Akasia 
T688 S 01 September 2009 19 July 2010 10 P F Alberton 
T920 S 12 March 2010 19 July 2010 4 P M Middelburg 
T707 S 20 December 2006 19 July 2010 43 P F Trichardt 
T885 S 14 September 2009 19 July 2010 10 P M Wilgers 
T764 S 03 January 2010 20 July 2010 6 P M Centurion 
T686 S 03 January 2010 20 July 2010 6 P M Centurion 
T625 S 04 February 2010 20 July 2010 5 P F Middelburg 
T711 S 27 March 2009 20 July 2010 16 P M Montana 
T664 S 26 April 2009 20 July 2010 15 P M Trichardt 
T789 S 23 April 2009 21 July 2010 15 P F Akasia 
T783 A 26 September 2008 21 July 2010 22 P M Centurion 
T779 S 19 May 2010 21 July 2010 2 P M Centurion 
T643 S 12 November 2009 21 July 2010 8 P M Centurion 
T715 S 02 February 2008 21 July 2010 29 P M PTA Central 
T655 S 12 November 2007 21 July 2010 32 P M PTA East 
T767 S 19 February 2010 22 July 2010 5 P F Akasia 
T705 S 28 February 2006 22 July 2010 53 P M Brits 
T781 S 07 November 2008 22 July 2010 20 P M Centurion 
T680 S 04 August 2009 22 July 2010 11 P M PTA Central 
T641 S 25 March 2009 22 July 2010 16 P M PTA Central 
T650 S 06 January 2010 22 July 2010 6 P M PTA Central 
Sample leaked out   08 April 2010 22 July 2010 3 P F PTA East 
T660 S 12 July 2007 22 July 2010 36 P M PTA East 
T776 S 20 December 2006 22 July 2010 43 P F Trichardt 
T682 S 18 March 2009 23 July 2010 16 P M Akasia 
T752 S 27 January 2009 23 July 2010 18 P M Brits 
 183 
 
T593 S 13 February 2010 23 July 2010 5 P F Montana 
T681 S 24 January 2009 23 July 2010 18 P M Montana 
T639 S 23 August 2009 23 July 2010 11 P M Montana 
T616 S 07 September 2009 23 July 2010 10 P F PTA Central 
T603 S 23 July 2008 23 July 2010 24 P F PTA Central 
T630 S 11 January 2007 23 July 2010 42 P M PTA East 
T723 S 08 February 2010 23 July 2010 5 P F Trichardt 
T629 S 31 December 2007 24 July 2010 31 P M Centurion 
T727 S 21 October 2007 24 July 2010 33 P F Montana 
T612 S 01 August 2009 24 July 2010 11 P M PTA Central 
T614 S 01 May 2009 24 July 2010 14 P M PTA East 
T633 S 07 June 2007 25 July 2010 37 P F Centurion 
T687 S 20 June 2008 25 July 2010 25 P F Montana 
T675 S 23 July 2008 25 July 2010 24 P F PTA Central 
T624 S 10 March 2010 25 July 2010 4 P M PTA Central 
T605 S 30 April 2008 26 July 2010 27 P F Centurion 
T792 S 23 June 2008 26 July 2010 25 P F PTA East 
T654 S 06 November 2008 26 July 2010 20 P F PTA East 
T731 S 15 October 2009 27 July 2010 9 P M PTA Central 
T747 S 16 October 2008 27 July 2010 21 P M PTA Central 
T689 S 08 April 2010 27 July 2010 3 P F PTA East 
T756 S 29 September 2008 27 July 2010 22 P F Standerton 
T734 S 26 January 2010 27 July 2010 6 P M Trichardt 
T750 S 03 July 2007 28 July 2010 36 P M Centurion 
T691 S 31 July 2006 28 July 2010 48 P M Centurion 
T740 S 08 February 2010 28 July 2010 5 P F Groblersdal 
T772 S 28 July 2009 28 July 2010 12 P M Groenkloof 
T737 S 15 June 2008 28 July 2010 25 P M Montana 
T728 S 12 May 2009 28 July 2010 14 P F Montana 
T673 S 15 June 2008 28 July 2010 25 P M Montana 
T771 S 12 February 2009 29 July 2010 17 P M Kloof 
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T774 S 18 February 2010 29 July 2010 5 P F Les Marais 
T700 A 23 December 2008 29 July 2010 19 P M Montana 
T748 S 13 February 2010 29 July 2010 5 P F Montana 
T729 S 12 May 2009 29 July 2010 14 P F Rustenburg 
T721 S 27 July 2009 31 July 2010 12 P F Akasia 
To little sample to analyse   04 December 2008 31 July 2010 19 P M Centurion 
T745 A 22 May 2009 31 July 2010 14 P M PTA Central 
T786 S 30 April 2008 31 July 2010 27 P F PTA East 
T761 S 26 July 2007 01 August 2010 37 P M PTA Central 
T670 S 08 August 2006 01 August 2010 48 P M PTA Central 
Sample dried out and too little to analyse   08 January 2009 01 August 2010 19 P F PTA Central 
T713 S 12 February 2008 02 August 2010 30 P M Centurion 
T704 S 25 June 2009 02 August 2010 14 P M Middelburg 
T724 S 21 June 2008 02 August 2010 26 P F PTA Central 
T782 S 19 April 2010 02 August 2010 4 P M PTA Central 
T556 S 07 April 2010 02 August 2010 4 P F Rustenburg 
T666 S 17 May 2008 02 August 2010 27 P F Thabazimbi 
T778 S 26 May 2009 02 August 2010 15 P M Trichardt 
T527 S 31 May 2009 03 August 2010 15 P F Akasia 
T514 A 04 July 2007 03 August 2010 37 P F Montana 
T586 S 04 February 2009 03 August 2010 18 P M PTA Central 
T1745 S 05 March 2009 03 August 2010 17 P F PTA Central 
T541 S 02 October 2009 04 August 2010 10 P M Ermelo 
Sample dried out   25 September 2008 04 August 2010 23 P M Montana 
T528 S 23 July 2008 05 August 2010 25 P F Montana 
T595 S 23 January 2009 05 August 2010 19 P M Montana 
T637 S 15 August 2007 05 August 2010 36 P M Trichardt 
T636 S 22 July 2009 06 August 2010 13 P M Ermelo 
T485 A 30 July 2008 06 August 2010 25 P F PTA Central 
T574 S 07 May 2010 06 August 2010 3 P M Standerton 
T497 S 15 December 2009 06 August 2010 8 P F Trichardt 
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T490 S 23 January 2009 07 August 2010 19 P M Montana 
T596 S 13 April 2010 07 August 2010 4 P M Montana 
Sample collected using tissue paper - unable 
to transfer   02 September 2009 07 August 2010 11 P M PTA Central 
T576 S 16 September 2008 08 August 2010 23 P M Montana 
T567 S 27 December 2007 09 August 2010 32 P M Akasia 
T642 S 14 May 2010 09 August 2010 3 P F PTA Central 
T506 S 18 July 2008 09 August 2010 25 P M PTA Central 
T488 S 09 March 2008 09 August 2010 29 P F PTA Central 
T610 S 27 November 2009 09 August 2010 9 P F PTA Central 
T531 S 26 January 2010 10 August 2010 7 P F Brits 
T496 A 30 January 2008 10 August 2010 31 P M Centurion 
T493 S 07 August 2009 10 August 2010 12 P F Centurion 
T516 S 14 May 2008 10 August 2010 27 P F Trichardt 
T559 S 23 April 2009 11 August 2010 16 P F Centurion 
T558 S 29 January 2009 11 August 2010 19 P F Kloof 
T534 S 03 May 2008 11 August 2010 27 P F PTA East 
T608 S 09 March 2009 12 August 2010 17 P M Groenkloof 
T547 S 05 November 2007 13 August 2010 33 P F PTA Central 
T563 S 25 July 2008 13 August 2010 25 P F PTA Central 
T572 S 08 August 2008 15 August 2010 24 P M PTA Central 
T484 S 26 February 2010 16 August 2010 6 P M PTA Central 
T502 S 14 May 2009 16 August 2010 15 P M PTA East 
T565 S 21 December 2009 16 August 2010 8 P M PTA East 
T501 S 23 June 2009 16 August 2010 14 P F Trichardt 
T1809 S 21 July 2009 17 August 2010 13 P F Kloof 
T1793 S 05 April 2010 17 August 2010 4 P F PTA East 
T1829 S 23 June 2009 18 August 2010 14 P F Trichardt 
T1841 S 18 January 2008 18 August 2010 31 P M Wilgers 
T1873 S 08 December 2009 19 August 2010 8 P M Akasia 
T1849 S 01 August 2008 19 August 2010 24 P F PTA Central 
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T1865 A 03 September 2008 20 August 2010 23 P M Akasia 
T1852 S 09 April 2009 20 August 2010 16 P M Brits 
T1859 A 28 February 2008 20 August 2010 30 P M PTA East 
T1860 S 02 December 2009 20 August 2010 8 P F Trichardt 
T1818 S 15 December 2008 20 August 2010 20 P F Wilgers 
T1850 S 16 January 2010 21 August 2010 7 P F Akasia 
T1817 S 17 April 2009 21 August 2010 16 P M Centurion 
T1806 A 28 February 2008 21 August 2010 30 P M PTA East 
T1831 S 18 March 2009 23 August 2010 17 P F Centurion 
Sample container empty   03 March 2009 23 August 2010 17 P M Les Marais 
T1833 S 28 January 2009 23 August 2010 19 P F Trichardt 
T1843 S 04 April 2010 23 August 2010 4 P M Trichardt 
T1803 S 18 January 2008 23 August 2010 31 P M Wilgers 
T1857 S 20 January 2010 24 August 2010 7 P F Akasia 
T1883 S 22 October 2007 24 August 2010 34 P F Groenkloof 
T1871 S 10 January 2009 25 August 2010 19 P F Akasia 
T1867 S 08 January 2007 25 August 2010 43 P M Centurion 
T1762 S 16 November 2009 26 August 2010 9 P M Brits 
T1782 S 15 May 2009 26 August 2010 15 P F Trichardt 
T1755 S 08 January 2010 27 August 2010 7 P F Centurion 
T1729 S 26 May 2008 27 August 2010 27 P M Centurion 
T1783 S 17 November 2007 27 August 2010 33 P F Montana 
T1771 A 21 May 2009 27 August 2010 15 P M PTA Central 
T1756 S 18 August 2008 27 August 2010 24 P F PTA East 
T1779 S 31 May 2010 27 August 2010 3 P M Standerton 
T1778 S 18 February 2010 27 August 2010 6 P M Trichardt 
T1787 S 22 July 2009 28 August 2010 13 P F Centurion 
T1742 A 04 June 2008 30 August 2010 26 P F Les Marais 
T1708 S 03 July 2008 31 August 2010 25 P F Centurion 
T1714 S 29 November 2009 31 August 2010 9 P M Rustenburg 
T1697 A 23 March 2009 02 September 2010 18 P F Les Marais 
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T1683 S 25 April 2008 03 September 2010 29 P M Middelburg 
T1690 S 30 December 2009 03 September 2010 9 P M PTA Central 
T1720 S 30 December 2009 04 September 2010 9 P M PTA Central 
Sample container empty   09 February 2009 06 September 2010 19 P M PTA Central 
T1711 S 15 April 2009 09 September 2010 17 P M Centurion 
T1693 S 06 February 2010 09 September 2010 7 P M Montana 
T1707 S 16 March 2010 11 September 2010 6 P M Ermelo 
T1709 S 05 January 2010 11 September 2010 8 P F Les Marais 
T1716 S 24 July 2009 11 September 2010 14 P M Middelburg 
T826 S 10 June 2010 14 September 2010 3 P M Bethal 
T831 A 09 June 2008 15 September 2010 27 P M PTA Central 
Sample dried out and too little to analyse   20 May 2006 16 September 2010 52 P F PTA Central 
T839 S 03 January 2010 16 September 2010 8 P M PTA East 
T834 S 19 June 2009 18 September 2010 15 P M PTA East 
T844 S 16 April 2009 21 September 2010 17 P F Wilgers 
T1647 S 18 June 2010 25 September 2010 3 P M Brits 
T1672 S 18 February 2010 30 September 2010 7 P F Secunda 
T1637 S 29 July 2010 04 October 2010 3 P F Trichardt 
T1650 A 22 October 2008 06 October 2010 24 P M PTA East 
T1663 S 14 November 2009 06 October 2010 11 P F Rustenburg 
T1629 S 26 August 2009 07 October 2010 14 P M Trichardt 
T1612 S 20 January 2006 10 October 2010 57 P M Centurion 
T1664 S 21 January 2009 10 October 2010 21 P F Montana 
T1532 S 27 February 2008 16 October 2010 32 P F Trichardt 
T1523 S 21 July 2007 17 October 2010 39 P F Wilgers 
T1589 S 06 August 2007 21 October 2010 38 P F Les Marais 
T1578 S 05 July 2010 23 October 2010 3 P F PTA Central 
T1574 S 17 September 2008 24 October 2010 25 P M Centurion 
T1609 S 23 August 2010 29 October 2010 2 P M PTA Central 
T1551 S 16 September 2010 02 November 2010 2 P M PTA Central 
T1548 S 16 September 2010 02 November 2010 2 P M PTA East 
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T1479 S 26 January 2010 17 November 2010 10 P M Krugersdorp 
T1420 A 01 June 2007 19 November 2010 41 P M Midrand 
2288 A 03 October 2010 06 December 2010 2 P F JHB Central  
T430 S 25 August 2009 15 December 2010 16 P F PTA Central 
2266 S 29 October 2010 22 December 2010 2 P F Bethal 
2221 S 01 January 2010 01 January 2011 12 P F Sandton 
2042 S 01 June 2009 28 January 2011 19 P M Krugersdorp 
2043 A 08 July 2010 29 January 2011 6 P F PTA Central 
T194 S 16 November 2009 26 February 2011 15 P F PTA Central 
T122 S 25 January 2010 29 March 2011 14 P F Centurion 
T868 S 16 August 2006 07 April 2011 56 P F Montana 
T2050 S 13 July 2010 27 April 2011 9 P M Sandton 
T2152 S 10 February 2009 12 May 2011 27 P F Akasia 
T2538 S 05 May 2009 17 May 2011 24 P M Krugersdorp 
T2622 S 15 July 2009 17 May 2011 22 P M Midrand 
T2647 S 22 September 2009 18 May 2011 20 P F Midrand 
T2446 S 18 January 2010 27 May 2011 16 P M Montana 
T2150 A 16 March 2010 31 May 2011 14 P M Akasia 
T2611 S 18 November 2010 03 June 2011 7 P F Trichardt 
T2507 A 23 March 2009 06 June 2011 27 P F Akasia 
T2329 S 10 January 2010 06 June 2011 17 P M Krugersdorp 
T2524 S 17 March 2010 06 June 2011 15 P F Middelburg 
T2359 S 20 December 2007 07 June 2011 42 P M Midrand 
T2298 S 18 September 2008 08 June 2011 33 P F Akasia 
T2318 S 12 February 2009 08 June 2011 28 P F Centurion 
T2398 A 20 July 2009 09 June 2011 23 P M Akasia 
T2397 S 26 March 2010 09 June 2011 15 P M Les Marais 
T2390 S 18 September 2009 09 June 2011 21 P F Roodepoort 
T2334 S 08 February 2010 10 June 2011 16 P F Midrand 
T2364 S 15 February 2010 10 June 2011 16 P F Montana 
T2341 S 18 November 2010 10 June 2011 7 P M PTA Central 
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T2309 A 20 July 2009 11 June 2011 23 P M Akasia 
T2332 S 06 May 2010 11 June 2011 13 P M Akasia 
T2339 S 10 August 2010 11 June 2011 10 P M Krugersdorp 
T2345 S 04 May 2010 11 June 2011 13 P F Midrand 
T2306 S 17 January 2009 12 June 2011 29 P F Brits 
T2323 S 03 May 2010 12 June 2011 13 P F Midrand 
T2388 S 03 March 2010 13 June 2011 15 P M JHB Central  
T2436 S 25 February 2010 13 June 2011 16 P M Midrand 
T2409 S 11 August 2010 14 June 2011 10 P F JHB Central 
T2396 S 14 November 2010 14 June 2011 7 P F Midrand 
T2404 S 09 October 2007 15 June 2011 44 P F Lenasia 
T2391 S 29 April 2009 15 June 2011 26 P M Mulbarton 
T2426 S 26 February 2008 15 June 2011 40 P M PTA Central 
T2200 S 23 May 2009 17 June 2011 25 P M Brits 
T2286 S 10 March 2010 17 June 2011 15 P M Midrand 
T2241 S 08 March 2010 17 June 2011 15 P M Montana 
T2223 S 16 October 2009 17 June 2011 20 P M PTA Central 
T2238 S 25 February 2010 17 June 2011 16 P M PTA Central 
T2253 S 02 January 2009 17 June 2011 29 P F PTA Central 
T2249 S 23 February 2010 17 June 2011 16 P F Rustenburg 
T2190 S 10 June 2010 18 June 2011 12 P F Midrand 
T2250 S 27 October 2010 18 June 2011 8 P F Midrand 
T2199 S 19 March 2008 18 June 2011 39 P F Randburg 
T2185 S 19 February 2010 19 June 2011 16 P F JHB Central  
T2247 S 05 December 2008 19 June 2011 30 P F Krugersdorp 
T2273 S 29 July 2010 19 June 2011 11 P M Middelburg 
T2235 S 27 October 2010 19 June 2011 8 P F Midrand 
T2262 S 04 March 2011 19 June 2011 3 P M Midrand 
T2255 S 30 November 2009 19 June 2011 19 P F PTA Central 
T2188 S 10 February 2009 19 June 2011 28 P F Rietfontein 
T2270 A 06 April 2008 20 June 2011 38 P F JHB Central  
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T2217 S 29 March 2010 20 June 2011 15 P F Midrand 
T2220 S 09 March 2009 20 June 2011 27 P F PTA East 
T2186 A 09 October 2007 20 June 2011 44 P F Randburg 
T2312 S 14 February 2009 21 June 2011 28 P M JHB Central  
T2209 S 30 November 2010 21 June 2011 7 P F Lenasia 
T2290 A 03 November 2008 21 June 2011 31 P F Mulbarton 
T2254 S 03 October 2009 21 June 2011 20 P M Trichardt 
T3415 S 26 September 2009 23 June 2011 21 P M Rustenburg 
T2230 S 22 April 2009 25 June 2011 26 P F Montana 
T2294 S 23 September 2008 25 June 2011 33 P M Mulbarton 
T2198 S 30 August 2010 25 June 2011 10 P F PTA Central 
T2201 S 28 February 2011 25 June 2011 4 P M Randburg 
T2214 S 11 December 2010 26 June 2011 6 P F Akasia 
T2204 S 27 April 2010 26 June 2011 14 P F PTA Central 
T2205 S 02 November 2009 26 June 2011 19 P F PTA Central 
T2216 S 29 March 2010 26 June 2011 15 P F Randburg 
T2847 S 31 March 2009 26 June 2011 27 P F Sandton 
T2775 S 08 March 2009 27 June 2011 27 P M Midrand 
T2781 S 14 August 2010 27 June 2011 10 P M Montana 
T2757 S 16 July 2010 27 June 2011 11 P M PTA Central 
T2798 S 22 June 2010 27 June 2011 12 P M Trichardt 
T2773 S 07 May 2009 28 June 2011 25 P F Centurion 
T2794 S 24 October 2008 28 June 2011 32 P F Ermelo 
T2760 S 27 March 2009 28 June 2011 27 P M JHB Central 
T2868 S 13 December 2010 28 June 2011 6 P F Middelburg 
T2776 S 04 July 2006 28 June 2011 59 P M Midrand 
T2758 S 21 January 2011 28 June 2011 5 P M Montana 
T2765 S 22 February 2011 28 June 2011 4 P F PTA Central 
T2785 S 04 January 2007 28 June 2011 53 P M PTA East 
T2833 S 26 May 2010 28 June 2011 13 P M Randburg 
T2761 S 23 November 2009 28 June 2011 19 P M Sandton 
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T2860 S 10 May 2010 29 June 2011 13 P F Les Marais 
T2848 S 20 November 2010 29 June 2011 7 P F Montana 
T2792 S 24 April 2008 29 June 2011 38 P F PTA East 
T2820 S 15 June 2010 29 June 2011 12 P F PTA East 
T2791 S 14 March 2008 29 June 2011 39 P F Randburg 
T2845 S 11 June 2010 29 June 2011 12 P F Trichardt 
T2858 S 16 February 2007 30 June 2011 52 P M Akasia 
T2810 A 30 March 2009 30 June 2011 27 P F Brits 
T2855 S 11 July 2009 30 June 2011 23 P F Krugersdorp 
T2851 S 25 May 2009 30 June 2011 25 P F Les Marais 
T2854 S 09 March 2010 30 June 2011 15 P F Midrand 
T2871 S 15 October 2009 30 June 2011 20 P F Mulbarton 
T2813 S 08 March 2010 30 June 2011 15 P F PTA Central 
T2822 S 15 January 2009 30 June 2011 29 P M Roodepoort 
T2864 S 15 May 2009 01 July 2011 26 P F Centurion 
T2826 S 17 February 2011 01 July 2011 5 P M Klerksdorp 
T2825 S 26 March 2010 01 July 2011 16 P M Lenasia 
T2874 S 11 December 2009 01 July 2011 19 P M Midrand 
T2880 S 19 October 2010 01 July 2011 9 P F Trichardt 
T2883 S 17 April 2009 02 July 2011 27 P M Faerie Glen 
T2841 S 28 February 2011 02 July 2011 5 P F Montana 
T2832 S 26 April 2009 02 July 2011 27 P M Mulbarton 
T2840 S 28 July 2008 03 July 2011 36 P M Mulbarton 
T2722 S 08 June 2009 04 July 2011 25 P M Krugersdorp 
T2720 S 01 March 2010 05 July 2011 16 P F Centurion 
T2727 S 14 September 2010 05 July 2011 10 P F Groenkloof 
T2721 S 23 June 2010 05 July 2011 13 P F Klerksdorp 
T2714 S 01 January 2010 05 July 2011 18 P F Krugersdorp 
T2708 S 05 November 2008 05 July 2011 32 P F Midrand 
T2732 S 24 February 2009 05 July 2011 29 P M PTA Central 
T2733 S 17 June 2009 05 July 2011 25 P F PTA Central 
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T2742 S 07 April 2009 05 July 2011 27 P M Sandton 
T2745 S 27 January 2010 06 July 2011 18 P F JHB Central 
T2737 S 20 April 2010 06 July 2011 15 P M Midrand 
T2739 S 15 April 2010 06 July 2011 15 P F PTA Central 
T2677 S 03 August 2009 07 July 2011 23 P F JHB Central  
T2664 S 08 January 2009 07 July 2011 30 P F Krugersdorp 
T2681 S 13 October 2010 08 July 2011 9 P M Brits 
T2688 S 03 May 2009 08 July 2011 26 P M Bronkhorspruit 
T2672 S 27 August 2010 08 July 2011 11 P F Centurion 
T2675 S 20 January 2010 08 July 2011 18 P F Krugersdorp 
T2697 S 24 June 2008 08 July 2011 37 P F Krugersdorp 
T2707 S 12 February 2010 08 July 2011 17 P M Montana 
T2701 A 03 July 2010 08 July 2011 12 P F PTA Central 
T2666 S 19 November 2008 08 July 2011 32 P M Sandton 
T2678 S 25 October 2007 09 July 2011 45 P M Groenkloof 
T2668 S 16 September 2009 09 July 2011 22 P M JHB Central  
T2659 S 31 August 2009 09 July 2011 23 P F Montana 
T2667 S 18 March 2010 09 July 2011 16 P M Sandton 
T2690 S 02 August 2010 10 July 2011 11 P M Centurion 
T2670 S 20 May 2010 10 July 2011 14 P M PTA Central 
T2676 S 09 March 2011 10 July 2011 4 P M PTA Central 
T2691 S 08 February 2007 10 July 2011 53 P M Sandton 
T3290 S 17 November 2010 11 July 2011 8 P M JHB Central 
T3301 S 29 March 2010 11 July 2011 16 P M Midrand 
T3225 S 07 August 2010 12 July 2011 11 P F Centurion 
T3283 S 16 November 2010 12 July 2011 8 P F Centurion 
T3310 S 19 February 2010 12 July 2011 17 P M Ermelo 
T3298 S 05 January 2010 12 July 2011 18 P M JHB Central  
T3230 S 20 February 2009 12 July 2011 29 P M Midrand 
T3258 S 08 August 2007 12 July 2011 47 P M Montana 
T3319 S 23 April 2010 12 July 2011 15 P M Montana 
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T3303 S 12 October 2006 12 July 2011 57 P M PTA Central 
T3186 S 12 August 2010 12 July 2011 11 P M PTA East 
T3207 S 03 December 2007 12 July 2011 43 P F Roodepoort 
T3326 S 15 September 2010 12 July 2011 10 P M Roodepoort 
T3239 S 15 September 2010 12 July 2011 10 P M Trichardt 
T3266 S 16 March 2009 13 July 2011 28 P F Centurion 
T3306 S 18 October 2010 13 July 2011 9 P M PTA Central 
T3280 S 31 March 2010 13 July 2011 16 P F PTA Central 
T3270 S 19 April 2010 13 July 2011 15 P F PTA East 
T3323 S 02 January 2010 13 July 2011 18 P F Trichardt 
T3244 S 21 December 2009 14 July 2011 19 P M Centurion 
T3272 S 05 August 2010 14 July 2011 11 P F Centurion 
T3261 S 08 April 2010 14 July 2011 15 P M PTA Central 
T3291 S 31 March 2010 14 July 2011 16 P F PTA Central 
T3314 S 05 May 2010 14 July 2011 14 P F Rietfontein 
T3264 S 11 April 2009 14 July 2011 27 P M Sandton 
T3262 S 18 January 2009 14 July 2011 30 P M Sandton 
T3275 S 24 April 2010 14 July 2011 15 P M Witbank 
T3228 S 21 December 2009 15 July 2011 19 P M Centurion 
T3287 S 17 June 2009 15 July 2011 25 P F Ermelo 
T3212 S 04 November 2010 15 July 2011 8 P F Krugersdorp 
T3249 S 03 September 2009 15 July 2011 22 P M Krugersdorp 
T3202 S 07 December 2007 15 July 2011 43 P F Middelburg 
T3240 S 21 July 2010 15 July 2011 12 P M Montana 
T3221 S 15 March 2010 15 July 2011 16 P F PTA Central 
T3274 S 25 June 2010 15 July 2011 13 P F PTA Central 
T3196 S 28 October 2010 15 July 2011 9 P M PTA East 
T3297 S 13 September 2009 15 July 2011 22 P M PTA East 
T3281 S 19 October 2008 15 July 2011 33 P M Randburg 
T3213 S 15 December 2010 15 July 2011 7 P F Rustenburg 
T3286 S 31 May 2010 15 July 2011 14 P F Rustenburg 
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T3216 S 22 October 2010 16 July 2011 9 P F Centurion 
T3231 S 21 April 2008 16 July 2011 39 P F Mulbarton 
T3214 S 01 March 2009 16 July 2011 28 P M PTA East 
T3277 S 13 September 2009 16 July 2011 22 P M PTA East 
T3168 S 03 June 2008 17 July 2011 37 P M Centurion 
T3227 S 03 January 2010 17 July 2011 18 P F JHB Central  
T3305 S 18 May 2010 17 July 2011 14 P F PTA East 
T3053 S 18 December 2007 19 July 2011 43 P F Centurion 
T3023 S 15 August 2010 19 July 2011 11 P M PTA East 
T3038 S 02 December 2010 20 July 2011 7 P M Centurion 
T3107 S 28 August 2010 20 July 2011 11 P F Centurion 
T3082 S 29 June 2008 20 July 2011 37 P F Krugersdorp 
T3090 S 20 September 2009 20 July 2011 22 P F Krugersdorp 
T3030 S 07 April 2010 20 July 2011 15 P F Montana 
T3054 S 13 June 2008 20 July 2011 37 P M Montana 
T3144 S 04 May 2011 20 July 2011 2 P M Montana 
T3078 S 29 July 2010 20 July 2011 12 P M PTA East 
T3143 S 27 March 2009 20 July 2011 28 P F Rietfontein 
T3092 S 21 May 2009 20 July 2011 26 P M Secunda 
T3040 S 11 October 2006 20 July 2011 57 P M Standerton 
T3036 S 20 November 2009 21 July 2011 20 P F Centurion 
T3043 S 26 June 2009 21 July 2011 25 P F Faerie Glen 
T3022 S 07 April 2010 21 July 2011 15 P M Krugersdorp 
T3069 S 17 September 2010 21 July 2011 10 P M Montana 
T3137 S 03 February 2011 21 July 2011 5 P M Montana 
T3020 S 04 March 2010 21 July 2011 16 P M PTA East 
T3037 S 14 December 2010 21 July 2011 7 P F PTA East 
T3063 S 20 November 2008 21 July 2011 32 P M Randburg 
T3057 S 23 June 2008 21 July 2011 37 P F Trichardt 
T3086 S 02 February 2009 21 July 2011 29 P F Trichardt 
T3094 S 24 July 2010 22 July 2011 12 P F Centurion 
 195 
 
T3076 S 15 October 2009 22 July 2011 21 P F JHB Central  
T3019 S 09 November 2009 22 July 2011 20 P M Krugersdorp 
T3106 S 04 February 2009 22 July 2011 29 P M Midrand 
T3029 S 06 September 2010 22 July 2011 10 P F PTA Central 
T3085 S 08 April 2010 23 July 2011 15 P M Midrand 
T3042 S 12 August 2008 23 July 2011 35 P F PTA Central 
T3139 S 26 February 2009 24 July 2011 29 P M Alberton 
T3241 S 03 September 2008 24 July 2011 34 P M JHB Central  
T3166 S 28 February 2011 24 July 2011 5 P M Kemptonpark 
T3193 S 24 January 2011 24 July 2011 6 P M PTA Central 
T3151 S 24 February 2009 24 July 2011 29 P F Sandton 
T3190 S 02 December 2010 24 July 2011 7 P M Sandton 
T3105 S 20 February 2007 24 July 2011 53 P F Vanderbijlpark 
T3273 S 11 May 2007 25 July 2011 50 P F Benoni 
T3243 S 18 August 2009 25 July 2011 23 P M Centurion 
T3173 S 16 June 2009 25 July 2011 25 P F Germiston 
T3171 S 26 May 2009 25 July 2011 26 P M JHB Central 
T3235 S 05 May 2011 25 July 2011 2 P F Klerksdorp 
T3035 S 27 August 2009 25 July 2011 23 P F Krugersdorp 
T3217 S 23 July 2009 25 July 2011 24 P M Krugersdorp 
T3130 S 31 March 2009 25 July 2011 28 P M Montana 
T3185 S 16 August 2006 25 July 2011 59 P F PTA Central 
T3175 S 03 February 2009 25 July 2011 29 P M PTA East 
T3197 S 17 May 2010 25 July 2011 14 P F PTA East 
T3127 S 16 June 2008 25 July 2011 37 P M Sandton 
T3179 S 27 May 2010 25 July 2011 14 P F Sandton 
T3156 S 21 December 2007 25 July 2011 43 P F Sandton 
T3233 S 19 April 2009 25 July 2011 27 P M Trichardt 
T3061 S 31 March 2009 25 July 2011 28 P M Vanderbijlpark 
T3210 S 10 September 2010 25 July 2011 10 P F Wilgers 
T3104 S 11 August 2009 26 July 2011 23 P M Akasia 
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T3129 S 15 March 2008 26 July 2011 40 P F Centurion 
T3169 S 08 July 2010 26 July 2011 12 P F Germiston 
T3161 S 17 December 2010 26 July 2011 7 P M JHB Central  
T3255 S 03 November 2010 26 July 2011 8 P M Kemptonpark 
T3159 S 11 January 2011 26 July 2011 6 P F Montana 
T3170 S 25 October 2009 26 July 2011 21 P M PTA East 
T3184 S 25 February 2009 26 July 2011 29 P F Vanderbijlpark 
T3098 S 07 December 2009 27 July 2011 19 P M Alberton 
T3122 S 17 February 2011 27 July 2011 5 P M Centurion 
T3135 S 02 March 2009 27 July 2011 28 P F Centurion 
T3146 S 02 March 2009 27 July 2011 28 P F Centurion 
T3103 S 01 December 2008 27 July 2011 31 P F Germiston 
T3095 S 21 September 2009 27 July 2011 22 P M Montana 
T3110 S 04 March 2010 27 July 2011 16 P M PTA East 
T3128 S 16 October 2009 27 July 2011 21 P M PTA East 
T3163 S 15 October 2009 27 July 2011 21 P M PTA East 
T3132 S 21 January 2010 27 July 2011 18 P M Randburg 
T3018 S 23 July 2010 27 July 2011 12 P M Rustenburg 
T3148 S 12 January 2010 27 July 2011 18 P M Secunda 
T3119 S 04 October 2010 27 July 2011 9 P M Springs 
T3187 S 19 December 2008 27 July 2011 31 P F Wilgers 
T3142 S 13 September 2010 28 July 2011 10 P F PTA Central 
T2919 S 04 September 2009 29 July 2011 22 P M JHB Central  
T2885 S 16 December 2009 29 July 2011 19 P M Krugersdorp 
T2942 S 10 July 2009 29 July 2011 24 P M Krugersdorp 
T2971 S 27 May 2009 29 July 2011 26 P M Randburg 
T2937 S 19 July 2010 29 July 2011 12 P M Sandton 
T2952 S 20 November 2007 29 July 2011 44 P F Vanderbijlpark 
T2897 S 14 June 2009 30 July 2011 25 P F Alberton 
T2903 S 19 May 2009 30 July 2011 26 P M Benoni 
T2899 S 01 July 2011 30 July 2011 0 P M Centurion 
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T2921 S 04 January 2010 30 July 2011 18 P F Centurion 
T2962 S 12 April 2009 30 July 2011 27 P F Krugersdorp 
T2891 S 14 December 2010 30 July 2011 7 P F Montana 
T2920 S 09 September 2009 30 July 2011 22 P M Montana 
T2978 S 20 September 2008 30 July 2011 34 P M PTA Central 
T2906 S 16 November 2010 30 July 2011 8 P F PTA East 
T2953 S 25 September 2009 30 July 2011 22 P F PTA East 
T2968 S 08 July 2011 30 July 2011 0 P F PTA East 
T2927 S 01 December 2010 31 July 2011 7 P F Lenasia 
T2900 S 16 April 2010 31 July 2011 15 P F Randburg 
T2973 S 22 June 2011 31 July 2011 1 P F Springs 
T2983 S 11 March 2009 03 August 2011 29 P M Akasia 
T2957 S 30 July 2010 03 August 2011 13 P F Centurion 
T2909 S 11 October 2008 03 August 2011 34 P F Krugersdorp 
T2938 S 22 September 2009 03 August 2011 23 P M Mulbarton 
T2945 S 26 November 2010 03 August 2011 9 P M PTA Central 
T2951 S 11 April 2010 03 August 2011 16 P F PTA Central 
T2950 S 17 September 2008 03 August 2011 35 P F Randburg 
T2958 S 25 September 2007 04 August 2011 47 P M Akasia 
T2985 S 22 February 2010 04 August 2011 18 P M Centurion 
T2987 S 06 July 2010 04 August 2011 13 P F Kemptonpark 
T3014 S 12 September 2008 04 August 2011 35 P F Potchefstroom 
T3006 S 15 February 2010 04 August 2011 18 P F PTA Central 
T2926 S 03 March 2010 04 August 2011 17 P F PTA East 
T2979 S 11 February 2009 04 August 2011 30 P F PTA East 
T3013 S 28 November 2009 04 August 2011 21 P M Randburg 
T3001 S 28 June 2010 04 August 2011 14 P M Sandton 
T3427 S 09 May 2011 17 August 2011 3 P M Klerksdorp 
T3408 S 01 February 2010 18 August 2011 18 P F Alberton 
T3431 S 26 March 2007 18 August 2011 53 P M JHB Central  
T3436 S 05 August 2008 19 August 2011 36 P F Akasia 
 198 
 
T3448 S 04 January 2009 19 August 2011 31 P F Centurion 
T3438 S 20 August 2010 19 August 2011 12 P F Groenkloof 
T3442 S 18 August 2010 19 August 2011 12 P F Montana 
T3422 S 05 May 2007 19 August 2011 51 P M Mulbarton 
T3378 S 11 February 2010 22 August 2011 18 P F Trichardt 
T3393 S 22 February 2010 23 August 2011 18 P M Centurion 
T3388 S 21 October 2009 23 August 2011 22 P F Krugersdorp 
T3363 S 15 January 2010 23 August 2011 19 P M Sandton 
T3334 S 18 January 2010 24 August 2011 19 P M Brits 
T3400 S 25 May 2011 24 August 2011 3 P M Centurion 
T3369 S 01 March 2010 24 August 2011 17 P M Kloof 
T3337 S 09 June 2008 24 August 2011 38 P F Mulbarton 
T3350 S 26 January 2010 24 August 2011 19 P M PTA Central 
T3406 S 29 July 2009 24 August 2011 25 P F PTA East 
T3429 S 03 November 2009 24 August 2011 21 P M Sandton 
T3412 S 21 November 2006 26 August 2011 57 P M Sandton 
T3433 S 21 October 2009 26 August 2011 22 P F Sandton 
T3203 A 04 April 2009 25 September 2011 29 P F Krugersdorp 
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APPENDIX G (EIA results)
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Table G.1  EIA results 
MRC / UNISA # 
SENSITIVITY 
S = Symptomatic 
A = Asymptomatic 
DATE OF BIRTH COLLECTION DATE AGE IN MONTHS 
RAPID TEST STRIP 
RESULT 
A = Absent 
P = Present 
EIA RESULT 
N = Negative 
P = Positive 
GENDER LOCATION 
1604 S 17 July 2008 20 April 2010 21 A N M Trichardt 
1612 S 06 January 2009 19 April 2010 15 A N F Middelburg 
1618 S 23 February 2009 17 April 2010 14 A N F Trichardt 
1634 S 03 January 2009 21 April 2010 15 A N M Trichardt 
1645 S 06 April 2009 16 April 2010 12 A N M Trichardt 
1653 S 26 June 2008 16 April 2010 22 A N F Middelburg 
1668 S 13 December 2009 29 April 2010 4 A N M Middelburg 
1702 S 25 May 2009 27 April 2010 11 A N M Middelburg 
1704 S 13 August 2009 30 April 2010 8 A N M Trichardt 
1715 S 27 August 2009 23 April 2010 8 A N F Trichardt 
1723 S 17 September 2007 25 April 2010 31 A N F Trichardt 
1738 S 30 July 2009 23 April 2010 9 A N M Trichardt 
1753 S 12 January 2010 06 May 2010 4 A N M Trichardt 
1805 S 28 May 2006 10 May 2010 48 A N F Middelburg 
1850 S 22 December 2007 12 May 2010 29 A N M Trichardt 
1853 S 29 November 2008 11 May 2010 18 A N F Middelburg 
1883 S 15 October 2009 15 May 2010 7 A N M Trichardt 
1896 A 19 September 2008 16 May 2010 20 A N M Middelburg 
1901 S 20 January 2009 16 May 2010 16 A N F Middelburg 
1917 S 22 December 2009 18 May 2010 5 A N F Trichardt 
1920 S 14 December 2009 18 May 2010 5 A N F Middelburg 
1956 A 03 September 2009 21 May 2010 8 A N F Middelburg 
1965 S 14 October 2009 21 May 2010 7 A N F Trichardt 
2054 A 04 March 2009 21 January 2011 22 A N M Middelburg 
2082 A 20 July 2010 25 January 2011 6 A N M Trichardt 
2112 S 23 June 2009 18 January 2011 19 A N F Trichardt 
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2144 S 11 March 2009 04 January 2011 22 A N M Trichardt 
2167 S 26 July 2010 04 February 2011 7 A N F Middelburg 
2168 A 02 February 2010 04 February 2011 12 A N F Middelburg 
2170 A 02 April 2009 02 February 2011 22 A N F Trichardt 
2197 S 15 July 2009 19 January 2011 18 A N M Trichardt 
2208 S 19 April 2009 29 January 2011 21 A N M Middelburg 
2226 A 08 September 2009 31 December 2010 15 A N M Middelburg 
2242 S 29 March 2010 20 December 2010 9 A N F Middelburg 
2265 S 21 March 2009 23 December 2010 21 A N M Trichardt 
2281 A 23 February 2010 06 December 2010 10 A N F Middelburg 
2285 S 09 February 2009 05 December 2010 22 A N F Trichardt 
2307 S 11 April 2009 07 December 2010 20 A N F Trichardt 
2432 S 10 November 2010 31 December 2010 1 A N F Rustenburg 
2453 A 15 October 2010 20 January 2011 3 A N M Middelburg 
2474 A 23 November 2009 21 January 2011 14 A N M Trichardt 
2481 S 10 October 2009 11 January 2011 15 A N F Middelburg 
2510 S 11 August 2006 17 January 2011 53 A N M Middelburg 
2520 S 08 November 2008 18 January 2011 26 A N M Middelburg 
2581 S 01 February 2007 19 January 2011 47 A N M Trichardt 
2601 A 14 December 2010 01 January 2011 1 A N M Trichardt 
2622 S 28 October 2010 09 December 2010 2 A N M Trichardt 
2658 S 31 May 2007 22 December 2010 43 A N M Trichardt 
2672 S 18 July 2008 06 December 2010 29 A N M Trichardt 
2683 S 15 October 2008 08 December 2010 26 A N M Trichardt 
B142 S 16 February 2008 28 March 2011 37 A N M Middelburg 
B146 S 19 October 2010 22 March 2011 5 A N F Trichardt 
B159 S 06 October 2010 22 March 2011 5 A N F Trichardt 
B173 S 27 July 2007 23 February 2011 43 A N M Middelburg 
B180 S 07 May 2008 22 February 2011 33 A N M Trichardt 
B206 S 23 October 2006 18 March 2011 53 A N M Middelburg 
B209 S 09 December 2010 17 March 2011 3 A N M Trichardt 
 202 
 
B215 S 19 November 2010 16 March 2011 4 A N M Trichardt 
B218 S 01 December 2010 19 March 2011 3 A N F Trichardt 
B23 S 04 February 2009 10 March 2011 25 A N F Middelburg 
B235 S 02 January 2008 19 March 2011 38 A N M Rustenburg 
B278 S 13 August 2008 26 November 2010 27 A N M Trichardt 
B289 S 21 June 2007 26 November 2010 41 A N M Trichardt 
B294 S 09 June 2010 29 November 2010 5 A N M Trichardt 
B307 A 01 October 2010 28 November 2010 1 A N M Middelburg 
B335 S 15 March 2006 06 February 2011 59 A N M Middelburg 
B354 S 09 August 2010 03 December 2010 4 A N F Rustenburg 
B396 A 20 January 2009 03 March 2011 26 A P M Trichardt 
B436 S 04 February 2011 27 February 2011 0 A N F Trichardt 
B451 S 15 April 2010 23 September 2010 5 A N M Trichardt 
B455 A 01 April 2010 23 September 2010 5 A N M Middelburg 
B463 A 06 January 2008 16 September 2010 32 A N M Trichardt 
B469 S 25 October 2007 18 September 2010 35 A N F Trichardt 
B47 S 10 January 2008 07 March 2011 38 A N F Trichardt 
B502 S 21 December 2008 07 April 2011 28 A N F Middelburg 
B508 S 27 September 2010 19 November 2010 2 A N F Trichardt 
B513 S 22 October 2010 23 November 2010 1 A N M Trichardt 
B531 A 03 October 2007 23 November 2010 37 A N F Middelburg 
B540 S 14 September 2010 23 November 2010 2 A N F Trichardt 
B570 S 01 June 2010 15 November 2010 5 A N M Middelburg 
B574 S 12 August 2010 13 November 2010 3 A N F Trichardt 
B575 S 19 January 2006 23 November 2010 58 A N F Trichardt 
B576 S 17 April 2007 08 November 2010 43 A N F Trichardt 
B577 S 04 August 2010 14 November 2010 3 A N F Trichardt 
B581 S 11 September 2008 04 November 2010 26 A N F Middelburg 
B609 S 09 November 2010 14 November 2010 0 A N M Trichardt 
B620 S 26 August 2010 12 October 2010 2 A N M Trichardt 
B626 S 15 July 2008 07 November 2010 28 A N F Trichardt 
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B637 S 16 July 2010 22 October 2010 3 A N M Trichardt 
B652 S 14 July 2010 22 October 2010 3 A N M Middelburg 
B658 S 28 June 2010 15 October 2010 4 A N M Trichardt 
B661 S 15 July 2010 26 October 2010 3 A N F Trichardt 
B679 S 04 August 2008 07 October 2010 26 A N M Trichardt 
B681 S 27 July 2010 06 October 2010 3 A N F Trichardt 
B684 S 13 July 2010 08 October 2010 3 A N M Trichardt 
B693 A 10 January 2008 09 October 2010 33 ? N F Trichardt 
B694 S 06 June 2008 05 October 2010 28 A N M Trichardt 
B7 S 18 April 2007 12 March 2011 47 A N M Middelburg 
B703 A 17 October 2008 02 October 2010 24 A N M Middelburg 
B712 S 28 April 2008 08 October 2010 30 A N F Trichardt 
B714 S 09 September 2010 02 October 2010 1 A N M Trichardt 
B719 S 10 June 2008 08 October 2010 28 A N F Trichardt 
B722 S 23 September 2010 19 October 2010 1 A N M Trichardt 
B731 A 12 November 2008 08 September 2010 22 A N M Middelburg 
B732 S 10 June 2010 09 September 2010 3 A N M Trichardt 
B736 S 15 April 2010 02 September 2010 5 A N F Trichardt 
B740 S 06 August 2007 11 September 2010 37 A N M Trichardt 
B764 S 21 April 2010 07 September 2010 5 A N F Trichardt 
B789 S 28 September 2007 04 April 2010 31 A N M Middelburg 
B795 A 21 September 2007 07 April 2010 31 A N M Rustenburg 
B80 S 27 October 2010 14 February 2011 4 A N M Trichardt 
B808 A 19 December 2009 07 April 2010 4 A N M Rustenburg 
B813 A 26 March 2008 07 April 2010 25 A N F Trichardt 
B818 A 17 February 2008 25 March 2010 25 A N M Trichardt 
B82 S 12 September 2010 15 February 2011 5 A N F Trichardt 
B820 S 04 February 2010 22 March 2010 1 A N M Trichardt 
B837 A 08 January 2008 19 March 2010 26 A N M Trichardt 
B843 S 03 February 2010 25 March 2010 1 A N F Trichardt 
B845 S 08 July 2007 05 April 2010 33 A N F Middelburg 
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B854 S 26 April 2008 03 April 2010 24 A N M Trichardt 
B861 S 22 January 2009 10 April 2011 27 A N M Trichardt 
B871 A 13 January 2011 18 April 2011 3 A N F Rustenburg 
B874 S 16 December 2010 14 April 2011 4 A N M Trichardt 
B883 S 22 March 2011 19 April 2011 1 A N M Middelburg 
B885 S 16 April 2009 19 April 2011 24 A N M Trichardt 
B890 A 02 April 2008 29 April 2011 36 A N M Rustenburg 
B912 S 30 October 2008 29 April 2011 30 A N F Trichardt 
B913 S 11 March 2011 29 April 2011 1 A N F Trichardt 
T10 S 28 April 2010 12 March 2011 11 A N M Trichardt 
T1000 S 14 February 2009 08 July 2010 17 P P F PTA Central 
T1001 A 24 November 2009 30 June 2010 7 A N M Centurion 
T1002 S 02 November 2009 09 July 2010 8 A N F Trichardt 
T1004 S 23 October 2009 30 June 2010 8 P P F PTA Central 
T1007 S 10 September 2008 01 July 2010 22 P P M PTA East 
T1008 S 19 November 2009 02 July 2010 8 A N F Trichardt 
T1012 S 02 January 2009 03 July 2010 18 A N M Trichardt 
T1015 S 04 July 2008 12 July 2010 24 P P F Middelburg 
T1016 S 20 August 2009 09 July 2010 11 A P F Middelburg 
T1018 S 23 December 2008 09 July 2010 19 A N F Wilgers 
T1019 S 24 August 2009 08 July 2010 11 P P M Trichardt 
T1020 S 17 September 2009 02 July 2010 10 A N F PTA East 
T1022 S 02 July 2009 02 July 2010 12 P P M Brits 
T1023 S 06 May 2010 29 June 2010 1 A N F Trichardt 
T1027 S 13 February 2009 29 June 2010 16 P P M Wilgers 
T1045 S 19 February 2009 05 July 2010 17 P P M Akasia 
T105 S 15 April 2010 30 March 2011 11 A N M Trichardt 
T1053 S 12 January 2009 03 July 2010 18 A N M Centurion 
T1062 S 23 September 2008 29 June 2010 21 P P M Faerie Glen 
T1064 S 25 June 2009 04 July 2010 13 A N F Akasia 
T1065 S 30 August 2008 09 July 2010 23 A N F Centurion 
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T1077 S 23 December 2009 01 July 2010 7 A N M Montana 
T1086 S 27 October 2009 03 July 2010 9 A N F Les Marais 
T1091 S 29 June 2009 23 June 2010 12 P P F Trichardt 
T1096 S 16 October 2009 23 June 2010 8 P P F PTA East 
T1106 S 03 August 2008 22 June 2010 22 P P M Akasia 
T1107 S 06 July 2009 04 July 2010 12 P P F Montana 
T1108 A 24 August 2009 24 June 2010 10 A N M Middelburg 
T1118 S 16 July 2008 27 June 2010 23 A N M Middelburg 
T1119 S 14 April 2007 24 June 2010 38 A N M Trichardt 
T1124 S 22 January 2009 25 June 2010 17 A N F Bethal 
T1128 A 19 June 2010 27 June 2010 0 A N F Trichardt 
T1131 S 17 February 2009 22 June 2010 16 P P M Centurion 
T1134 S 21 May 2009 23 June 2010 13 P P M Trichardt 
T1139 S 31 March 2009 26 June 2010 15 P P F PTA Central 
T1144 S 17 June 2008 27 June 2010 24 A N M Rietfontein 
T1149 S 28 September 2009 28 June 2010 9 A N M Trichardt 
T1157 S 08 April 2009 15 July 2010 15 P P M Akasia 
T1160 S 16 October 2008 13 July 2010 21 P P M Akasia 
T1166 S 23 November 2009 21 June 2010 7 P P M Centurion 
T1169 S 23 April 2009 20 June 2010 14 A N F Centurion 
T1177 S 14 October 2005 15 June 2010 56 A N M Trichardt 
T1185 A 30 October 2008 20 June 2010 20 P P F Trichardt 
T1188 A 23 April 2009 21 June 2010 14 A N M Trichardt 
T1190 S 09 September 2009 21 June 2010 9 A N M Standerton 
T1198 S 04 February 2009 18 June 2010 16 P P F Trichardt 
T1199 S 15 February 2010 19 June 2010 4 P P F Trichardt 
T1202 S 03 June 2009 16 June 2010 12 A N M Trichardt 
T1216 S 03 December 2008 21 June 2010 18 A N F Les Marais 
T1221 S 08 December 2009 17 June 2010 6 P P M PTA Central 
T1223 S 30 June 2009 09 June 2010 12 P P F PTA Central 
T1224 S 19 October 2009 21 June 2010 8 P P F Montana 
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T1225 S 13 July 2009 02 June 2010 11 A N F Secunda 
T1228 A 02 February 2007 15 June 2010 40 A N F Trichardt 
T123 S 19 September 2010 26 March 2011 6 A N F Middelburg 
T1234 S 15 February 2010 17 June 2010 4 P P F Trichardt 
T1237 S 04 June 2007 08 June 2010 36 A N M Trichardt 
T1244 S 09 November 2009 09 June 2010 7 A N F Wilgers 
T1248 S 18 November 2009 12 June 2010 7 P P M Trichardt 
T1251 S 27 December 2006 01 June 2010 42 A N M Trichardt 
T1253 S 11 December 2009 15 June 2010 6 A N F Trichardt 
T1254 S 08 May 2009 31 May 2010 12 P P M PTA Central 
T1257 S 06 December 2008 20 June 2010 18 P P F PTA East 
T1266 S 10 February 2010 30 May 2010 3 A N M Middelburg 
T1268 S 10 December 2009 10 June 2010 6 A N M Trichardt 
T1272 S 23 January 2007 08 June 2010 41 ? N F Middelburg 
T1275 S 04 February 2009 01 June 2010 16 A N F Middelburg 
T1276 S 27 April 2009 08 June 2010 14 P P F Akasia 
T1278 S 27 September 2008 31 May 2010 20 P P M PTA Central 
T1280 S 27 February 2009 19 June 2010 16 A N M Akasia 
T1289 S 15 October 2008 05 June 2010 20 A N M Trichardt 
T1294 S 02 August 2008 08 June 2010 22 A N F PTA East 
T130 A 12 May 2009 29 March 2011 22 A N M Middelburg 
T1300 A 12 January 2009 08 June 2010 17 A N F Trichardt 
T131 S 17 May 2010 03 March 2011 10 A N F Trichardt 
T1313 A 22 January 2009 04 June 2010 17 A N M Trichardt 
T132 S 14 June 2010 28 March 2011 9 A N M Rustenburg 
T1331 S 29 November 2009 08 June 2010 7 A N M Faerie Glen 
T1336 S 11 March 2009 07 June 2010 15 A N M Centurion 
T1342 S 22 December 2009 02 June 2010 6 A N F Secunda 
T1349 S 11 October 2008 02 June 2010 20 A N M Groenkloof 
T1350 S 26 January 2010 05 June 2010 5 A N M Trichardt 
T1351 S 30 April 2009 04 June 2010 14 P P M Trichardt 
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T1358 S 25 November 2009 08 June 2010 7 P P F Trichardt 
T1359 S 08 September 2007 08 June 2010 33 A N F Middelburg 
T1364 S 11 February 2009 04 June 2010 16 P P F Wilgers 
T1369 S 19 July 2009 07 June 2010 11 P P M Middelburg 
T1371 S 05 September 2009 02 June 2010 9 A N M PTA Central 
T1372 A 15 October 2008 07 June 2010 20 A N M Trichardt 
T1373 S 28 December 2009 24 May 2010 5 A N F Trichardt 
T1390 S 08 June 2008 28 May 2010 23 A N F Les Marais 
T1392 A 17 November 2009 04 June 2010 7 A N F Trichardt 
T1394 S 29 April 2009 04 June 2010 14 A N M PTA East 
T140 S 30 August 2010 21 March 2011 7 A N M Trichardt 
T1401 S 15 October 2008 02 June 2010 20 P P M Centurion 
T1402 S 05 March 2009 10 June 2010 15 A N F Middelburg 
T1408 S 10 March 2009 10 June 2010 15 A N F Trichardt 
T1434 A 02 June 2009 23 November 2010 17 A N F Middelburg 
T1442 A 09 November 2009 23 November 2010 12 A N M Trichardt 
T146 A 28 June 2009 22 March 2011 21 A N F Rustenburg 
T1467 S 18 March 2007 06 November 2010 44 A N F Middelburg 
T1480 S 19 August 2009 15 November 2010 15 A N F Middelburg 
T1486 S 16 November 2007 14 November 2010 36 A N F Middelburg 
T1502 S 02 June 2009 16 November 2010 17 A N F Middelburg 
T1518 S 15 December 2008 31 October 2010 22 A N M Trichardt 
T1532 S 27 February 2008 16 October 2010 32 P P F Trichardt 
T1533 S 04 December 2008 17 October 2010 22 A N M Wilgers 
T1542 S 18 February 2010 07 November 2010 9 A N F Trichardt 
T1544 S 28 January 2010 08 November 2010 10 A N F Trichardt 
T1545 S 29 October 2009 13 November 2010 13 A N M Trichardt 
T155 S 20 July 2010 22 March 2011 8 A N M Middelburg 
T1553 S 13 April 2010 10 November 2010 7 A N M Trichardt 
T1556 S 30 October 2009 08 November 2010 13 A N M Trichardt 
T1561 S 13 February 2010 10 November 2010 9 A N F Middelburg 
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T1581 S 21 December 2009 22 October 2010 10 A N F Trichardt 
T1583 S 25 January 2010 21 October 2010 9 A N F PTA East 
T1588 S 06 December 2008 28 October 2010 22 A N F Groblersdal 
T1590 S 30 November 2009 22 October 2010 11 A N M Trichardt 
T1611 S 05 November 2009 30 September 2010 10 A N M Les Marais 
T1618 S 17 February 2009 10 October 2010 20 A N M Centurion 
T1629 S 26 August 2009 07 October 2010 14 P P M Trichardt 
T1632 S 21 December 2009 06 October 2010 10 A N F Trichardt 
T1637 S 29 July 2010 04 October 2010 3 P P F Trichardt 
T1638 S 02 March 2009 27 September 2010 18 A N F Brits 
T1640 S 26 March 2009 02 October 2010 19 A N M JHB Central  
T1642 S 26 August 2009 30 September 2010 13 A N M Trichardt 
T1657 S 05 November 2009 27 October 2010 11 A N M Middelburg 
T1663 S 14 November 2009 06 October 2010 11 P P F Rustenburg 
T1664 S 21 January 2009 10 October 2010 21 P P F Montana 
T1669 S 06 November 2008 03 October 2010 23 A N M Middelburg 
T1683 S 25 April 2008 03 September 2010 29 P P M Middelburg 
T1684 S 05 February 2010 01 September 2010 7 A N F Bronkhorspruit 
T1685 S 21 February 2009 10 September 2010 19 A N M Middelburg 
T1705 S 15 July 2009 07 September 2010 14 A N F Middelburg 
T1706 S 20 January 2010 10 September 2010 8 A N M Middelburg 
T1707 S 16 March 2010 11 September 2010 6 P P M Ermelo 
T1711 S 15 April 2009 09 September 2010 17 P P M Centurion 
T1714 S 29 November 2009 31 August 2010 9 P P M Rustenburg 
T1715 S 28 July 2008 31 August 2010 25 A N M Middelburg 
T1716 S 24 July 2009 11 September 2010 14 P P M Middelburg 
T172 A 26 November 2009 07 February 2011 15 A N M Rustenburg 
T1721 S 02 April 2009 07 September 2010 17 A N F Montana 
T1732 S 10 April 2010 26 August 2010 4 A N M Trichardt 
T1736 A 30 April 2007 26 August 2010 40 A N M Trichardt 
T1738 S 04 June 2008 27 August 2010 26 A N F Middelburg 
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T1741 S 10 April 2010 28 August 2010 4 A N M Trichardt 
T1745 S 05 March 2009 03 August 2010 17 P P F PTA Central 
T1748 S 01 July 2009 28 August 2010 13 A N M Brits 
T1752 S 09 July 2009 31 August 2010 13 A N F Montana 
T1757 S 30 October 2009 13 September 2010 11 A N F Standerton 
T1762 S 16 November 2009 26 August 2010 9 P P M Brits 
T1768 S 24 January 2006 28 August 2010 55 A N M Trichardt 
T1773 S 30 March 2010 28 August 2010 5 A N F Trichardt 
T1776 S 13 January 2009 24 August 2010 19 A N M PTA Central 
T1778 S 18 February 2010 27 August 2010 6 P P M Trichardt 
T1780 A 27 December 2007 29 August 2010 32 A N F Middelburg 
T1781 A 01 July 2008 29 August 2010 25 A N F Middelburg 
T1782 S 15 May 2009 26 August 2010 15 P P F Trichardt 
T180 A 22 April 2009 22 February 2011 22 A N F Rustenburg 
T1802 A 24 July 2009 17 August 2010 13 A N F Middelburg 
T1810 A 24 April 2009 27 August 2010 16 A N M Middelburg 
T1811 S 25 December 2009 20 August 2010 8 A N F PTA Central 
T1819 S 18 September 2009 22 August 2010 11 A N M PTA Central 
T1821 S 27 December 2007 29 August 2010 32 A N F Middelburg 
T1823 S 19 November 2008 17 August 2010 21 A N F Secunda 
T1825 S 08 January 2008 17 August 2010 31 A N F Trichardt 
T1829 S 23 June 2009 18 August 2010 14 P P F Trichardt 
T1831 S 18 March 2009 23 August 2010 17 P P F Centurion 
T1833 S 28 January 2009 23 August 2010 19 P P F Trichardt 
T1843 S 04 April 2010 23 August 2010 4 P P M Trichardt 
T1849 S 01 August 2008 19 August 2010 24 P P F PTA Central 
T1852 S 09 April 2009 20 August 2010 16 P P M Brits 
T1856 S 14 April 2009 25 August 2010 16 A N F Middelburg 
T1857 S 20 January 2010 24 August 2010 7 P P F Akasia 
T186 S 25 May 2009 10 February 2011 21 A N M Middelburg 
T1860 S 02 December 2009 20 August 2010 8 P P F Trichardt 
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T1874 S 10 March 2010 19 August 2010 5 A N M Middelburg 
T1875 S 10 January 2010 20 August 2010 7 A N F Trichardt 
T1879 A 30 July 2009 25 August 2010 13 A N M Trichardt 
T1882 A 03 December 2008 24 August 2010 20 A N M Trichardt 
T1886 S 25 April 2010 24 August 2010 4 A P F Rustenburg 
T1894 A 14 September 2009 15 April 2010 7 A N M Rustenburg 
T1897 S 22 May 2009 10 April 2010 11 A N M Centurion 
T1898 S 25 November 2008 12 April 2010 17 A N F Rustenburg 
T190 A 17 February 2010 22 March 2011 13 A N M Trichardt 
T1901 S 27 May 2009 14 April 2010 11 A N F Groblersdal 
T1902 S 04 August 2008 13 April 2010 20 A N M Trichardt 
T1918 A 26 July 2009 03 April 2010 9 A N M Middelburg 
T1926 S 25 September 2008 11 April 2010 19 A N M Trichardt 
T1931 A 19 March 2009 31 March 2010 12 A N M Trichardt 
T1932 S 19 February 2009 08 April 2010 14 A N M Middelburg 
T1933 S 28 January 2009 05 April 2010 15 A N M Middelburg 
T1937 S 25 January 2009 12 April 2010 15 A N F Trichardt 
T1943 S 05 November 2008 13 April 2010 17 A N M Middelburg 
T1945 A 22 September 2009 25 March 2010 6 A N M Trichardt 
T1953 S 21 July 2009 25 March 2010 8 A N M Trichardt 
T1967 S 25 May 2009 31 March 2010 10 A N F Trichardt 
T1973 S 24 March 2009 08 April 2010 13 A N F Brits 
T1983 S 08 October 2009 13 April 2011 18 A N F Trichardt 
T1986 S 01 August 2010 14 April 2011 8 A N M Trichardt 
T199 S 21 May 2009 18 March 2011 22 A P M Trichardt 
T1995 S 16 September 2010 13 April 2011 7 A N F Sandton 
T2004 S 25 April 2010 14 April 2011 12 A N F Rustenburg 
T2006 S 28 May 2009 14 April 2011 23 A N F Trichardt 
T2008 S 07 September 2009 14 April 2011 19 A N M Brits 
T2009 S 12 May 2010 19 April 2011 11 A N F Middelburg 
T2013 S 08 April 2010 19 April 2011 12 A N F Middelburg 
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T2022 S 23 March 2010 30 April 2011 13 A N M Randburg 
T2023 S 25 January 2010 01 May 2011 16 A N F Les Marais 
T2024 A 14 January 2010 29 April 2011 15 A N M Rustenburg 
T2026 S 06 October 2010 29 April 2011 6 A N F Trichardt 
T2030 S 16 August 2010 27 April 2011 8 A N M Wilgers 
T204 S 26 September 2009 18 March 2011 18 A N M Trichardt 
T2040 S 20 September 2010 28 April 2011 7 A N M Trichardt 
T2041 S 28 June 2010 27 April 2011 10 A N M Trichardt 
T2048 S 02 February 2009 30 April 2011 26 A N F Middelburg 
T2050 S 13 July 2010 27 April 2011 9 P P M Sandton 
T2053 S 09 February 2010 30 April 2011 14 A N M Trichardt 
T2057 S 05 November 2009 21 April 2011 17 A N F Mafikeng 
T2064 S 25 May 2009 12 May 2011 24 A N M Roodepoort 
T2068 S 10 September 2010 04 May 2011 8 A N F JHB Central  
T2069 S 16 March 2011 28 April 2011 1 A N M Rustenburg 
T2071 A 24 March 2007 12 May 2011 50 A N F Trichardt 
T2077 S 11 March 2010 04 May 2011 14 A N M Krugersdorp 
T2086 S 07 October 2010 20 April 2011 6 A N M Roodepoort 
T2090 S 15 October 2009 11 May 2011 19 A N M JHB Central 
T2096 S 17 January 2010 09 May 2011 16 A N F PTA Central 
T2101 S 07 October 2009 07 May 2011 19 A N M Les Marais 
T2103 S 06 June 2008 09 May 2011 35 A N M Trichardt 
T2104 S 28 May 2010 03 May 2011 12 A N F Randburg 
T2108 S 20 January 2010 06 May 2011 16 A N M Centurion 
T2111 S 25 April 2008 04 May 2011 37 A N M Middelburg 
T2120 S 15 June 2010 09 May 2011 11 A N F Wilgers 
T2124 S 24 January 2011 23 May 2011 4 A N M Rustenburg 
T2132 S 05 August 2009 09 May 2011 21 A N M JHB Central  
T2141 S 14 May 2010 04 May 2011 12 A N F Les Marais 
T2160 S 31 August 2010 12 May 2011 9 A N F Krugersdorp 
T2162 S 05 November 2010 10 May 2011 6 A N F Trichardt 
 212 
 
T2169 S 25 February 2010 04 May 2011 15 A N F Mulbarton 
T2170 S 10 March 2011 05 May 2011 2 A N M Rustenburg 
T2185 S 19 February 2010 19 June 2011 16 P P F JHB Central  
T2189 S 14 October 2009 19 June 2011 20 A N M Midrand 
T2190 S 10 June 2010 18 June 2011 12 P P F Midrand 
T2197 A 31 May 2009 25 June 2011 25 A P F Trichardt 
T2202 S 30 August 2010 25 June 2011 10 A N F Krugersdorp 
T2209 S 30 November 2010 21 June 2011 7 P P F Lenasia 
T2214 S 11 December 2010 26 June 2011 6 P P F Akasia 
T2223 S 16 October 2009 17 June 2011 20 P P M PTA Central 
T2229 A 29 May 2008 18 June 2011 37 A N F Middelburg 
T2231 S 23 March 2011 25 June 2011 3 A N F Trichardt 
T2233 S 12 June 2010 19 June 2011 12 A N F PTA Central 
T2235 S 27 October 2010 19 June 2011 8 P P F Midrand 
T2238 S 25 February 2010 17 June 2011 16 P P M PTA Central 
T2242 S 04 August 2010 20 June 2011 10 A N F PTA East 
T2249 S 23 February 2010 17 June 2011 16 P N F Rustenburg 
T2254 S 03 October 2009 21 June 2011 20 P P M Trichardt 
T2255 S 30 November 2009 19 June 2011 19 P P F PTA Central 
T2258 S 10 March 2010 20 June 2011 15 A N F Middelburg 
T2265 S 14 August 2009 20 June 2011 22 A N F Sandton 
T2268 S 28 April 2011 21 June 2011 2 A N M Trichardt 
T2273 S 29 July 2010 19 June 2011 11 P P M Middelburg 
T2288 S 09 November 2010 18 June 2011 7 A N M Krugersdorp 
T2293 S 22 March 2011 25 June 2011 3 A N M Rustenburg 
T230 S 15 October 2009 15 March 2011 17 A N M Trichardt 
T2300 S 20 July 2010 12 June 2011 11 A N M Groenkloof 
T2319 S 23 April 2010 11 June 2011 14 A N M Sandton 
T2321 A 14 December 2010 07 June 2011 6 A N M Trichardt 
T2325 S 12 October 2010 11 June 2011 8 A N M Centurion 
T2329 S 10 January 2010 06 June 2011 17 P P M Krugersdorp 
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T2334 S 08 February 2010 10 June 2011 16 P P F Midrand 
T2338 S 21 March 2011 08 June 2011 3 A N F Trichardt 
T2346 S 12 May 2011 08 June 2011 1 A N M Trichardt 
T2352 S 03 April 2010 12 June 2011 14 A N F Roodepoort 
T2356 S 22 April 2010 09 June 2011 14 A N M Middelburg 
T2363 S 12 January 2010 11 June 2011 17 A N M Akasia 
T2384 S 02 July 2009 06 June 2011 23 A N F JHB Central  
T2388 S 03 March 2010 13 June 2011 15 P P M JHB Central  
T2390 S 18 September 2009 09 June 2011 21 P P F Roodepoort 
T2393 S 17 March 2010 11 June 2011 15 A N F Trichardt 
T2397 S 26 March 2010 09 June 2011 15 P P M Les Marais 
T2406 S 04 December 2008 08 June 2011 30 A N F Trichardt 
T2409 S 11 August 2010 14 June 2011 10 P P F JHB Central 
T2414 S 20 June 2010 13 June 2011 12 A N M Les Marais 
T2422 S 18 February 2010 15 June 2011 16 A N M Midrand 
T2434 A 06 December 2010 15 June 2011 6 A N M Rustenburg 
T2437 A 01 September 2009 12 June 2011 21 A N M Middelburg 
T2442 A 17 July 2010 01 May 2011 10 A N M Trichardt 
T2445 S 19 October 2010 29 May 2011 7 A N F Trichardt 
T2446 S 18 January 2010 27 May 2011 16 P P M Montana 
T2449 S 17 August 2010 10 May 2011 9 A N F Trichardt 
T2454 S 13 April 2010 03 June 2011 14 A N M Middelburg 
T2455 S 09 September 2010 26 May 2011 8 A N F Mulbarton 
T2459 S 24 July 2009 03 June 2011 23 A N F Trichardt 
T2469 S 01 February 2011 26 May 2011 3 A N M Trichardt 
T2471 A 04 February 2008 17 May 2011 39 A N M Rustenburg 
T2472 S 16 August 2010 03 June 2011 10 A N M Randburg 
T2494 S 16 September 2010 03 June 2011 9 A N M JHB Central 
T2497 S 16 February 2010 30 April 2011 14 A N M Trichardt 
T2501 S 25 January 2011 30 May 2011 4 A N F Trichardt 
T2503 S 04 May 2011 11 May 2011 0 A N F Trichardt 
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T2510 S 02 December 2009 10 May 2011 17 A N F Wilgers 
T2513 S 23 December 2009 06 June 2011 18 A N M Rietfontein 
T2518 S 04 February 2010 04 May 2011 15 A N F Midrand 
T2524 S 17 March 2010 06 June 2011 15 P P F Middelburg 
T2532 S 18 January 2011 26 May 2011 4 A N F Trichardt 
T2538 S 05 May 2009 17 May 2011 24 P P M Krugersdorp 
T2539 S 21 November 2010 06 June 2011 7 A N M Midrand 
T2548 S 01 July 2010 03 June 2011 11 A N M Randburg 
T2568 S 07 November 2009 23 May 2011 18 A N F Sandton 
T2579 S 22 December 2009 30 May 2011 17 A N M Sandton 
T2585 A 23 December 2009 16 May 2011 17 A N M Trichardt 
T2594 S 25 February 2008 31 May 2011 39 A N M Trichardt 
T2595 S 05 September 2010 30 May 2011 8 A N M PTA Central 
T2605 S 23 October 2009 20 May 2011 19 A N M Nelspruit 
T2611 S 18 November 2010 03 June 2011 7 P P F Trichardt 
T2612 S 12 July 2010 18 May 2011 10 A N M Centurion 
T2613 S 10 March 2008 16 May 2011 38 A N M Trichardt 
T2621 S 02 June 2010 10 May 2011 11 A N F JHB Central 
T2622 S 15 July 2009 17 May 2011 22 P P M Midrand 
T2626 S 12 June 2009 02 May 2011 23 A N M Mulbarton 
T2630 S 29 July 2010 15 May 2011 10 A N M Trichardt 
T2638 A 20 April 2011 18 May 2011 1 A N F Middelburg 
T2644 S 05 November 2010 17 May 2011 6 A P F Bronkhorspruit 
T2647 S 22 September 2009 18 May 2011 20 P P F Midrand 
T2662 S 05 January 2010 08 July 2011 18 A N M JHB Central  
T2667 S 18 March 2010 09 July 2011 16 P P M Sandton 
T2670 S 20 May 2010 10 July 2011 14 P P M PTA Central 
T2672 S 27 August 2010 08 July 2011 11 P P F Centurion 
T2675 S 20 January 2010 08 July 2011 18 P P F Krugersdorp 
T2681 S 13 October 2010 08 July 2011 9 P P M Brits 
T2687 S 13 October 2010 08 July 2011 9 A N F Lenasia 
 215 
 
T2694 S 25 July 2010 08 July 2011 12 A N F Sandton 
T2714 S 01 January 2010 05 July 2011 18 P P F Krugersdorp 
T2721 S 23 June 2010 05 July 2011 13 P P F Klerksdorp 
T2727 S 14 September 2010 05 July 2011 10 P P F Groenkloof 
T2737 S 20 April 2010 06 July 2011 15 P P M Midrand 
T2743 S 09 August 2010 06 July 2011 11 A N M Rustenburg 
T2745 S 27 January 2010 06 July 2011 18 P P F JHB Central 
T2748 S 26 January 2010 06 July 2011 18 A N F Bronkhorspruit 
T2753 S 10 May 2010 27 June 2011 13 A N F Wilgers 
T2761 S 23 November 2009 28 June 2011 19 P P M Sandton 
T2768 S 03 August 2010 25 June 2011 10 A N F Thabazimbi 
T2771 A 07 April 2011 26 June 2011 2 A N F Trichardt 
T2777 S 22 April 2010 27 June 2011 14 A N M Witbank 
T2782 S 01 July 2010 28 June 2011 11 A N M Centurion 
T2784 S 24 November 2010 27 June 2011 7 A N M Trichardt 
T2788 S 05 July 2010 27 June 2011 11 A N M Centurion 
T279 S 26 May 2009 18 February 2011 21 A N M Trichardt 
T2798 S 22 June 2010 27 June 2011 12 P P M Trichardt 
T281 S 15 February 2010 07 February 2011 12 A N F Trichardt 
T2811 S 11 May 2011 28 June 2011 1 A N F Rustenburg 
T2812 S 06 August 2010 30 June 2011 10 A N F Trichardt 
T2819 S 23 December 2010 29 June 2011 6 A N F Mulbarton 
T2820 S 15 June 2010 29 June 2011 12 P P F PTA East 
T2821 S 21 August 2009 01 July 2011 23 A N M Sandton 
T2825 S 26 March 2010 01 July 2011 16 P P M Lenasia 
T2833 S 26 May 2010 28 June 2011 13 P P M Randburg 
T2839 A 11 July 2010 01 July 2011 12 A N F Middelburg 
T2842 S 28 September 2010 03 July 2011 10 A N F Sandton 
T2844 S 29 October 2010 01 July 2011 9 A N M Centurion 
T2845 S 11 June 2010 29 June 2011 12 P P F Trichardt 
T2854 S 09 March 2010 30 June 2011 15 P P F Midrand 
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T2861 S 20 July 2010 30 June 2011 11 A N F PTA East 
T2867 S 07 April 2011 30 June 2011 2 A N F Trichardt 
T2868 S 13 December 2010 28 June 2011 6 P P F Middelburg 
T2871 S 15 October 2009 30 June 2011 20 P P F Mulbarton 
T2874 S 11 December 2009 01 July 2011 19 P P M Midrand 
T2875 S 01 October 2010 29 June 2011 8 A N M Middelburg 
T2880 S 19 October 2010 01 July 2011 9 P P F Trichardt 
T2882 S 30 March 2010 30 June 2011 15 A P M Roodepoort 
T2885 S 16 December 2009 29 July 2011 19 P P M Krugersdorp 
T2894 S 15 December 2010 31 July 2011 7 A N F Montana 
T2898 S 30 December 2009 29 July 2011 19 A N F Vanderbijlpark 
T2900 S 16 April 2010 31 July 2011 15 P P F Randburg 
T2918 S 24 July 2010 04 August 2011 13 A N F Mulbarton 
T2919 S 04 September 2009 29 July 2011 22 P P M JHB Central  
T2926 S 03 March 2010 04 August 2011 17 P P F PTA East 
T2927 S 01 December 2010 31 July 2011 7 P P F Lenasia 
T2938 S 22 September 2009 03 August 2011 23 P P M Mulbarton 
T2940 S 15 September 2010 04 August 2011 11 A N F Sandton 
T2945 S 26 November 2010 03 August 2011 9 P P M PTA Central 
T2948 S 20 September 2010 04 August 2011 11 A N F PTA East 
T2949 S 10 January 2010 04 August 2011 19 A N F Trichardt 
T2951 S 11 April 2010 03 August 2011 16 P P F PTA Central 
T2957 S 30 July 2010 03 August 2011 13 P P F Centurion 
T2969 S 28 October 2010 29 July 2011 9 A N F Benoni 
T2977 S 01 January 2010 04 August 2011 19 A N M Middelburg 
T2980 S 10 November 2010 29 July 2011 8 A N M Alberton 
T2985 S 22 February 2010 04 August 2011 18 P P M Centurion 
T2987 S 06 July 2010 04 August 2011 13 P P F Kemptonpark 
T2990 S 09 September 2010 04 August 2011 11 A N F Montana 
T2992 S 18 November 2009 04 August 2011 21 A N F Middelburg 
T3001 S 28 June 2010 04 August 2011 14 P P M Sandton 
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T3008 S 17 August 2010 04 August 2011 12 A N F Rustenburg 
T3013 S 28 November 2009 04 August 2011 21 P P M Randburg 
T3018 S 23 July 2010 27 July 2011 12 P P M Rustenburg 
T3023 S 15 August 2010 19 July 2011 11 P P M PTA East 
T3035 S 27 August 2009 25 July 2011 23 P P F Krugersdorp 
T3038 S 02 December 2010 20 July 2011 7 P P M Centurion 
T3040 S 11 October 2006 20 July 2011 57 P P M Standerton 
T3056 S 04 August 2008 21 July 2011 35 A N M Rustenburg 
T3057 S 23 June 2008 21 July 2011 37 P P F Trichardt 
T3067 S 21 October 2010 23 July 2011 9 A P M Ermelo 
T3070 S 16 November 2010 22 July 2011 8 A N F Krugersdorp 
T3078 S 29 July 2010 20 July 2011 12 P P M PTA East 
T308 S 27 May 2010 02 December 2010 7 A N M Trichardt 
T3086 S 02 February 2009 21 July 2011 29 P P F Trichardt 
T3089 S 28 March 2011 20 July 2011 4 A N F Trichardt 
T3090 S 20 September 2009 20 July 2011 22 P P F Krugersdorp 
T3098 S 07 December 2009 27 July 2011 19 P P M Alberton 
T3104 S 11 August 2009 26 July 2011 23 P P M Akasia 
T3109 S 31 January 2011 20 July 2011 6 A N F Mulbarton 
T3112 S 13 February 2009 27 July 2011 29 A N F Rustenburg 
T3119 S 04 October 2010 27 July 2011 9 P P M Springs 
T313 S 13 January 2010 25 November 2010 10 A N M Trichardt 
T3131 A 29 April 2010 19 July 2011 15 A N M Trichardt 
T3133 S 16 September 2010 25 July 2011 10 A N F Randburg 
T3140 S 11 May 2010 25 July 2011 14 A N F Trichardt 
T3148 S 12 January 2010 27 July 2011 18 P P M Secunda 
T315 S 12 February 2009 01 December 2010 22 A N M Trichardt 
T3155 S 10 June 2011 27 July 2011 1 A N F Trichardt 
T3159 S 11 January 2011 26 July 2011 6 P P F Montana 
T3169 S 08 July 2010 26 July 2011 12 P P F Germiston 
T3182 S 04 August 2009 25 July 2011 23 A N F Roodepoort 
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T3190 S 02 December 2010 24 July 2011 7 P P M Sandton 
T3197 S 17 May 2010 25 July 2011 14 P P F PTA East 
T32 S 14 October 2009 10 March 2011 17 A N F Trichardt 
T3202 S 07 December 2007 15 July 2011 43 P P F Middelburg 
T3213 S 15 December 2010 15 July 2011 7 P P F Rustenburg 
T3221 S 15 March 2010 15 July 2011 16 P P F PTA Central 
T3222 S 03 July 2010 24 July 2011 12 A P M Sandton 
T3229 S 04 August 2010 27 July 2011 11 A N F Germiston 
T3233 S 19 April 2009 25 July 2011 27 P P M Trichardt 
T3239 S 15 September 2010 12 July 2011 10 P P M Trichardt 
T3240 S 21 July 2010 15 July 2011 12 P P M Montana 
T3243 S 18 August 2009 25 July 2011 23 P P M Centurion 
T3245 S 19 August 2009 16 July 2011 23 A N M Wilgers 
T3248 S 21 February 2011 12 July 2011 5 A N F Trichardt 
T3253 S 23 October 2010 12 July 2011 9 A N F Roodepoort 
T3255 S 03 November 2010 26 July 2011 8 P P M Kemptonpark 
T3257 S 06 January 2011 13 July 2011 6 A N M Trichardt 
T3263 S 24 August 2009 14 July 2011 23 A N M PTA Central 
T3272 S 05 August 2010 14 July 2011 11 P P F Centurion 
T3275 S 24 April 2010 14 July 2011 15 P P M Witbank 
T3280 S 31 March 2010 13 July 2011 16 P P F PTA Central 
T3286 S 31 May 2010 15 July 2011 14 P P F Rustenburg 
T3289 S 16 November 2010 12 July 2011 8 A N M Groenkloof 
T3293 S 13 October 2010 12 July 2011 9 A P M Brits 
T3298 S 05 January 2010 12 July 2011 18 P P M JHB Central  
T3301 S 29 March 2010 11 July 2011 16 P P M Midrand 
T3304 S 09 May 2010 14 July 2011 14 A P M Rustenburg 
T3305 S 18 May 2010 17 July 2011 14 P P F PTA East 
T3308 S 15 January 2010 13 July 2011 18 A N F Montana 
T3314 S 05 May 2010 14 July 2011 14 P P F Rietfontein 
T3315 S 28 May 2010 24 July 2011 14 A N M Krugersdorp 
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T3317 S 05 September 2009 14 July 2011 22 A N M Trichardt 
T3320 S 21 September 2010 16 July 2011 10 A N F PTA Central 
T3323 S 02 January 2010 13 July 2011 18 P P F Trichardt 
T3324 S 25 February 2010 13 July 2011 17 A N M Roodepoort 
T3326 S 15 September 2010 12 July 2011 10 P P M Roodepoort 
T3329 S 18 January 2011 13 July 2011 6 A N M PTA East 
T3334 S 18 January 2010 24 August 2011 19 P P M Brits 
T3338 S 03 September 2010 22 August 2011 11 A N M Springs 
T3348 S 30 September 2010 23 August 2011 11 A N M PTA Central 
T3353 S 01 March 2010 24 August 2011 17 A N F Brits 
T3363 S 15 January 2010 23 August 2011 19 P P M Sandton 
T3369 S 01 March 2010 24 August 2011 17 P P M Kloof 
T3372 S 08 December 2010 23 August 2011 8 A N F Sandton 
T3375 A 05 August 2009 23 August 2011 24 A N F Rustenburg 
T3378 S 11 February 2010 22 August 2011 18 P P F Trichardt 
T3381 S 10 June 2010 26 August 2011 14 A N M PTA East 
T3387 S 17 February 2010 24 August 2011 18 A N M Midrand 
T3388 S 21 October 2009 23 August 2011 22 P P F Krugersdorp 
T3394 S 27 May 2010 26 August 2011 15 A N F PTA Central 
T3402 S 14 September 2010 23 August 2011 11 A N F Centurion 
T3408 S 01 February 2010 18 August 2011 18 P P F Alberton 
T3415 S 26 September 2009 23 June 2011 21 P P M Rustenburg 
T3421 S 13 May 2011 22 August 2011 3 A N F Rustenburg 
T3423 S 28 February 2011 26 August 2011 6 A N M Krugersdorp 
T3429 S 03 November 2009 24 August 2011 21 P P M Sandton 
T343 S 13 May 2009 26 February 2011 21 A N F Trichardt 
T3432 S 01 January 2010 19 August 2011 19 A N F Randburg 
T3433 S 21 October 2009 26 August 2011 22 P P F Sandton 
T3438 S 20 August 2010 19 August 2011 12 P P F Groenkloof 
T3442 S 18 August 2010 19 August 2011 12 P P F Montana 
T3445 S 09 May 2010 26 August 2011 15 A N M Randburg 
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T3447 S 30 March 2010 19 August 2011 17 A N M Germiston 
T3453 S 17 August 2010 19 August 2011 12 A N F Benoni 
T3454 S 11 August 2009 19 August 2011 24 A N F Germiston 
T348 S 20 April 2010 11 February 2011 10 A N M Middelburg 
T36 S 28 September 2009 10 March 2011 18 A N F Trichardt 
T391 S 05 January 2009 02 December 2010 23 A N M Trichardt 
T406 A 15 May 2009 20 February 2011 21 A N F Trichardt 
T41 S 27 August 2009 10 March 2011 19 A N M Middelburg 
T423 A 18 March 2009 15 December 2010 21 A N F Trichardt 
T426 S 13 August 2009 02 February 2011 18 A N M Trichardt 
T438 S 21 October 2009 03 March 2011 17 A N M Trichardt 
T440 S 31 May 2010 04 March 2011 10 A N F Trichardt 
T441 S 09 July 2010 28 February 2011 7 ? N F Rustenburg 
T444 S 31 August 2009 02 February 2011 18 A N M Middelburg 
T446 A 17 July 2009 02 February 2011 19 A N M Trichardt 
T447 S 08 January 2010 28 February 2011 13 A N M Rustenburg 
T451 S 29 July 2010 03 March 2011 8 A N M Trichardt 
T471 S 11 August 2010 01 March 2011 7 A N F Rustenburg 
T473 S 03 December 2009 28 February 2011 14 A N F Trichardt 
T483 S 09 September 2009 10 August 2010 11 A N M Bethal 
T486 S 01 October 2009 16 August 2010 10 A N M Centurion 
T490 S 23 January 2009 07 August 2010 19 P P M Montana 
T493 S 07 August 2009 10 August 2010 12 P P F Centurion 
T497 S 15 December 2009 06 August 2010 8 P P F Trichardt 
T501 S 23 June 2009 16 August 2010 14 P P F Trichardt 
T503 S 10 March 2010 05 August 2010 5 A N F Middelburg 
T516 S 14 May 2008 10 August 2010 27 P P F Trichardt 
T517 S 31 May 2010 06 August 2010 3 A N M Trichardt 
T524 S 03 February 2009 12 August 2010 18 A N F Montana 
T526 S 03 January 2010 06 August 2010 7 A N F Centurion 
T527 S 31 May 2009 03 August 2010 15 P P F Akasia 
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T533 S 20 May 2010 09 August 2010 3 A N F Trichardt 
T538 S 23 February 2010 06 August 2010 6 A N M Wilgers 
T541 S 02 October 2009 04 August 2010 10 P P M Ermelo 
T551 S 03 March 2009 06 August 2010 17 A N F Trichardt 
T553 S 06 March 2009 10 August 2010 17 A N M Montana 
T556 S 07 April 2010 02 August 2010 4 P P F Rustenburg 
T558 S 29 January 2009 11 August 2010 19 P P F Kloof 
T560 S 24 October 2008 04 August 2010 22 A N F Montana 
T565 S 21 December 2009 16 August 2010 8 P P M PTA East 
T569 A 23 January 2009 03 August 2010 19 A N F Trichardt 
T571 S 17 February 2009 11 August 2010 18 A N M Centurion 
T572 S 08 August 2008 15 August 2010 24 P P M PTA Central 
T573 S 09 February 2009 06 August 2010 18 A N M PTA East 
T576 S 16 September 2008 08 August 2010 23 P P M Montana 
T578 S 15 January 2009 04 August 2010 19 A N F Middelburg 
T586 S 04 February 2009 03 August 2010 18 P P M PTA Central 
T588 S 26 March 2009 10 August 2010 17 A N M Witbank 
T599 S 30 April 2009 23 July 2010 15 A N F PTA Central 
T603 S 23 July 2008 23 July 2010 24 P P F PTA Central 
T612 S 01 August 2009 24 July 2010 11 P P M PTA Central 
T613 S 01 June 2009 09 August 2010 14 A P F PTA East 
T616 S 07 September 2009 23 July 2010 10 P P F PTA Central 
T621 S 22 February 2009 23 July 2010 17 A N M Middelburg 
T625 S 04 February 2010 20 July 2010 5 P P F Middelburg 
T627 S 16 January 2009 21 July 2010 18 A N M PTA North 
T636 S 22 July 2009 06 August 2010 13 P P M Ermelo 
T637 S 15 August 2007 05 August 2010 36 P P M Trichardt 
T646 S 09 February 2010 01 August 2010 6 A P M Montana 
T664 S 26 April 2009 20 July 2010 15 P P M Trichardt 
T668 S 20 May 2010 23 July 2010 2 A N F Trichardt 
T674 S 17 July 2008 29 July 2010 24 A N M Trichardt 
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T675 S 23 July 2008 25 July 2010 24 P P F PTA Central 
T680 S 04 August 2009 22 July 2010 11 P P M PTA Central 
T683 S 01 December 2009 22 July 2010 7 A N M Middelburg 
T685 S 16 January 2010 21 July 2010 6 A N F Middelburg 
T688 S 01 September 2009 19 July 2010 10 P P F Alberton 
T694 S 12 December 2009 27 July 2010 7 A P M Standerton 
T695 S 17 April 2009 25 July 2010 15 A N F Trichardt 
T698 S 04 December 2009 28 July 2010 7 A N M PTA East 
T704 S 25 June 2009 02 August 2010 14 P P M Middelburg 
T707 S 20 December 2006 19 July 2010 43 P P F Trichardt 
T711 S 27 March 2009 20 July 2010 16 P P M Montana 
T714 S 22 September 2009 18 July 2010 10 A N F Ermelo 
T716 S 18 September 2009 26 July 2010 10 A N F Les Marais 
T717 S 09 July 2008 28 July 2010 24 A N F Trichardt 
T720 S 12 January 2010 20 July 2010 6 A N M PTA North 
T722 A 25 November 2008 28 July 2010 20 A N M Trichardt 
T723 S 08 February 2010 23 July 2010 5 P P F Trichardt 
T729 S 12 May 2009 29 July 2010 14 P P F Rustenburg 
T734 S 26 January 2010 27 July 2010 6 P P M Trichardt 
T739 S 10 January 2010 28 July 2010 6 A N F Trichardt 
T746 S 10 March 2008 22 July 2010 28 A N M Trichardt 
T747 S 16 October 2008 27 July 2010 21 P P M PTA Central 
T752 S 27 January 2009 23 July 2010 18 P P M Brits 
T755 A 01 September 2009 01 August 2010 11 A N F Middelburg 
T756 S 29 September 2008 27 July 2010 22 P P F Standerton 
T764 S 03 January 2010 20 July 2010 6 P P M Centurion 
T776 S 20 December 2006 22 July 2010 43 P P F Trichardt 
T778 S 26 May 2009 02 August 2010 15 P P M Trichardt 
T781 S 07 November 2008 22 July 2010 20 P P M Centurion 
T787 S 21 November 2009 26 July 2010 8 A N F Trichardt 
T80 S 09 May 2010 18 February 2011 9 A N M Trichardt 
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T804 A 01 May 2009 15 September 2010 16 A N F Rustenburg 
T806 S 17 November 2009 14 September 2010 10 A N M PTA Central 
T819 S 29 June 2009 17 September 2010 15 A N M Centurion 
T820 A 09 September 2009 14 September 2010 12 A N M Trichardt 
T821 S 16 September 2009 19 September 2010 12 A N M PTA East 
T836 S 24 November 2008 15 September 2010 22 A N M Middelburg 
T839 S 03 January 2010 16 September 2010 8 P P M PTA East 
T843 S 06 January 2010 17 September 2010 8 A N M PTA Central 
T850 S 14 September 2010 08 April 2011 7 A N F Trichardt 
T852 S 10 December 2009 04 April 2011 16 A N F PTA East 
T855 S 07 March 2010 08 April 2011 13 A N F Trichardt 
T866 S 07 September 2009 05 April 2011 19 A N M Ermelo 
T875 S 07 December 2009 07 April 2011 16 A N F JHB Central  
T882 S 14 August 2009 06 April 2011 20 A N F Mulbarton 
T889 S 17 March 2009 14 July 2010 16 P P M Standerton 
T895 S 01 March 2010 13 July 2010 4 P P F Middelburg 
T916 S 11 June 2009 16 July 2010 13 A N F Middelburg 
T920 S 12 March 2010 19 July 2010 4 P P M Middelburg 
T933 S 29 January 2010 07 July 2010 6 A N F Trichardt 
T935 S 11 February 2010 06 July 2010 5 P P M Trichardt 
T940 S 18 November 2008 12 July 2010 20 P P M Middelburg 
T944 A 29 April 2009 05 July 2010 15 A N F Trichardt 
T946 S 14 December 2005 12 July 2010 55 A N M Middelburg 
T948 S 21 December 2009 10 July 2010 7 A N F Trichardt 
T949 S 14 January 2010 06 July 2010 6 A N F Rustenburg 
T95 S 13 January 2010 21 February 2011 13 A N M Trichardt 
T958 A 09 January 2010 06 July 2010 6 A N M Rustenburg 
T965 S 25 August 2008 06 July 2010 23 P P F Standerton 
T974 S 15 January 2008 08 July 2010 30 P P M Trichardt 
T985 A 31 May 2010 09 July 2010 2 A N M Montana 
T986 S 03 January 2009 08 July 2010 18 A N F Centurion 
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T987 A 16 April 2010 10 July 2010 3 A N M PTA Central 
T988 A 20 December 2006 05 July 2010 43 A N M PTA Central 
T989 S 30 April 2010 03 July 2010 3 P P M Trichardt 
T990 S 09 February 2010 07 July 2010 5 A N F PTA East 
T991 S 13 March 2009 09 July 2010 16 P P M Middelburg 
T992 S 27 September 2008 07 July 2010 22 ? N M Louis Trichardt 
T993 S 11 May 2009 08 July 2010 14 A N M Montana 
T994 S 18 February 2007 07 July 2010 41 A N M PTA Central 
T995 S 12 June 2009 09 July 2010 13 P P M Middelburg 
T996 S 24 March 2010 12 July 2010 4 A N M Middelburg 
T997 S 07 January 2010 01 July 2010 6 P P F PTA Central 
T998 S 12 June 2009 12 July 2010 13 A N M PTA East 
T999 S 12 January 2009 12 July 2010 18 A N M Centurion 
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Reduced incidence of rotavirus infection involving uncommon rotavirus strains in 
children from small South African towns in 2010 and 2011 
Elizabeth MC Theron, John B Dewar, Mapaseke L Seheri, Martin Nyaga and Ina Peenze 
 
Abstract 
Diarrhoeal disease is associated with high morbidity as, during the first five years of life 
almost all children will experience at least one diarrhoeal episode per year.  Globally, 
rotaviruses have been identified as the most common cause of severe diarrhoea in children in 
this age group, accounting for more than 70% of all serious diarrhoeal cases. Commonly 
occurring rotavirus strains include G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8]. 
During the 18 months of sample collection from March 2010 to August 2011, 6050 samples 
were collected from a Private Pathology Practice in Pretoria, of which a total of 664 samples 
tested positive for rotavirus infections using rapid test-strips, showing an average overall 
incidence rate of 11% for both 2010 and 2011. This figure is less than half of the national 
rotavirus infection incidence average of 25% as reported by the National Institute of 
Communicable Disease.  Rotavirus strains from a subset of these samples from three towns in 
northern South Africa were determined to show that commonly occurring strains were 
G8P[4] and G12P[8] at an average incidence of over 60 percent.  Compared to the national 
surveillance results reflecting rotavirus diarrhoea and rotavirus strains in children seeking 
care in South African state hospitals, these results indicate a high incidence of relatively 
uncommon rotavirus strains in the study communities.  Taken together, these findings 
highlight a relatively low incidence of rotavirus infection involving relatively uncommon 
rotavirus strains within communities whose patients seek medical treatment at either private 
care or at private healthcare facilities. This allows speculation as to the impact of recently 
introduced rotavirus vaccines on the evolution of rotaviruses within these communities.   
 
Introduction 
Acute gastrointestinal infection, or gastroenteritis, is generally associated with the occurrence 
of diarrhoea and is clinically associated with three or more loose stools within 24 hours 
and/or vomiting.  Diarrhoeal disease is also associated with a high morbidity rate, as during 
the first five years of life almost all children will experience diarrhoea at least once, and in 
most cases, they will experience more than one diarrhoeal episode per year (Basu et al. 2003).  
Rosenberg (2007) indicated that children in developing countries on average have 3.2 
diarrhoeal episodes per year. 
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Diarrhoeal diseases are associated with various agents, including microorganisms and toxins.  
Viral gastroenteritis, however, is an acute infection and has a higher incidence compared to 
bacterial and parasitic gastroenteritis.  It causes relatively higher rates of morbidity and 
mortality among children in developing countries (Logan et al. 2006; Elliot 2007; Ospino et 
al. 2008).  Globally, rotaviruses have been identified as the most common cause of severe 
diarrhoea in children younger than five years of age (Bernstein et al. 1998; Bernstein et al. 
1999; Arguelles et al. 2000; Barnes et al. 2002; Bernstein et al. 2002), accounting for more 
than 70% of all serious diarrhoeal cases (Adler et al. 2005).      
 
The morbidity rate of rotavirus infections is similar in developing and developed countries.  
However, the severity and mortality of the disease is higher in developing countries (Audu et 
al. 2002a; Perez-Schael et al. 2009).  Virtually all children will be infected by rotavirus at 
least once before the age of five (Woods et al. 1992; WHO 2002; Page 2006; Ramani et al. 
2007; Rosenberg 2007; van Damme et al. 2007a; Chouikha et al. 2009; Ciarlet and Schödel 
2009; Hauber et al. 2011), and many children will also be infected more than once during this 
time period (van Damme et al. 2007a).  In South Africa, rotavirus has been identified as a 
significant cause of both sporadic and epidemic gastroenteritis in infants (Van Zyl et al. 
2006). 
 
Group A rotaviruses have been identified as most frequently being responsible for acute 
gastroenteritis in young children worldwide (Estes and Cohen 1989; Donelli and Superti 
1994; White and Fenner 1994; Nimzing et al. 1998; Iturriza-Gomara et al. 2000a; Audu et al. 
2002a; Mwenda et al. 2003; Percival et al. 2004; Logan et al. 2006; van Zyl et al. 2006; 
Mascarenhas et al. 2007; Ramani et al. 2007; van Damme et al. 2007b; Ospino et al. 2008; 
Chouikha et al. 2009; Esona et al. 2009; Hasing et al. 2009; Sanchez-Padilla et al. 2009; 
AnnaRita et al. 2010; Atchison et al. 2010; Kargar et al. 2011) resulting in approximately 111 
million cases of gastroenteritis requiring home care, 25 million cases requiring hospital or 
emergency room visits and 2 million cases requiring hospitalisation (Dewar et al. 2005; 
Santos and Hoshino 2005; WHO, 2008; Wang et al. 2009).  This group has also been 
identified as being responsible for more than 90% of all rotavirus infections diagnosed 
(Armah et al. 2003; Pietruchinski et al. 2006).  
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Classification of rotaviruses is based on the two outer capsid proteins, the glycoprotein VP7 
(G-types) and the protease-sensitive protein VP4 (P-types), these proteins are the targets of 
neutralising antibodies that are produced following natural rotavirus infection (Estes and 
Cohen 1989; Steele et al. 1995; Mphahlele et al. 1999; Arguelles et al. 2000; Iturriza-Gomara 
et al. 2000a; Pager et al. 2000; Armah et al. 2001; Honma et al. 2007; McCormack and Keam 
2009; Sanchez-Padilla et al. 2009; AnnaRita et al. 2010; Seheri et al. 2010b).   
 
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of viral RNA is a process 
during which the RNA is converted to complementary deoxyribonucleic acid (cDNA) which 
is then amplified to detectable levels by PCR.  Such RT-PCR assays are used in the G and P 
typing of Group A rotaviruses by using type-specific primers which target specific regions of 
the VP4 and VP7 genes (Farkas and Jiang 2007).  Using RT-PCR as an analysis tool has 
reduced the number of non-typeable strains, but strains containing spontaneous mutations at 
the primer binding sites, however, remain non-typeable by RT-PCR (Santos and Hoshino 
2005).  Several sensitive conventional RT-PCT methods based on primers specific to several 
different rotavirus genes have been developed to date (WHO 2009b).  As a detection method, 
RT-PCR improves Group A rotavirus detection compared to enzyme immunoassay or 
electron microscopy (Logan et al. 2006).   
 
Pan African rotavirus surveillance indicated, from June 2006 through December 2008, that 
2200 (40%) of 5461 stool samples collected from children enrolled in 8 countries (Uganda, 
Ghana, Kenya, Zambia, Zimbabwe, Cameroon, Ethiopia and Tanzania) tested positive for 
rotavirus.  Of these children, 90% of all rotavirus hospitalisations occurred in young children 
between three and 18 months of age.  Commonly occurring rotavirus types included G1P[8] 
(22%), G2P[4] (7%), and G9P[8] (7%); however, unusual types were also detected, including 
G8P[6] (5%), G8P[8] (2%), G12P[6] (1%), and G12P[8] (1%) (Mwenda et al. 2010).     
 
In a review study conducted by Todd et al. (2010) on samples analysed in 16 studies between 
1997 and 2006 in 10 African countries (Botswana, Egypt, Ghana, Guinea-Bissau, Kenya, 
Libya, Malawi, Nigeria, Tunisia and Zambia), the following common G/P combinations 
identified included; G1P[8] (17.4%), G2P[6] (9.6%), G8P[6] (9.4%), and G3P[8] (7%), 
unusual strains identified during this period included G8P[14], G9P[10], G8P[2], G3P[9], 
G4P[9], G8P[1], and G6P[6].  In this review Todd et al. (2010) also showed the shift in 
strains associated with infections with G1 as the most prevalent strain observed, together with 
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G2, G3, G4, and a high number (approximately 25%) of non-typeable strains being 
responsible for infections before 2007.  However, studies reviewed post 2007 showed a 
decrease in the number of infections associated with the more common strains and the 
emergence of uncommon strains, including G8, G12 and P[6] as being more commonly 
associated with rotavirus infections, especially on the African continent. 
 
A vaccine should form part of a diarrhoea disease control strategy that also includes 
improvement of hygiene and sanitation, zinc supplementation and community-based 
administration of oral-rehydration solutions (WHO 2009a).  A comprehensive analysis of all 
circulating rotavirus geno/serotypes is important in order to fully evaluate the suitability of 
vaccines worldwide (AnnaRita et al. 2010).  Atchison et al. (2010) indicated that the expected 
long-term effectiveness of rotavirus vaccination would be similar to that of the DTP 
(diphtheria, tetanus and polio) vaccine, which is approximately 91% at the child’s first 
birthday in the United Kingdom.  These authors, however, predicted that during the first two 
years post vaccination introduction there will be an increasing decline in the number of 
rotavirus incidences requiring medical treatment and that this will be followed by the third 
year where a large epidemic of rotavirus infections will be experienced before the disease 
incidence will stabilize at long-term, post-vaccination levels.  Chang et al. (2010) determined 
that an approximate 27% drop in hospitalisation due to rotavirus infections post-vaccination 
will also lead to a decrease in hospitalisation costs. 
 
Based on global studies and the identification of G1P[8] as the most prevalent strain 
responsible for rotavirus infection, many of the pharmaceutical companies focused on 
preparing a vaccine that would increase the immunity of young children against this strain.  
The Rotarix and RotaTeq rotavirus vaccines were introduced in South Africa in 2009.  The 
Rotarix vaccine was identified as being effective in preventing serious rotavirus 
gastroenteritis caused by G1P[8], G3P[8], G4P[8] and G9P[8] (Sanchez-Padilla et al. 2009).  
McCormack and Keam (2009) used data from various clinical trials to indicate a protective 
efficacy of Rotarix against rotavirus gastroenteritis of any severity to be 90-96% against 
G1P[8], 73-90% against non-G1P[8] rotaviruses and 58-62% against G2P[4].  The RotaTeq 
vaccine was proven to be 75% efficacious against all rotavirus gastroenteritis and 100% 
efficacious against severe disease in the United States (Ciarlet and Schödel 2009; Atchison et 
al. 2010).  Sanchez-Padilla et al. (2009) indicated a reduction in hospitalisation and visits to 
the emergency room due to infections caused by rotavirus strains G1, G3, G4 and G9 after 
 230 
 
introduction of RotaTeq in sub-Saharan Africa, with limited data being available with regards 
to effectiveness of RotaTeq on rotavirus strain G2.   
 
Objectives 
The objectives of the study was to compare the incidence rate of rotavirus infections as 
observed by a Private Pathology Practice with the incidence rate observed in Government 
owned hospitals and care-facilities, to determine the circulating strains during 2010 and 2011 
in Trichardt, Middelburg and Rustenburg, and to compare the data with published data from 
Government hospitals in South Africa. 
 
Materials and Methods 
Stools samples were received from a Private Pathology Practice in Pretoria from March 2010 
to August 2011, and screened to determine the age and gender of the patients, sample 
collection date, location of sample origins and if samples were rotavirus positive or negative 
as determined by rapid test kits upon receipt.  The stool samples were received from private 
hospitals, clinics and general practitioners using the Pathology Practice as diagnostic 
laboratory.  Data on the vaccination status of children included in the study was not known, 
as samples was received from the Pathology Practice and there was no direct contact with the 
patients, it can however be assumed that the majority of patients did receive a rotavirus 
vaccination as most patients would have been a member of a medical aid.   
 
All stool samples received, both adults and children, were screened to determine the date of 
birth of the patient, in order to evaluate if the sample would be included or excluded from the 
study.  Inclusion criteria for the study were based only on the date of birth of the patient, i.e. 
only stool samples for children younger than five years of age was retained for inclusion in 
the research study.  As the reason for the patient’s visit to a doctor or emergency room was 
not known, it was not used as an inclusion or an exclusion criterion.   The positive results 
from the Pathology Practice were used to determine the incidence of rotavirus infections 
during the 2010 and 2011 seasons. 
 
Samples included in the study were received from suburbs within Pretoria, Centurion, 
Cullinan, Bronkhorstspruit, Rustenburg, Brits, Witbank, Middelburg, Groblersdal, Secunda, 
Trichardt, Standerton, Ermelo, Bethal, Phalaborwa, Laudium, Makopane, Tzaneen, Witbank, 
Mafikeng and Thabazimbi, South Africa.  From November 2010, samples were also received 
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from suburbs within Johannesburg, the East Rand, West Rand, Potchefstroom and 
Klerskdorp, South Africa.  Rotavirus negative samples were also sent to the Pathology 
laboratory for additional analysis, as required by the referring doctor, from Pietermaritzburg, 
Polokwane, Nelspruit, Louis Trichart, Newcastle and Ellisras. 
 
Data from the study were compared with the data published by the National Institute for 
Communicable Diseases (NICD) and other scientists in South Africa, to establish if a 
difference can be observed in the incidence rate of rotavirus infections between the private 
and public sector. 
 
The RT-PCT procedure can be divided into three main processes: RNA extraction, reverse 
transcription of dsRNA, and genotype amplification of cDNA as described in the World 
Health Organizations Manual of Rotavirus detection and characterisation methods (WHO 
2009b).  Agarose gel electrophoresis followed by ethidium bromide staining allowed 
comparison of the migration distance of rotavirus amplicons through the gel to a 100 bp 
molecular weight marker to identify the VP7 and VP4 genotypes.  The genotyping primers 
used for RT-PCR analysis was based on the primers as described for the rotavirus G-specific 
genotypes in Gouvea et al. 1990 and Iturriza-Gomara et al. 2004, and and P genotype in 
Gentsch et al. 1992 and Iturriza-Gomara et al. 2000b. 
 
 
Results 
During the 18 months of sample collection from March 2010 to August 2011, 6050 samples 
were collected from a Private Pathology Practice in Pretoria, of which a total of 664 samples 
tested positive for rotavirus infections using rapid test-strips, showing an overall incidence 
rate of 10.98% for 2010 and 2011.  The detection rate, in percentages, for rotavirus positive 
samples received for 2010 was 10.37% (342 of 3299), and for 2011 the total number was 
11.7% (322 of 2751), as seen in Figure 1.  To ensure the accuracy of the incidence of 
rotavirus infection in samples received by the Pathology Practice, results were recorded for 
all samples, including samples which could not be transferred and stored for the study.   
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Figure 1 Incidence of rotavirus positive samples for the 2010 and 2011 season. 
 
These RT-PCR results, please see Figure 2, were collated in the table below.  This table links 
the three study sites as rotavirus genotype per year. 
  Middelburg Rustenburg Trichardt 
 2010 2011 2010 2011 2010 2011 
 n % n % n % n % n % n % 
G1P[8] 1 7 0 0 0 0 1 7 1 7 1 7 
G2P[4] 0 0 0 0 0 0 0 0 2 13 0 0 
G8P[4] 2 13 0 0 0 0 1 7 6 40 1 7 
G9P[8] 1 7 0 0 0 0 0 0 0 0 0 0 
G12P[8] 0 0 2 13 2 13 2 13 0 0 6 40 
Non typeable 0 0 0 0 0 0 1 7 0 0 0 0 
Table 1: Genotyping results for Middelburg, Rustenburg and Trichardt for 2010 and 
2011. 
 
Figure 2 RT-PCR Genotyping – Gel Two.  Lanes 1 and 16, 100 bp molecular weight 
marker; Lanes 2, 11 and 15, VP7 – G8; Lane 3, Non-specific amplification; Lanes 4, 5, 6, 7, 
8, 9, 13 and 14, VP7 – G12; Lanes 10 and 12, VP7 – G1. 
10.37 
11.70 
2010 
2011 
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Detection of rotavirus strains in these three towns indicates: 
• A low incidence of G1P[8] in all three towns during the study period. 
• The transient, low level occurrence in Trichardt only of G2P[4] during the 2010 
season. 
• G8P[4] occurred at a similar incidence to that of G1P[8] but appeared to spike in 
Trichardt during 2010.  This may be associated with an isolated outbreak of G8P[4] 
rotavirus at this time but a review of data from the Trichardt specimens showed that 
there were 2 specimens collected each month from June to August  making an 
epidemic unlikely. 
• The rotavirus strain profile in Trichardt changed from particularly G8P[4] in 2010 to 
be replaced by G12P[8] in 2011. 
• G12P[8] occurred in Rustenburg in 2010 and in all three towns in 2011, particularly 
in Trichardt.  
• G9P[8] showed only a transient, low level occurrence in Middelburg in 2010. 
 
Discussion 
The incidence rate for rotavirus infections observed over the study period, as indicated in 
Figure 1, was slightly higher in 2011 (11.70%), compared to 2010 (10.37%), however there is 
no significant difference between the incidence of rotavirus infections during the 2010 and 
2011 seasons.   
 
The NICD reported a detection rate of 21% for rotavirus infections in 2010 and 2011 as 
observed in five hospitals in South Africa, viz. Chris Hani Baragwanath Hospital in Gauteng, 
Dr. George Mukhari Hospital in the North West Province, and Mapulaneng, Matikwana and 
Edendale Hospitals in KwaZulu Natal (NICD 2011; NICD 2012).  In addition, a detection 
rate of 22.8% was reported by Seheri et al. (2010) over the period 2003 to 2005 in a study 
conducted at the Dr. George Mukhari in the Gauteng/North West, and Brits hospital in the 
North West Province. 
 
These latter rotavirus surveillance studies performed by the NICD and Seheri et al. (2010a) 
were conducted on a hospital surveillance model in Government hospitals in South Africa.  
The lower detection rate observed in this study (average=10.98%) compared to a published 
detection rates of >20% may be ascribed to a difference in incidence of rotavirus infection in 
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children seeking treatment in public healthcare facilities as opposed to the relative rotavirus 
incidence in children seeking treatment in private practice.  In the latter case, sample 
collection is largely dependent on the decision of a private General Practitioner to send 
samples for analysis to a Private Pathology Practice to determine cause of illness.  This may 
or may not contribute to an inaccurate reflection of the incidence of rotavirus disease as 
experienced by patients seeking private health treatment.  It should also be noted that the 
samples received for inclusion in this study did not form part of a specific surveillance study 
were samples would have been collected from any patient visiting a private health care 
practitioner. Another consideration that may influence the relative differences in rotavirus 
infection reflects possible differences as to the effectiveness of introduction and uptake of 
rotavirus vaccines by different communities, leading to mild gastroenteritis symptoms 
observed in children who received the rotavirus vaccine and thus, their exclusion from 
sample collection and diagnosis at the Private Pathology firm.  This raises speculation as to 
the involvement of other agents responsible for acute gastroenteritis within this study cohort, 
including viral, bacterial, protozoan or helminth agents commonly associated with 
gastroenteritis, and other agents such as members of the Picornaviridae (Knox et al. 2012).   
 
Nevertheless, these findings highlight a significant, high incidence of rotavirus infection in 
communities whose patients seek medical advice at either private care or at primary 
healthcare facilities.  As such, both these patient groups as well as their respective healthcare 
facilities experience a significant burden associated with rotavirus gastroenteritis, as 
diarrhoeal disease is generally associated with an increased emotional and financial burden 
on the family and caregivers of children ill with diarrhoea.    
 
From Table 1, it can be noted that the rotavirus genotypes for 2010 included G1P[8] were 
observed in two of the samples, G2P[4] in two of the samples, G8P[4] in eight samples, 
G9P[8] in one sample and G12P[8] in two samples.  Based on these results, the G8P[4] strain 
was the most predominant strain in the study area for 2010, being associated with 60% of the 
15 samples analysed from these three towns.  Apart from the relatively low incidence of the 
G1P[8] strains in the study samples, these results may be considered to be consistent with 
South African data published by the NICD for 2010.  Here, national surveillance identified 
the G1P[8] and G8P[4] strains to be most commonly associated with rotavirus gastroenteritis 
in three of the five hospitals included in their surveillance and the G12P[8] strain showed an 
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increase in association with rotavirus gastroenteritis and the most predominant strain of 2010 
was identified as the G1P[8] strain (NICD 2011; NICD 2012).   
 
Genotyping results from the study year 2011 indicated the predominant occurrence of 
G12P[8] - as noted in ten samples - and the equal, low distribution of G1P[8] and G8P[4] in 
each of another two samples.  One strain was non-typeable for either VP4 or VP7.  It should 
be mentioned that some non-specific amplification occurred in some of the VP7 strain PCR 
reactions.   For 2011, the national data published by the NICD identified the G12P[8] strain 
in all five hospitals included in their surveillance and, consequently, the G12P[8] strain as 
being the most predominant strain surveilled.  The G9P[8] strain was identified in two out of 
the five hospitals (NICD 2012).  Consistent with these South African G12P[8] data - but not 
for the G9P[8] data - the current study showed that the G12P[8] strain was the most 
predominant rotavirus strain circulating in these three towns during 2011, being associated 
with 66% (n=10) of the 15 samples analysed. 
 
Clinical trials conducted in developing countries, including South Africa, showed positive 
results in decreasing the number of serious gastroenteritis cases.  Questions can, however, 
still be raised on the potential impact the vaccines will have on the more uncommon strains 
and the potential vaccine effectiveness when new rotavirus reassortants are formed.   
 
Rotaviruses are not associated with only one country or one community, and published data 
have shown a consistency as to the expected results involving most prevalent strains 
responsible for rotavirus infections globally, with G1P[8], G2P[4], G3P[8], G4P[8] and 
G9P[8] being considered the most common causes of gastroenteritis (Woods et al. 1992; 
Audu et al. 2002b; Iturriza-Gomara et al. 2000a; Pietruchinski et al. 2006; Linhares et al. 
2008; Antunes et al. 2009; Dey et al. 2009; McCormack and Keam 2009; van Doorn et al. 
2009; Aminu et al. 2010; AnnaRita et al. 2010; Aladin et al. 2010).  Data by the WHO have, 
however, shown that these strains are more commonly found in the American, European and 
Western Pacific regions, with uncommon strains more often being responsible for infections 
in the African, South East Asian, and Eastern Mediterranean Regions (WHO 2011a).  Based 
on the published information and data obtained from this study on the most prevalent strains 
occurring in three small towns in 2010 and 2011, it shows the importance of continually 
surveying the circulating genotypes, thereby determining changes in trends of infectious 
rotavirus strains.   
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Annualised globally, in 2010 the predominant strains for rotavirus gastroenteritis included 
G1P[8] (31%), G2P[4] (19%) and uncommon strains (20%) including the G8P[4] strain.  
Upon further analysis, the following observation were made for the European, American and 
Western Pacific Regions where the G1P[8] strain was the predominant strain and responsible 
for more than 30% of all rotavirus associated gastroenteritis cases.  However, in the African, 
South East Asian and Eastern Mediterranean Regions the uncommon strains (>30%) were 
responsible for the greatest number of rotavirus associated gastroenteritis cases.  During this 
time period the G1P[8] strain was associated with 14% of infections in the African region, 
G2P[4] and G9P[8] with 10% each.  Uncommon strains in the African region included 
G2P[6] (28%), G3P[6] (21%), G1P[6] (11%), G9P[6] (9%), G12P[6] (7%), G12P[8] (7%), 
and G8P[4] (5%) (WHO 2011a). 
 
Todd et al. (2010) highlighted the difference in strain prevalence globally compared to strains 
observed in African countries.  In this review, global strains was identified as including, 
G1P[8] (52%), G2P[4] (11%), G4P[8] (8%), G3P[8] (3%), G9P[6] (2%), G9P[8] (2%) and 
uncommon strains (6%).  These data compare to African countries where the following 
observations were made, G1P[8] (17%), G1P[6] (3%), G2P[4] (5%), G2P[6] (10%), G3P[4] 
(4%), G3P[6] (2%), G3P[8] (7%), G8P[4] (3%), G8P[6] (9%), G9P[8] (5%), and other 
uncommon strains (5%). 
Data from the current study showed a relatively minor presence of G1P[8] in samples 
analysed.  However for 2010 and 2011, two relatively uncommon strains - G8P[4] and 
G12P[8] - were found to be predominant in the study area.  Data from this study and various 
other studies show an increase in more uncommon strains including G8 and G12 and P[6], 
not included in current available rotavirus vaccines.  This raises the question as to whether 
the introduction of rotavirus vaccines may enhance immunity against the more common 
strains, but at the same time enhance the chances of uncommon or novel strains taking their 
place?  Results from the current study provide a qualified “yes” to this question and underline 
the relevance of continuing rotavirus research and surveillance so that constant review of 
known characteristics of rotavirus gastroenteritis and identification of changes in rotavirus 
infection trends allows, particularly, primary healthcare practitioners and policy makers to act 
appropriately in updating testing protocols and/or immunization programmes.  By using data 
from this study and many other similar studies conducted now and in the future, 
pharmaceutical companies can keep an eye on the changes in trends and predominance of 
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rotavirus strains thereby ensuring that the most effective vaccines are produced and available 
to patients. 
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Age-occurrence of rotavirus infections for 2010 and 2011 as observed in samples 
collected by a Private Pathology Practice in South Africa 
Elizabeth MC Theron and John B Dewar 
 
Abstract 
Various viruses are associated with gastroenteritis and rotaviruses have been identified as the 
most common cause of severe diarrhoea in children younger than five years of age.  Studies 
have shown that approximately 30% of infants have been affected with rotavirus by the age 
of 9 months and 90% during the first 18 months and the most susceptible individuals are 
children aged between six months and two years of age. 
Stools samples were received from a Private Pathology Practice in Pretoria from March 2010 
to August 2011, and screened to determine if samples were rotavirus positive or negative as 
determined by rapid test kits upon receipt, to determine the age-occurrence of rotavirus 
infections observed in samples received. 
Based on the mean value (≥1.64%) the age-specific incidence for rotavirus infection in the 
study area was between three and 29 months of age.  From a broad perspective, data from the 
study supports published data that indicates that children younger than five years of age are 
most susceptible to rotavirus infections. 
 
Introduction 
Various viruses are associated with gastroenteritis including astrovirus, adenovirus, 
calicivirus, coronavirus, enterovirus, norovirus, pestivirus, picobirnavirus, rotavirus and 
torovirus (Wilhelmi et al. 2003; Elliot 2007; Ospino et al. 2008).     
 
Globally, rotaviruses have been identified as the most common cause of severe diarrhoea in 
children younger than five years of age (Bernstein et al. 1998; Bernstein et al. 1999; 
Arguelles et al. 2000; Barnes et al. 2002; Bernstein et al. 2002).  The WHO estimated in 2008 
that rotavirus infections are responsible for an average of 527 000 (range of 475 000 – 580 
000) deaths annually (WHO 2006; Parashar et al. 2009; WHO 2008; WHO 2009).  The WHO 
(2006) estimated that more than 90% of these annual deaths occur in developing countries, 
and it is estimated that between 140 000 and 230 000 of the annual death rate due to rotavirus 
infections occur in sub-Saharan Africa (Page, 2006; Van Zyl et al. 2006; Steele et al. 2008; 
Aminu et al. 2010; Madhi et al. 2010). 
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Armah et al. (2003) indicated various differences between developing and developed 
countries with regards to rotavirus infections as including the age of primary infection and the 
level of co-infections.  Thus, in developing countries primary infections tend to occur at an 
earlier childhood age and there is also a high level of co-infections with other pathogens. 
 
Studies have shown that approximately 30% of infants have been affected with rotavirus by 
the age of 9 months and 90% during the first 18 months (Wang et al. 2009) and the most 
susceptible individuals are children aged between six months and two years of age (Donelli 
and Superti 1994; Percival et al. 2004; King 2006; van Damme et al. 2007; Heymann 2008; 
Linhares et al. 2008; Atchison et al. 2009; Wang et al. 2009; van Doorn et al. 2009; Atchison 
et al. 2010; Kargar et al. 2011; Sherchand et al. 2012).  Studies indicate that rotavirus has a 
lower pathogenicity in children older than two years of age (Seheri et al. 2010), and 
newborns (Donelli and Superti 1994; Lundgren and Svensson 2001; WHO 2002) with adults 
generally experience asymptomatic infections (Donelli and Superti 1994; Linhares et al. 
2002; WHO 2002).  Steele and Ivanoff (2003) indicated that rotavirus infects African 
children at younger ages compared to children in Europe or America.  Uchida et al. (2006) 
indicated that while the majority of diarrhoea cases caused by rotavirus are observed in 
children younger than five years of age, approximately 5-7% of diarrhoeal cases in older 
children and adults in Nepal were caused by rotavirus.  Thus, the severity of rotavirus 
gastroenteritis is significantly greater during the first year of life compared to the second or 
third years of life (Perez-Schael et al. 2009). 
 
Studies have been done to determine the effect of season of birth on the burden and incidence 
of the disease.  Children are at the highest risk of infection during their first year after birth 
and are thereby also more likely to be infectious to other individuals, Atchison et al. (2009) 
therefore estimates that children born during spring and summer play an important role in 
spreading rotavirus infections, as these children will be more susceptible to infection in 
temperate countries where rotavirus peaks during winter months.  Likewise, children born 
during winter months would experience less severe incidences of infection, as infection in 
children born during winter months will only occur at an older age. 
 
Objectives 
The objective of the study was to determine the age-occurrence of rotavirus infections as 
observed in stool samples received by a Private Pathology Practice. 
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Materials and Methods 
Stools samples were received from a Private Pathology Practice in Pretoria from March 2010 
to August 2011, and screened to determine the age and gender of the patients, sample 
collection date, location of sample origins and if samples were rotavirus positive or negative 
as determined by rapid test kits upon receipt. 
 
All stool samples received, adults and children, were screened to determine the date of birth 
of the patient, in order to evaluate if the sample would be included or excluded from the 
study.  Inclusion criteria for the study were based only on the date of birth of the patient, i.e. 
only stool samples for children younger than five years of age was retained for inclusion in 
the research study.  As the reason for the patient’s visit to a doctor or emergency room was 
not known, it was not used as an inclusion or an exclusion criterian.   The positive results 
from the Pathology Practice were used to determine the incidence of rotavirus infections 
during the 2010 and 2011 seasons. 
 
Samples included in the study were received from suburbs within Pretoria, Centurion, 
Cullinan, Bronkhorstspruit, Rustenburg, Brits, Witbank, Middelburg, Groblersdal, Secunda, 
Trichardt, Standerton, Ermelo, Bethal, Phalaborwa, Laudium, Makopane, Tzaneen, Witbank, 
Mafikeng and Thabazimbi.  From November 2010, samples were also received from suburbs 
within Johannesburg, the East Rand, West Rand, Potchefstroom and Klerskdorp.  Rotavirus 
negative samples were also sent to the Pathology laboratory for additional analysis, as 
required by the referring doctor, from Pietermaritzburg, Polokwane, Nelspruit, Louis 
Trichart, Newcastle and Ellisras. 
 
Results 
The WHO recommends that when determining the specific age groups of children infected 
with rotavirus, the age groups should be clustered into the following age groups (in months); 
0-2, 3-5, 6-8, 9-11, 12-17, 18-23, 24-35, 36-47 and 48-59 (or 60) months (WHO 2002), as 
seen in figure 1, representing the data from the study.  
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Figure 1 Age-specific rotavirus infection incidence rates as recommended by the WHO 
(WHO 2002). 
 
Based on the mean value (≥1.64%) the age-specific incidence for rotavirus infection in the 
study area was between three and 29 months of age.  A high incidence (≥2.50%) was 
observed in children aged five, 7-19, 22, 25, 27 and 29 months, with the highest incidence 
rate (5.42%) observed in children 15 months of age. From a broad perspective, data from the 
study supports published data that indicates that children younger than five years of age are 
most susceptible to rotavirus infections.   
 
As seen in Figure 2, comparing the age-specific incidence rate of 2010 and 2011, the 
incidence in rotavirus infections for 2010 follows the age-specific incidence generally 
observed in rotavirus infections, except for a slightly increased incidence observed in 
children aged between three and five months of age, with the highest incidences observed in 
children younger than two years of age.  In 2011 however a high, abnormal, peak was 
observed in children between 25 and 29 months of age. 
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Figure 2 Age-specific rotavirus infection incidence rates per month for 2010 and 2011. 
 
Discussion 
The WHO specifies that children younger than five years of age should be included when 
conducting a surveillance study (WHO 2002).  Various studies have shown the most 
susceptible age groups for rotavirus gastroenteritis to be between six months and two years of 
age.  This study has complemented published data that rotavirus is responsible for 
gastroenteritis in children younger than five years, and particularly under the age of 29 
months.  The results have also shown the occurrence of higher number than generally 
expected observed in patients falling within slightly older, more uncommon age groups, than 
is reflected in the literature. 
 
Since the discovery of rotavirus particles in the stool samples of young children in 1973, 
there have been many studies conducted to research the various aspects associated with this 
virus, including symptoms, characteristics and outcomes of the associated disease.  
Rotaviruses are, to date, still associated in many developing countries with a high mortality 
and morbidity rate among young children and this is reflected in the recent introduction of 
vaccination programmes against rotavirus.  Various changes in rotavirus infections have been 
observed prior to and following the introduction of vaccines, including seasonality, age-
specific incidences, and circulating rotavirus genotypes that are responsible for infection.  
Rotaviruses respond to a changing and challenging environment and such changes are due 
not only to genetic reassortment commonly observed in RNA viruses, but also to external 
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factors, including environmental changes, such as climate change; and host population 
changes, such as population growth and changes in living habits.      
 
Based on the expected age groups (six months to two years of age), suggested as being 
particularly susceptible to rotavirus infection, the current study showed a contrasting 
relatively high incidence of rotavirus infection in children aged between 24 and 35 months 
during the 2011 season.  This relatively high incidence rate for this age group is mainly due 
to a high number of positive samples collected from children aged 25, 27 and 29 (>2.8%) 
months of age.  This may be ascribed to mini rotavirus epidemics within the winter seasonal 
epidemic however the increase in rotavirus infection in these children was noted in 
communities from different areas.  An alternative explanation may have been provided by 
Atchison et al. (2009) who suggested that children born in the winter months may show a 
delayed susceptibility to rotavirus infection and may skew surveillance results regarding the 
relationship between the age of the infant treated for gastroenteritis and susceptibility to 
rotavirus infection, 59% of the children in this age group was born between March and 
September.  The introduction of a vaccine within the study area, and/or the emergence of 
uncommon strains, may also have contributed to the high incidence observed within this age 
group, information if the children received a vaccine was however not available.  The change 
in age-occurrence was observed during only one of the rotavirus seasons, and it is therefore 
strongly recommended that additional studies are preformed to identify any change in the 
age-trend of rotavirus infections and to determine the associate cause for this change. 
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